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TÓM TẮT 
 
Sốt xuất huyết Dengue (SXHD) là bệnh truyền nhiễm cấp tính, gây dịch do vi rút 
Dengue gây nên. Dịch bệnh Sốt xuất huyết đã và đang là một đại dịch nguy hiểm, đe dọa 
đến sức khỏe và tính mạng của hàng triệu người dân trên toàn Thế giới. Bệnh sốt xuất 
huyết lưu hành chủ yếu ở vùng nhiệt đới và cận nhiệt đới. Hơn 50 năm qua, sốt xuất huyết 
dengue lan truyền với tốc độ rất nhanh, từ 9 nước báo cáo dịch bệnh vào năm 1970, cho 
đến nay vi rút dengue lan rộng tới 144 nước. Theo ước tính của WHO, hàng năm có 
khoảng 50 đến 100 triệu người nhiễm virus Dengue, trong đó có hơn 500.000 người phải 
nhập viện.   
Chikungunya bệnh lần đầu tiên được phát hiện vào năm 1952 ở châu Phi tại cao 
nguyên Makonde. Đây là một khu vực biên giới giữa Tanzania và Mozambique. Bệnh cảnh 
lâm sàng của bệnh sốt Chikungunya có dấu hiệu gần giống với bệnh sốt xuất huyết, vì vậy 
nó có thể khó chẩn đoán ở những nơi có bệnh sốt xuất huyết lưu hành phổ biến. Cũng như 
bệnh sốt xuất huyết, bệnh sốt do vỉ rút Chikungunya chưa có vaccine phòng bệnh và thuốc 
điều trị đặc hiệu. Khi bị mắc bệnh, biện pháp điều trị chỉ tập trung vào việc giải quyết triệu 
chứng và biến chứng. Ở những nơi điều kiện thuận lợi, muỗi truyền bệnh Aedes aegypti và 
Aedes albopictus và có tập tính sống gần gũi với người là yếu tố nguy cơ quan trọng cho 
bệnh sốt Chikungunya và dengue lưu hành, phát triển và gây bệnh. Bệnh xảy ra ở châu Phi, 
châu Á và tiểu lục địa Ấn Độ. Trong nhiều thập kỷ gần đây, muỗi truyền bệnh sốt 
chikungunya đã có cơ hội lây lan sang cả châu Âu và châu Mỹ. Trong năm 2007, sự lây 
truyền bệnh này đã được thông báo phát hiện lần đầu tiên tại châu Âu trong một ổ dịch nội 
địa ở phía đông bắc nước Italia. Năm 2013, 2014 những vụ dịch lớn xảy ra của vi rút 
chikungynya tại Ametican và Caribean.  
 Mặc dù chương trình phòng chống sốt xuất huyết quốc gia ở Vietnam đã được thực 
hiện từ năm 1999, tuy nhiên  sốt xuất huyết ở Việt Nam được coi là vùng dịch lưu hành địa 
phương, chủ yếu ở các tỉnh miền Nam và Nam Trung Bộ. Thống kê của Bộ Y tế Việt Nam 
cho thấy, hiện nay sốt xuất huyết Dengue đứng thứ 7 trong số 10 nguyên nhân nhập viện 
hàng đầu. Còn chikungunya vi rút được phát hiện ở Việt nam từ 10 người lính Mỹ vào năm 
1967, nhưng cho tới nay, bệnh sốt xuất huyết do vi rút chikungunya tại Việt nam vẫn còn 
là một vấn đề cần được quan tâm. Ở Việt nam, tập quán trữ nước trong các dụng cụ chứa 
nước sinh hoạt để đối phó với thời tiết khô của người dân cũng là yếu tố làm gia tăng quần 
thể muỗi truyền bệnh và gia tăng nguy cơ xảy ra dịch lớn, đặc biệt là tại Miền Nam.  Việc 
 
 
sử dụng các hoá chất diệt côn trùng không được kiểm soát làm ĵtăng tính kháng của vector 
truyền bệnh. Sự gia tăng các hoạt động giao lưu, buôn bán và du lịch giữa các vùng miền 
trong nước, ngoài nước như Cambodia và Lào  góp phần làm tăng nguy cơ lan truyền SXH 
trong cộng đồng.  
 Mục tiêu nghiên cứu của luận văn này nhằm hiểu rõ hơn về bệnh sốt xuất huyết 
và tình hình vi rút chikungunya ở một số tỉnh tại Việt nam, đặc biệt ở một số tỉnh có chung 
đường biên giới với Lào và Campuchia, nghiên cứu chỉ số Stegomya của hai véc tơ truyền 
bệnh sốt xuất huyết Ae. aegypti và Ae. Albopictus, với những tác động của véc tơ sốt xuất 
huyết dengue và chikungunya khác nhau tại năm huyện tại miền Bắc, miền Trung và miền 
Nam, Việt Nam. Ngoài ra nghiên cứu cũng mô tả vai trò của bệnh sốt xuất huyết ở những 
bệnh nhân thu thập được ở bệnh viện Đồng tháp, Việt Nam. Mặt khác, để hiểu rõ hơn về sự 
tương quan giữa mật độ của Ae. aegypti và Ae. Albopictus gây sốt xuất huyết Dengue bùng 
phát tại thủ đô Hà nội, Việt Nam. Bên cạnh đó, phân tích kiểu gen của quần thể muỗi được 
thực hiện để cung cấp thông tin rõ ràng về khả năng lan truyền của muỗi với xuất huyết 
dengue và chikungunya ở Việt Nam. Kết quả cho thấy rằng sự phát hiện vi rút 
chikungunya ở muỗi Ae. aegypti  nên được coi là cảnh báo vi rút chikungunya xuất hiện tại 
Việt Nam và có thể lưu hành cùng với bốn týp huyết thanh khác nhau là một vấn đề của 
sức khỏe cộng đồng và xã hội. 
 
 
 
Résumé étendu en français 
 
 
Depuis la seconde moitié du 20ème Siècle, avec les progrès de la médecine, en 
particulier dans le domaine de la vaccination, des antibiotiques, et avec l’amélioration des 
conditions de vie, la disparition des maladies infectieuses était espérée. Il n’en est toutefois 
rien. Dans les pays développés les efforts se sont concentrés sur les maladies non 
infectieuses, délaissant les maladies infectieuses. Ces maladies infectieuses, paludisme, 
SIDA, tuberculose, dengue, chikungunya, ont continué à s’étendre dans les pays en 
développement mais émergent aussi en zone tempérée, et en particulier en Europe, à la 
faveur des changements environnementaux et d’une société globalisée.  
 
Parmi ces maladies, la dengue est l’une des plus dynamiques en termes de 
propagation. Elle est particulièrement présente en Asie du Sud Est qui est sa zone 
d’origine. Elle est transmise par des moustiques du genre Aedes particulièrement adaptés à 
un environnement anthropisé. La dengue demeure un problème majeur de santé publique 
malgré des efforts de lutte antivectorielle et cela pour plusieurs raisons : 1) Il n’y a 
actuellement aucun traitement ni aucun vaccin connu, 2) Son incidence annuelle globale 
est estimée à 50 millions de cas entraînant plusieurs dizaines de milliers de morts, 3) Plus 
de 2.5 milliards de personnes sont à risque, 4) La maladie existe également sous deux 
formes sévères, la dengue hémorragique (DHF) qui peut évoluer en syndrome de choc 
(DSS) dont l’issue peut être mortelle, 5) Depuis les années 1950, l’incidence des formes 
graves (DHF/DSS) a été multipliée par 30, 6) L’infection est souvent asymptomatique, ce 
qui conduit à de mauvais diagnostics et une sous-estimation du nombre de cas. La dengue 
est causée par 4 virus ou sérotypes distincts, DENV1, DENV2, DENV3 etDENV4. Un 
cinquième serotype, DENV5, a récemment été isolé. Un patient infecté par un sérotype 
devient résistant à ce sérotype (immunité homologue) mais redevient sensible aux autres 
sérotypes après un délai d’environ12 semaines et présente alors un risque accru de 
développer une forme sévère suite à une seconde infection. 
 
Le chikungunya est une autre maladie arbovirale transmise par les mêmes vecteurs 
que la dengue. Le chikungunya et la dengue sont également très similaires du point de vue 
 
 
des symptômes (en particulier les symptômes précoces), de la période d’incubation et de la 
zone géographique. Le terme « chikungunya », utilisé à la fois pour le virus et la maladie, 
signifie « marcher avec le dos courbé » en Swahili et Makonde, et fait référence à l’effet 
incapacitant des arthralgies. Ce virus a été isolé pour la première fois en 1952 en Tanzanie. 
Des épidémies de chikungunya ont été décrites en Birmanie, Thaïlande, Cambodge, 
Vietnam, Inde, Sri Lanka, et Philippines. Les épidémies récentes causes par un virus 
variant ont causé plusieurs millions de cas dans l’Océan Indien et en Inde. La forme 
reémergente s’est étendue en Thaïlande et au Cambodge et plus récemment dans les 
Caraïbes, le Pacifique et l’Europe où plusieurs cas autochtones ont été observés à 
Montpellier en 2014. 
 
La dengue et le chikungunya sont parmi les maladies les plus difficiles à distinguer, 
en particulier en phase précoce, du fait de symptômes similaires, de co-infections et de la 
transmission par les mêmes moustiques péridomestiques du genre Aedes. Aedes aegypti est 
considéré comme le vecteur principal en zone urbaine avec Aedes albopictus et d’autres 
moustiques anthropophiles du genre Aedes comme vecteur secondaires.  
 
Le Vietnam est en Asie du Sud Est situé entre le Golfe du Tonkin et le Golfe de 
Thaïlande et est limitrophe de la Chine, de Laos et du Cambodge. Le climat est tropical au 
sud et sous régime de mousson au nord avec quatre saisons marquées. Cette distribution 
climatique affecte l’apparition des épidémies de dengue. La dengue a pour la première fois 
été décrite au Vietnam en 1958 dans le nord puis à partir de 1960. En raison de la 
différence climatique, la dengue est présente toute l’année dans le sud alors qu’elle est liée 
à la saison des pluies dans les autres régions. Le chikungunya a lui été détecté pour la 
première fois en 1967 chez des soldats américains durant la guerre du Vietnam. Le 
chikungunya a cependant été détecté dans certaines études chez des patients présentant des 
symptômes de dengue.  
 
La dynamique de ces deux maladies n’est toutefois pas claire et de nombreuses 
informations manquent encore sur les facteurs d’influence et les mécanismes. Ces 
connaissances sont essentielles pour comprendre les dynamiques en jeu et améliorer les 
capacités de gestion et maîtrise de ces maladies. Si la dengue est depuis longtemps 
 
 
hyperendémique au Vietnam, ce n’est pas encore le cas du chikungunya qui est très présent 
au Cambodge et au Laos et présente donc un risque d’émergence. Les échanges très 
importants entre le Vietnam, le Cambodge et le Laos, tant au niveau des biens que des 
personnes, constituent donc une voie d’entrée très plausible. 
 
L’objectif de ce travail de thèse était donc de conduire un travail de détection et de 
surveillance de la dengue et du chikungunya à la fois au niveau clinique chez des patients 
hospitalisés avec des symptômes fébriles aigus. Ces études se sont concentrées à la 
frontière avec le Cambodge et le Laos. Ce travail a été réalisé en partie au Vietnam dans le 
cadre du NIHE et en partie en France au CPBS (UMR 5236 UM-CNRS). 
 
Les objectifs étaient les suivants : 
  
1. Etablir une surveillance et une étude épidémiologique et entomologiques dans des 
zones frontalières avec le Laos et le Cambodge. 
 
2. Mieux comprendre la dynamique de circulation de la dengue au Vietnam et 
identifier les serotypes en cause. 
 
3. Evaluer la présence et la dynamique de circulation du chikungunya au Vietnam 
 
4. Comparer les incidences et dynamiques entre les diverses régions du Vietnam. 
 
5. Etudier le rôle des diverses populations de moustiques dans la transmission de la 
dengue et du chikungunya en période d’épidémie et hors période d’épidémie. 
 
6. Etudier la dynamique de transmission lors de l’épidémie de Hanoi en 2011. 
 
7. Evaluer le système hospitalier de surveillance 
 
8.  Analyser la structure génétique de populations de moustiques potentiellement 
vectrices. 
 
 
 
Cette thèse est donc présentée sous forme d’articles organisés en chapitres. Ces 
chapitres et articles sont les suivants :  
 
 
 
 
 
Partie 1: Etude bibliographique  
 
Pham Thi Kim Lien, Roger Frutos. Joint arboviral infections: risk and prospective. 
(Article en préparation) 
 
 
Partie 2 : Etudes de terrain et de laboratoire 
 
Chapitre 1 - Role of Aedes species in the transmission of dengue in urban areas in 
North Vietnam 
 
Pham Thi Kim Lien, Vu Trong Duoc, Laurent Gavotte, Emmanuel Cornillot, Phan Thi 
Nga, Laurence Briant, Roger Frutos, Tran Nhu Duong. Role of Aedes aegypti and Aedes 
albopictus during the 2011 dengue fever outbreaks in Hanoi, Vietnam. Asian Pacific 
Journal of Tropical Medicine, 2015; 8 (7); 543-548. 
 
L’objectif de ce travail était d’évaluer les correlations entre les cas de dengue et les 
densités de population de moustiques du genre Aedes durant l’épidémie de dengue de 
Hanoi en 2011. 24 foyers épidémiques ont été analysés sur 8 districts entre Août et 
Décembre 2011. 140 patients ont été hospitalisés suite à un diagnostic de dengue avec une 
prédominance masculine (59.3%) et une classe d’âge comprise entre 15 et 34 ans. Seuls 
DENV1 (11.27%) et DENV2 (88.79%) ont été détectés à partir des échantillons cliniques. 
L’échantillonnage des moustiques conduit dans et autour des habitations des patients a 
montré la prédominance d’A. aegypti (95.15%) par rapport à A. albopictus (4.85%). En 
 
 
conclusion, il y a une correlation positive entre les densités de population d’A. aegypti, le 
nombre de cas humains et la durée des épidémies. Ceci n’a pas été observé avec A. 
albopictus. Trois lots d’A. aegypti ont été trouvé positifs à la dengue. Deux avec DENV1 et 
un avec DENV2. 
 
 
Chapitre 2 – Surveillance of dengue and chikungunya virus infection in Dong Thap 
 
Pham Thi Kim Lien, Laurence Briant, Truong Ba Tang, Bui Minh Trang, Laurent 
Gavotte, Emmanuel Cornillot, Tran Nhu Duong, Roger Frutos, Phan Thi Nga. Virologic 
and serologic surveillance of arbovirus infection in Dong Thap, Vietnam with special 
reference to dengue and chikungunya viruses: a 13 months study. Asian Pacific Journal of 
Tropical Medicine, In Press. 
 
Cette étude visait à établir une surveillance dans la province de Dong Thap, qui est 
frontière avec le Cambodge, afin d’évaluer la présence de virus de la dengue et du 
chikungunya parmi les patients hospitalisés à l’hôpital général de Dong Thap. Une analyse 
descriptive a été conduite sur 131 patients hospitalisés avec une fièvre aiguë et des 
symptômes compatibles avec la dengue et le chikungunya. L’étude a été conduite de 
Janvier 2012 à Février 2013. Le tableau clinique complet a été établi, ainsi que la détection 
sérologique et moléculaire. L’analyse sérologique a été conduite de façon séquentielle sur 
des échantillons de sang collectés à l’admission et sept jours après admission. Les virus de 
la dengue et du chikungunya ont été recherché par ELISA et PCR. 101 patients sur 
131(77%) ont été confirmés positifs pour la dengue. Les quatre sérotypes ont été détectés 
avec une prédominance de DENV2 et DENV4. Aucun virus du chikungunya n’a été 
détecté. Un différentiel d’efficacité a été observé. L’efficacité de détection sérologique sur 
les mêmes patients était de 29% à l’admission et de 53% après 7 jours. 30 patients sur 131 
(23%) étaient négatifs pour la dengue et le chikungunya. En conclusion, la dengue est à 
 
 
risque de sous-estimation et le chikungunya n’est pas systématiquement détecté. Des 
changements devraient être opérés dans les procédures de surveillance afin de permettre un 
meilleur suivi de ces maladies. 
 
 
Chapitre 3 - Dengue virus, chikungunya virus and risk factors in several provinces of 
Vietnam 
 
Pham Thi Kim Lien, Laurence Briant, Laurent Gavotte,  Pierrick Labbe, Marco Perriat-
Sanguinet, Laurent Gavotte, Emmanuel Cornillot, Vu Trong Duoc, Nguyen Thi Yen, Tran 
Vu Phong, Nguyen Van Soai, Tran Duc Dong, Tran Chi Cuong, Phan Thi Nga, Tran Nhu 
Duong, Roger Frutos. Aedes mosquitoes mobility, diversity and risk factors for the 
diffusion of dengue and chikungunya in Vietnam. In preparation for submission to 
Emerging Infectious Diseases 
 
Une surveillance active a été conduite au Vietnam pour évaluer la présence de la 
dengue et du chikungunya chez des patients hospitalisés avec une fièvre aiguë dans cinq 
provinces frontières avec le Laos et el Cambodge. Ce travail, conduit de 2012 à 2014, a été 
complété par une évaluation des populations de moustiques collectées dans la même zone. 
Un total de 558 sérums humains a été prélevé ainsi que 1104 moustiques adultes (991 A. 
aegypti et 113 A. albopictus) et 10995 larves (8542 A. aegypti et 2453 A. albopictus) 
collectés à partir de 2250 foyers. Le virus de la dengue a été trouvé sur 17 (3%) serums 
humains. Le virus du chikungunya n’a pas été détecté dans les échantillons humains. Des 
densités de population variables ont été trouvées, la plus élevée étant dans la province sud 
de Long An frontière avec le Cambodge. Le virus de la dengue a été détecté 
essentiellement chez A. albopictus. Le virus du chikungunya a été détecté chez A. aegypti. 
L’analyse phylogénétique des moustiques adultes collectés a montré une large diversité de 
génotypes, tous ayant été décrits dans d’autres parties du globe. De nouveaux haplotypes 
ont été détectés. Un moustique de l’espèce Culex vishnui a été trouvé positif pour la 
dengue, faisant de cette espèce un vecteur potentiel.  
 
 
 
Ce travail sur la surveillance et la dynamique de la dengue et du chikungunya au 
Vietnam apporte un regard nouveau sur la situation actuelle et sur un certain nombre 
d’idées préconçues. En premier lieu cette étude est à notre connaissance la première 
analyse comparative à être conduite à une telle échelle sur le pays. Toutes les études 
précédentes concernaient des événements et épidémies à l’échelle locale et bien que 
correctes les conclusions ne reflètent qu’une vision locale et partielle de la dynamique. Une 
vision plus large est nécessaire pour mieux comprendre la dynamique de ces maladies.  
 
 La première conclusion de ce travail est qu’il est très difficile de tirer des 
conclusions sur le principal vecteur de la dengue. Dans ce travail, deux conclusions 
opposées ont été exprimées en fonction du lieu et peut être de la période. Durant 
l’épidémie de dengue de Hanoi en 2011, A. aegypti a été clairement identifié comme 
responsable de la propagation de la maladie. Une corrélation a été établie entre les densités 
de population locales d’A. aegypti et le nombre de cas cliniques. A. albopictus ne jouait 
aucun rôle. Quand une analyse globale a été réalisée dans plusieurs provinces du Nord, 
Centre et Sud Vietnam, le vecteur principal est apparu être A. albopictus. Encore plus 
important, les haplotypes impliqués ont été décrits dans d’autres parties du monde et un 
haplotype en particulier a été décrit récemment comme une population invasive en Europe. 
Plusieurs hypothèses peuvent émerger de cette apparente contradiction. La différence 
pourrait s’expliquer par la situation spécifique de Hanoi qui est une métropole urbaine à 
forte densité de population, un environnement favorable à A. aegypti par rapport à A. 
albopictus. A. aegypti est en effet plus anthropophile qu’A. albopictus et il est logiquement 
plus attendu dans une zone urbaine intense comme la capitale. L’étude conduite au sein de 
plusieurs provinces a montré à l’inverse qu’A. albopictus était le vecteur principal mais 
cette étude a été conduite en zone rurale où ce dernier est plus compétitif. Une autre 
explication pourrait être liée à la date des études. L’étude sur l’épidémie d’Hanoi a été 
conduite en 2011 alors que celle sur les diverses provinces a été réalisée entre 2012et 2014. 
Il n’est donc pas possible d’exclure un remplacement d’espèce dominante. Toutefois, cette 
hypothèse n’apparait pas très solide étant donné que dans l’étude sur plusieurs province, A. 
aegypti était très largement l’espèce dominante. Une dernière explication pourrait être 
trouvée dans la manière dont ces analyses ont été construites, ce qui représente aussi une 
forme d’autocritique. La conclusion issue de l’étude sur Hanoi était basée essentiellement 
 
 
sur une corrélation entre densité et période de pic des populations de moustiques et le 
nombre de cas cliniques. Cette étude était basée sur un nombre d’échantillon faible. Dans 
l’étude sur plusieurs provinces, un plus grand nombre d’échantillons a été analysé et A. 
albopictus a été identifié comme le vecteur principal alors que sa densité de population 
était nettement plus faible que celle d’A. aegypti. Ceci est particulièrement vrai dans la 
province de Long An où A. albopictus représentait 0.9 % des captures et 50% des 
moustiques infectés. Avec un plus faible échantillon, cette étude aurait pu conduire à la 
conclusion d’un rôle prédominant d’A. aegypti. 
 
 Ce travail de thèse montre le besoin d’une approche globale et coordonnée lors de 
l’analyse de la dynamique de la dengue et du chikungunya. De telles études ne peuvent pas 
être conduites à partir d’événements ponctuels et localisés du fait que la somme d’études 
ponctuelles ne conduit pas nécessairement une vision globale exacte. Les études de 
surveillance devraient être conçues au niveau national et basée sur un plan maître incluant 
à la fois des études cliniques et entomologiques avec détection de virus dans tous les 
échantillons. Le génotypage des populations de moustiques devrait être conduit de façon 
obligatoire ainsi que le génotypage des virus isolés d’échantillons humains et 
entomologiques afin de conduire les analyses de dynamique au niveau des lignées virales. 
La lignée est le véritable niveau de granulométrie à considérer. L’espèce et le sérotype ne 
sont pas suffisamment précis pour permettre une analyse de la circulation et une 
cartographie d’association. Une première recommandation issue de ce travail serait donc 
de développer une telle approche intégrée et de la proposer au NIHE ainsi qu’au niveau 
national. Ceci doit inclure une base de données et un système de gestion des bases de 
données homogènes et intégrés permettant une analyse spatio-temporelle.  
 
 Ceci est particulièrement pertinent si l’on considère une autre conclusion de ce 
travail de thèse, à savoir que les moustiques impliqués dans la vection ne sont pas des 
populations locales mais des populations circulant à l’échelon du globe. Une analyse de la 
dynamique ne doit donc pas se concentrer sur les populations locales de moustiques, bien 
qu’elles puissent néanmoins jouer un rôle, mais plutôt sur le monitoring régulier des 
populations de moustiques et en particulier aux points d’entrée comme les ports. De telles 
procédures devraient aussi être développées et cela pourrait être une autre perspective de 
 
 
ce travail. Génotypage, bases de données adaptées et analyses comparative des séquences 
de moustiques et de virus devront être développées ainsi que des analyses géographiques et 
des mouvements commerciaux internationaux. 
 
Un dernier aspect mis en évidence par ce travail est l’adaptation limitée des 
procédures actuelles de surveillance et de dépistage mises en œuvre à l’hôpital et dans les 
services de santé publique. Comme cela a été montré dans le cas de l’hôpital de Dong 
Thap, les tests sérologiques réalisés à l’admission sous-estiment le nombre de patients 
positifs pour la dengue. De plus, ils ne permettent pas l’identification des lignées virales. 
Le chikungunya n’est en outre pas dépisté du tout. Il serait trop onéreux et difficilement 
réalisable de mettre en place un test sérologique multi-étapes avec au final des résultats peu 
satisfaisants. La dernière recommandation et perspective issues de ce travail seraient donc 
la mise en place d’un test PCR multiplex pouvant détecter les quatre sérotypes de dengue 
ainsi que les deux variants, ancien et reémergent du chikungunya. Ce test devrait être 
associé au séquençage des échantillons positifs. Le cout de la PCR et du séquençage est 
désormais très compétitif et le bénéfice attendu pour la santé publique compense très 
largement l’investissement en surveillance. Ceci devrait être lié au même système intégré 
de bases de données dynamiques que pour la surveillance des moustiques. Un projet devra 
être soumis en ce sens au NIHE et aux instances nationales. 
 
En conclusion, ce travail de thèse a mis en évidence des points important à aborder 
de façon coordonnée afin de développer un système de surveillance efficace pour la 
dengue et le chikungunya au Vietnam. Développer ces systèmes et outils représentera un 
défi stimulant à relever et une valorisation intéressante de ce travail. 
 
 
 
 
SUMMARY 
 
Arthropod-borne viral infections (or arboviral infections) are common causes of 
fever syndromes worldwide, more than 130 arboviruses are known to cause disease in 
humans. Dengue fever (DF) caused by Flavivirus belong to the family Flaviviridae, and 
chikungunya is caused by an Alphavirus in the family Togaviridae. Both dengue and 
chikungunya diseases are transmitted by mosquitoes mainly Aedes aegypti (Ae. aegypti) 
and Aedes albopictus (Ae. albopictus) and can cause potentially severe and or debilitating 
chronic disease. Over the past 50 years, dengue has spread inexorably, with nine countries 
reporting dengue transmission prior to 1970 compared to over 144 now, and incidence 
having increased 30 fold. While dengue is the commonest and the most rapidly spreading 
mosquito - borne viral disease in the world, chikungunya (CHIK) has recently re - emerged 
after an interval of several decades to affect and place at risk millions of people in the 
Indian Ocean areas, Africa, Southeast Asia and more recently has spread to the Caribbean 
region. There are evidence countries in Asia, Africa and the Pacific of patients exhibiting 
co - infection with dengue and chikungunya simultaneously. Without a licensed vaccine, 
therapeutic druges and effective of vector transmission, the increasing number of case 
dengue virus (DENV), chikungunya virus (CHIKV) is associated with expanding 
geographyphic rage and increasing intensity of transmission in affected areas. 
Vietnam is one of five countries in the Southeast Asia with the higtest dengue 
burden. Cambodia and Laos countries share a long and extensive border with Vietnam that 
have endemic for dengue, reported increasing chikungunya activity in Laos and 
Cambodian provinces  bordering Vietnam. Dengue is highly endemics in tropical southern 
Vietnam, while increasing larger seasonal epidemics have occured in northern Vietnam 
over the last decade. Biomolecular level used to describes DENV serotypes. We have 
revealed that DENV serotypes circulating in Vietnam are similar to those observed in 
neighboring countries - in particular Cambodia and China. All four dengue virus serotypes 
founded circulating in Vietnam with dominant one varying through in southern and 
northern. 
Although CHIKV affected areas often overlap with DENV - endemic areas, 
however, stimultaneous outbreaks are rare. So far, no case of chikungunya in human 
reported in Vietnam, excepted 10 cases in 1967 of American soldiers in Vietnam. This 
 
 
study is the first to prospective investigate the circulation of the CHIKV and detected two 
Ae. Aegypti mosquitoes infected with CHIKV in the south of Vietnam. 
This thesis manuscript reports data obtained by multidisciplinary and integrative 
aproaches aiming to better understand dengue  and chikungunya virus situation in several 
provinces shares the  border  with Laos and Cambodia, and found that the proportion of 
Stegomya index of two vectors Ae. aegypti and Ae. albopictus, with the potential effects of  
DENV and CHIKV vector differed at the communes belong five districts in the north, 
center and south of Vietnam. Additionally, we described that a significant the role of 
DENV as cause of febrile illness in human, and also identified high proportion of dengue 
infection among patients in Dong Thap hospital, in south of Vietnam. On the other hand, to 
better understand on the positive correlation between the population density of Ae. aegypti 
and the number of DENV human cases of outbreaks in Hanoi capital, north of Vietnam. 
Beside, an integrative analysis encompassing the genetic study of viral lineages on human 
patents and in mosquitoes along with the genotyping of mosquito population should be 
undertaken to provide clear information on the dynamic of dengue and chikungunya in 
Vietnam. Our result suggested that the detected CHIKV in Ae. aegypti mosquito should be 
considered as warned of CHIKV appear in Vietnam and may be with DENV consists of 
four distinct serotypes combination remains a major public health problem.  
 
 
 
 
1 
GENERAL INTRODUCTION 
 
From the second half of the 20th century, with achievements of medical research in 
terms of vaccination, antibiotics and improvement of life and health conditions of 
mankind, it was expected that infectious diseases were going to disappear. However, in 
developed countries the efforts have been concentrated on illnesses as cancer. 
Consequently, at the dawn of the new century, infectious diseases are still causing 
suffering and mortality in developing countries. With the disease as Malaria, AIDS, 
Mycobacteria tuberculosis and other diseases will have marked the memory of humanity 
forever. 
Among these diseases, dengue fever, especially known in Southeast Asia, are 
hitting countries with tropical and warm climates. It is transmitted to the man by the 
mosquito of the genus Aedes (Ae.) is the principal vector of dengue and adapted extremely 
well to the urban environment. Dengue remains a major public health problem in tropical 
and subtropical countries despite lots of effort to control the mosquito vector (1) with an 
estimated global annual incidence of 50 million cases leading to ten of thousands of deaths 
(2) and more than 2.5 billion people being at risk of infection. Since the 1950s, the 
incidence of DHF/DSS has increased over 30 fold  (3),  with more than countries affected 
by outbreaks of dengue (4) Infection with any of DENV serotype may be asymptomatic in 
the majority of case or may result in a wide spectrum of clinical symptom (5). Dengue 
fever exists in two forms: the classic dengue or Dengue Fever (DF) and the Dengue 
Hemorrhagic Fever (DHF) which may evolve toward a severe form known as Dengue 
Shock Syndrome (DSS). The major problem with dengue is the fact that the disease is 
caused by five distinct serotypes known as DEN1, DEN2, DEN3, DEN4  (6)  and new  
DENV5 was detected in Thailand in 2013 (7). A person infected by one of the five 
serotypes will never be infected again by the same serotype (homologus immunity), but 
loses immunity to the three other serotypes (heterologus immunity) in about 12 weeks and 
then becomes more susceptible to developing dengue hemorrhagic fever. 
The latter distinguishes chikungunya virus (CHIKV) from dengue fever, which 
otherwise shares the same vectors, incubation period, clinical course, symptoms, and 
geographical distribution. The word chikungunya, which is used for both the virus and the 
disease, means “to walk bent over” in African dialect Swahili or Makonde, and refers to 
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the effect of the incapacitating arthralgia. The virus was first isolated in 1952 in Tanzania 
(8). Human chikungunya virus infection has been documented in Burma, Thailand, 
Cambodia, Viet Nam, India, Sri Lanka, and the Philippines (9). Recent chikungunya 
outbreaks caused several million clinical cases in the Indian Ocean Islands and India. 
Neither Europe nor the Americas have had outbreaks of chikungunya virus so far (9) (10) 
and more recently has spread to the Caribbean region (11). 
Dengue and Chikungunia are among the most difficult diseases to distinguish, 
especially because simultaneous co - infection can occur (12)(13)(14)(15)(16)(17). 
Chikungunya and dengue viruses are frequently transmitted to humans by peridomestic 
Aedes mosquitoes. Ae. aegypti has been considered to be the principal vector in the urban 
transmission cycle, with Ae. albopictus and other anthropophilic Aedes spp. serving as 
secondary vectors (18)(19). 
Vietnam is located in South Eastern Asia, bordering the Gulf of Thailand, Gulf of 
Tonkin, and shares the border with South China Sea, China, Laos, and Cambodia. The 
climate is tropical in south; monsoonal in north with 4 seasons are spring, summer, autumn 
and winter. Vietnam faced with many health problems including fever/ dengue 
haemorrhagic fever (DF/DHF). In 1958, dengue was first detected in the North, and in 
1960 was described in the South of Vietnam (20). Case occur year round in the South, and 
during the rainy season elsewhere. The incidence of DHF has increased from the first 
recorded outbreak in 1963, major epidemic occurred in 1969, 1983, and 1987 with a 
widespread epidemic in 1998 affecting 42 out of 61 provinces and resulting in 232,793 
cases and 447 deaths (21). An estimated average reported morbidity and mortality between 
1996 and 2005 was 75,407 cases and 145 deaths per year (22). In 2009, 27,000 cases (26 
fatal),  and in 2012 have 18,052 cases, 9 fatal, were reported during January to June (23). 
The outbreaks in 2013 were reported 25,300 cases and 16 fatal in August. (23) 
Since 1975, chikungunya virus is first detected in Vietnam arcording WHO 
reported (24), To date, no cases of chikungunya have been reported in Vietnam, since 1967 
when 10 cases were reported in American soldiers in Vietnam (25) and  other study  of anti 
- chikungunya antibodies in Vietnamese children in the South of Viet nam (26). In other 
research on anti - chikungunya antibodies in the North, Viet Nam show that, 60 percent of 
patients with classic dengue symptoms have tested negative for dengue virus. according to 
Vu Sinh Nam, Preventive Health and Environment Department, Ministry of health, and 4 
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of 17 provinces: Ha Noi, Nghe An, Ha Nam, Nam Dinh were positive to chikungunya 
virus with proportion 15/324 patients who have had classic dengue symptoms. Detected of 
chikungunya virus during dengue outbreak in the north, Viet Nam (27) . 
To find out suitability for surveillance chikungunya and dengue viruses infection in 
Viet Nam, the knowledge about mechanism of Chikungunya and Dengue virus interaction 
has essential activities that can help in the prevention of vector - born disease to improve 
the management, surveillance, control of dengue and chikungunya virus infection in 
Vietnam. On the other hand, the current knowledge on early events of chikungunya and 
dengue transmission from mosquitoes to human is limited. Besides, there are several 
reasons to believe that dengue and chikungunya may be co circulating in Vietnam as cases 
of CHIKV have been reported in neighbouring human populations. Cambodia reported the 
re - emergence of CHIKV in 2011 with 24 patients identified when samples were tested for 
Flaviviruses and Alphaviruses (28). In 2012, chikungunya outbreaks were reported in  
Laos with 197 cases in Moonlpamok and Khong Districts of Chamasak province (29). 
Vietnam shares borders with Cambodia and Laos, its therefore possible that cross - border 
transmission into Vietnam may occur as result of travel and traffic between the 
neighbouring countries from infected people or mosquitoes.  
Our aim is therefore to perform an epidemiological survey of dengue and 
chikungunya in several provinces in Vietnam shares the boder to Cambodia and Laos 
during the 2011 - 2014 periods. We will also investigate the interaction of mosquito to 
human transmission and the risk factors transmission dengue and chikungunya viruses. 
This part of the study is coordinated with the Center of National Research Scientific 
(CNRS), and Montpellier University 2, Montpellier, France. 
The specific objective of the research aims: 
9. To describe the surveillance data of chikungunya virus from several provinces 
presence in the north, center and south in Vietnam shares border with Laos and 
Cambodia.  
10. To better understand the monitor Dengue and identify the virus strains circulating in 
Vietnam. 
11. To obtain and analysis, of some dengue strains circulating in the North, with dengue 
viruses isolated in other regions in Vietnam. 
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12. To describes the spread of chikungunya and dengue viruses with the role of 
mosquitoes transmission in Ha noi, Vietnam. 
13.  To identify the molecular epidemiology of vector transmission chikungunya and 
dengue viruses in Viet Nam. 
The outline will be displayed in form of chapters with results presented as a form of 
published, submitted or in preparation articles. The articles included in this thesis are listed 
below: 
 
FIRST PART  
Pham Thi Kim Lien, Roger Frutos. Joint arboviral infections: risk and prospective. 
(in preparation) 
 
SECOND PART  
 CHAPTER 1 
Pham Thi Kim Lien, Vu Trong Duoc, Laurent Gavotte, Emmanuel Cornillot, Phan 
Thi Nga, Laurence Briant, Roger Frutos, Tran Nhu Duong. Role of Aedes aegypti 
and Aedes albopictus during the 2011 dengue fever outbreaks in Hanoi, Vietnam. 
Asian Pacific Journal of Tropical Medicine, 2015; 8 (7); 543-548. 
CHAPTER 2 
Pham Thi Kim Lien, Laurence Briant, Truong Ba Tang, Bui Minh Trang, Laurent 
Gavotte, Emmanuel Cornillot, Tran Nhu Duong, Roger Frutos, Phan Thi Nga. 
Virologic and serologic surveillance of arbovirus infection in Dong Thap, Vietnam 
with special reference to dengue and chikungunya viruses: a 13 months study. Asian 
Pacific Journal of Tropical Medicine, In Press. 
CHAPTER 3 
Pham Thi Kim Lien, Laurence Briant, Laurent Gavotte,  Pierrick Labbe, Marco 
Perriat-Sanguinet, Laurent Gavotte, Emmanuel Cornillot, Vu Trong Duoc, Nguyen 
Thi Yen, Tran Vu Phong, Nguyen Van Soai, Tran Duc Dong, Tran Chi Cuong, Phan 
Thi Nga, Tran Nhu Duong, Roger Frutos. Aedes mosquitoes mobility, diversity and 
risk factors for the diffusion of dengue and chikungunya in Vietnam. In preparation 
for submission to Emerging Infectious Diseases 
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PART I 
LITERATURE REVIEW 
1. Arboviruses 
 
Arthropod-borne viruses (arboviruses) are viruses that can be transmitted to human 
by arthropod vectors. The WHO definition is as follows: “Viruses  maintained  in nature 
principally, or to an important extent, throught biological transmission between susceptible  
vertebrate  hosts by haematophagus arthropods or through  transovarian and possibly 
venereal transmission in arthropods.” (30). 
Arboviruses that cause human encephalitis/animal or zoonotic disease have been 
identified, are members of four virus families: the Togaviridae (genus Alphavirus), 
Flaviviridae,  Bunyaviridae and Reoviride, contain most of the arbovirus that cause 
human/animal disease (31)(32)(33). The term of arboviruses is  not taxonomic indicator, it 
describers their  requirment for vertor in their transmission cycle (34)(33). According to 
International catalogue of Arbovirus, 1992,535 species belonging to 14 virus families were 
registered (33). More than 130 arboviruses are known to cause human disease. 
Human and animals infected by arboviruses, may suffer diseases ranging from sub-
clinical or mild through febrile to encephalitic or hemorrhagic with a significant proportion 
of facilites. Arboviruses infections can cause four types of illness: 1) Illnesses of the 
central nervous system, ranging in seriousness from mild viral meningitis to encephalitis 
(inflammation of the brain), with coma, paralysis, and death; 2) Mild fever illnesses with 
or without rash; 3) Hemorrhagic fevers that can be serious and life - threatening; 4) 
Arthritis and rash, with or without fever (35)(36).  
Three of a large number of neglected human pathogenic arthtopod- borne virus  are 
chikungunya virus ( CHIKV), dengue  virus ( DENV), and West Nile virus (WNV) whose 
combined figures for morbidity and mortality far exceed those for Ebola, severe acute 
respiratory syndrome and Middle East repiratory syndrome viruses (36). 
Approximately 300 type of mosquitoes could transmit arbovirus, special Aedes and 
Culex mosquitoes are the species most frequently associated with arbovirus transmission, 
respectively  more than 105 - 115 types of arbovirus (37) (33). Ticks are also prevalent 
vectors, 116 difference species are currently know to transmite arbovirses, in addition 25 
midge species mainly 24 types of Culicoides and Laisiohelea. Sandflies, blackflies, 
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stinkbugs, lice, mites, gadfly, and bedbugs can also transmit arboviruses (38). This 
diversity of species and the wide distribution of these transmission vectors explaine why 
arboviruses are so successful in dispersing globally via the mechanisms highlighted earlier 
(39)(33). A high proportion of Arbovirus associated with human and animal disease 
circulate in tropical and subtropical regions, where mosquitoes, and other flying insects, 
tend to be abundant. Also, many arboviruses circulate among wildlife species in temperate 
regions of the world. They have evolved a wide variety of strategies to ensure their long 
term success, dispersal and survival. Arbovirus adapt readily to new susseptible hosts by 
alteration of receptor specificity, transmission efficiency, antigencity, ecological and 
enviromental conditions. Changing anthropological behaviour, climate change and high 
mutation frequency are importannts determinants of arbovirus emergence (36).  
Up to date, in the 21 st  century, develope vaccine and antiviral drugs to prevent or 
treat humans against infection by pathogenic aboviruses will resolve the challenge 
associated with emerging  arboviruses. 
 
2. Different of Arbovirus families 
 
2.1. Family Flaviviridae 
 
2.1.1. Classification 
 
The International Committee on Taxonomy of Viruses (ICTV) began to devise and 
implement rules for the naming and classification of viruses early in the 1970s, an effort 
that continues to the present day. According to the ICTV of virus Flaviviruses consistitute 
on of three genera within the virus family Flaviviridae, and others two are the genera 
Pestivirus from Latin pestis is “Plague” and Hepacivirus from Greek hepatos is “liver”. 
The family Flaviviridae contains 58 species within three genera to include Flavivirus (53 
species), Herpacivirus (1 species), and Pestivirus (4 species). Fourteen species within the 
genus Flavivirus and all species within the Herpacivirus and Pestivirus genera are not 
known to be transmitted by arthropod vectors. (Beth K. Schweitzeer, 2009) (40). 
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Figue 1: Three genera of the Flaviviridae family in the Phylogenetic tree. 
 
The Flaviviruses are primarily transmitted by arthropods and consist of more than 
73 viruses include yellow fever virus, Japanese encephalitis virus, Dengue virus, West Nile 
virus, tick borne encephalitis, (41)(42). The first identified human virus in the flavivirus 
prototype is Yellow fever virus (YFV), this is name derived from Latin word “flavus”, 
meaning yellow, evoking the jaundice caused by YFV (43). 
In the genus Flavivirus, viruses share complex antigenic inter relationships, they 
can separate into four ecologicals or phylogentic group with regard to their vector 
association: mosquito - borne group, a tick - borne group, and non- vectored viruses. (See 
figure 2) Subtypes are written in parentheses after virus names. New world viruses are 
printed in bold and underlined (43). 
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Figure 2: Devided from the GenBank library, phylogenetic tree of the flaviviruses 
derived from partial Non-structural protein NS-S (NSS) sequences. 
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2.1.2 Genome structure 
 
The Flaviviridae genome contains a single, consists of a linear, positive-sense RNA 
molecule of about 10.8 kb in size, and the genome is not segmented.  The complete 
genome is 9500 - 12500 nucleotides long, Flavivirus virion are 50nm in diameter, 
spherical, and enveloped (44). The genome has a 5’- end carries a methylated nucleotide 
cap or genome - linked protein. It also has a 3’ polyadenylated tail, polyprotein from 
genomic RNA cleaved, three structural proteins and some non-structural proteins. The 
genome undergoes cytoplamsic replication (45). The translation initiation is cap - 
dependent in Flaviviruses (44). 
 
 
Note: M is protein, E is protein envelope, ORF is openreading frame, ssRNA is Singgle 
Stranded Ribonucleic Acid. 
Figure 3: Schematic structure of flavivirus virion (Philippe Buchy). 
 
As  study of Cleaves in 1981, the flavivirus genome has one open reading frame encoding 
a sing ger polyprotein at the origin of structural and non tructural  proteins (45). 
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 Figue 4: The single open reading frame is depicted with the structural and non 
structural protein coding region (colored is blue and green repectively).  
The 5’cap and the 5’ and 3’ untranslated region (UTR). The single open reading frame 
encodes an immature polyprotein pecursor that is co and post translationally cleaved in to 
three structural proteins (in blue) and seven nonstructural proteins (in green) (46). 
 
 
Figure 5: The detail of cleavage sites for cellular proteases, NS2B/ NS3 and unknown 
protease are indicated (47). 
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2.1.3 Vector 
 
Ticks and mosquitoes are too major group of arthropod vectors of Flaviviruses, of 
the known Flaviviruses, approximately 50% are recognized human pathogens causing 
fever, encephalitis, or hemorrhagic disease, however, for many of others, the pathogenic 
potential has not been well studied (Gubler Dj, Kuno G, 2007)(48) (49). Important 
mosquito was borne Flaviviruses include dengue virus serotypes 1 - 4, Yellow fever virus 
(YFV), West Nile virus (WNV), Japanese encephalitis virus (JEV) and St.Louis 
encephalitis virus (SLEV). The mosquito - born flaviviruses comprise two distinct 
epidemiology groups: neutrotropic viruses, often associated with encephalitic disease in 
human or livestock, culex spp. Mosquito vectors, and birth reservoirs, and  nonneutrotropic 
viruses are associated with hemorrhagic disease in humans, Aedes spp mosquito vector, 
and primate host (50). 
Ticks 
In nature, tick borne flaviviruses are maintained through a transmission cycle 
involving an ixodid tick vector and a vertebrate host (51). Tick transmitted flaviviruses 
comprise two distinct groups: mammalian and seabird virus groups. It is transmitted by the 
bite of several species of infected ticks, including Ixodes scapularis, Ixodes ricinus and 
Ixodes persulcatus (52) or  very rarely through the non - pasteurized milk of infected cows. 
 
 
Figure 6: Transmission cycle for tick-born encephalistic virus. 
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Tick - borne encephalitis virus (TBEV), which includes three subtypes, European, 
Far Eastern, and Siberian, was the most important role in human epidemiology, 
particularly in the old ‘‘Eastern bloc’’ countries, producing a wide range of diseases 
including subclinical infections, biphasic fever, encephalitis, and chronic disease. The 
vector of TBEV in European is Ixodes ricinus, and  I persulcatus for the other two 
subtypes  (53) (54)(55) (56)(57) (58) (59) (60). I ricinus is detected in the most of Europe, 
and the distribution extends to Turkey, Northern Iran, and in the Southeast of Caucasus 
(61). I persulcatus was found in the belt extending from Eastern Europe to China and 
Japan. Both tick species cocirculaten a restricted area in northeastern Europe, Russian 
Karelia, St Petersburg, and eastern Estonia and Latvia. An ectopic focus of TBE-Sib 
carried by I persulcatus has been discovered in western Finland. (62) (63)(64). 
The seabird tick - borne virus group has not been shown to induce disease in 
humans or in seabirds and the reasons why these relatively closely related viruses differ so 
significantly in this particular characteristic have not been investigated. However, human 
contact with seabirds is limited (65). 
Mosquitoes 
Culex 
The most dangerous and most widely distributed mosquito in the world is Culex 
mosquitos, Culex mosquito feeding normally happens at night. After feeding, the Culex 
mosquito will find somewhere cold and damp to rest and digest. Digestion of a meal can take 
2 to 7 days with 1 to 3 meals needed to produce a clutch of eggs. The female mosquitoes 
prefer to lay their eggs in standing water that contains plenty of organic matter  (66). 
The most importance of Culex vectors are member of Culex pipiens complex, 
known as the northern house mosquito.  Normally, Culex pipiens is considered to be a bird 
feeder but some urban strains have a predilection for mammalian hosts and feed readily on 
humans. According to a classification system for Northeastern mosquito, the life cycle of 
Culex pipiens represents a variation of the multivoltine life cycle: non - desiccation 
resistant eggs laid directly on water, larvae develop in polluted water habitats, multiple 
generations each year; overwinters as a mated female. 
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Figure 7: Life cycle of Culex mosquito 
The second of Culex vectors are C.autralicus, C,triaeniorhynchus, C.salinatius,  
C.tarsalis, C.quinequefasciatus, C.nigripalpus, C. nnulirostris. The major Asian vector of 
Japanese encephalitis (JE) is Culex triaeniorhynchus (67). In Australia, the main vector 
transmission to human of Murray Valeley (MVE) and Kunjin (KUN) viruses is Culex 
annulirostris (68)(69). 
Transmission cycles 
In Human, cycle of Culex mosquito is multipliers of the virus, and serving as a 
source of the virus for uninfected mosquitoes. Most female mosquitoes have to feed on 
human or an animal and get a sufficient blood meal before she can develope eggs, and 
Culex mosquito usually lay their eggs at night. 
Aedes aegyti and Aedes Albopictus 
Aedes aegypti  
Ae. aegypti is believed originated in the jungle of Africa where a sylvatic, where 
ancestral from (4)(70), and Ae. aegyti formosus is East and Central Africa (71). The domestic 
from Ae. aegypti was most likely spread throughout the rest of the world via slave and 
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trading ships during the seventeeth to nineteenth centuries (72). After that, Ae. aegypti could 
be found in the tropical and subtropical regions of the world. Arcording to Moritz UG 
Kraemer, 2015 prediction the distribution of the top ten countries in terrms of occurrence 
records for each continent for Ae. aegypti and Ae. albopictus (73) are shown  in table 1. 
Table 1: The geographic distribution of spatially unique occurrence for the 
Americas, Europe/ Africa, and Asia/ Oceania (source: Moritz UG Kraemer, 2015) (73) 
Americas Europe/Africa Asia/Oceania 
Ae. aegypti 
Brazil 5,044 Senegal 112 Taiwan 9,490 
USA 436 Cameroon 55 Indonesia 603 
Mexico 411 Kenya 52 Thailand 495 
Cuba 177 United Republic of 
Tanznia 
44 India 423 
Argentina 170 Côte d’loire 40 Australia 282 
Trinidad & 
Tobago 
152 Nigeria 35 Viet Nam 223 
Venezuela 130 Madgascar 28 Malaysia 112 
Colombia 128 Gabon 27 Singapore 44 
Puerto Rico 120 Mayotte 20 Philippines 36 
Peru 89 Sierra Leone 20 Cambodia 29 
Ae. albopictus 
Brazil 3,441 Italy 203 Taiwan 15,339 
USA 1,594 Madagascar 58 Malaysia 186 
Mexico 50 Cameroon 42 Indonesia 161 
Cayman Islands 15 France 37 India 150 
Haiti 13 Gabon 27 Japan 97 
Guatemala 12 Albania 22 Thailand 82 
Venezuela 7 Mayotte 21 Singapore 44 
Colombia 3 Greece 18 Laos 26 
Cuba 3 Israel 17 Philippines 22 
Puerto Rico 3 Lebanon 15 Viet Nam 18 
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Currently, Ae. aegypti   is presented and frequently abundant is most tropical and 
subtropical countries of the world (73). It seems probable that the geographical distribution 
of Ae. aegypti will continiue to expand, with incursion in previously uncolonised ares 
resulting in risk of vector born disease transmission to previously unaffected population (74).  
Ae. albopictus  
Ae. albopictus is believed to have originated in South - East Asia, islands of the 
Western Pacific and Indian Occean, has spread during recent decades to Africa, the mid - 
east, Europe and the Americas (75). 
Prior to 1979, Ae. albopictus was present from China, northern Japan to tropical 
Asia and in the Western Pacific, but is has spread to much of the rest of the world in recent 
decate, in 1983 Ae. albopictus was found in Memphis, Tennessee, United States, and 1995, 
confirmed with its discovery in Houston, Texas, United State. (76) (77). 
Ae. albopictus has been one of the fastest spreading animal species over the past 
two decades in central and South America (4). In addition to the ecological problems 
inherent in rapid spread of any species of particular importance are the serious public 
health risks posed by the introduction and establishment of an aggressive pest and efficient 
disease vector (78). 
Transmission cycles 
Infected humans are the main carriers and multipliers of the virus, and serving as a 
source of the virus for uninfected mosquitoes. The virus circulates in the blood of infected 
humans for two to seven days, at approximately the same time that they have a fever. 
Aedes mosquitoes may acquire the virus when they feed on an individual during this 
period. The transmission cycle may also involve jungle primates that act as a reservoir for 
the virus in parts of South East Asia and Africa (79)(80). 
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Figure 8: Depicting the hypothetical evolutionary history of endemic or epidemic 
DENV emergence from zoonotic transmission cycles (81). 
 
2.1.4 Flavivirus replication cycle 
 
In the host cell, Flavivirus enter by receptor - mediated endocytosis  (82). In human 
taget cell have two types of cell receptor appear to be involved in facilititating entry of 
Dengue virus depending on the cell (83). The first type corresponds to several primary 
receptors of low affinity and specificity including aminoglycan - type adhesion moleculas 
such as heparin sulfate that are expressed in many cell types (84) (85). The second type 
corresponds to lectin - type receptors such as the Dendric cell - specific intercellular 
adhesion mollecule 3 - grabbing non - antigen (DC-SIGN) expressed in some antigen - 
presenting cells such as immature dendritic cell (82). 
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Figure 9: Schematic of viral replication within host cell of a Flavivirus. (Tomlinson et 
al, 2009) (86). 
 
2.1.5 Main disease 
 
 Yellow fever 
Yellow fever (YF) is an acute viral haemorrhagic disease transmitted by infected 
Ae. aegypti (87), and other species mosquitoes (88). YF was found in tropical and 
subtropical areas in South America and Africa, but not in Asia  (89). The origin of the 
disease is most likely to be Africa, from where it was introduced to South America through 
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the slave trade in the 16th century. Since the 17th century, several major epidemics of the 
disease recorded in the Americas, Africa and Europe. In the 19th century, YF was deemed 
one of the most dangerous infectious diseases (90). According to the World Health 
Organization (WHO) estimates, there are approximately 200,000 cases of YF worldwide 
each year, and 30,000 deaths. About 90% of all cases occur in Africa. The virus is endemic 
in tropical areas of Africa and Latin America, with a combined population of over 900 
million people (91). 
The "yellow" in the name refers to the jaundice that affects some patient.  The signs 
and YF symptoms in some people have no symptom but in the more severe case is fever, 
nausea, vomiting, neck and back pain and it generally subsides after several days. 
There is no cure for yellow fever. Up to 50% of severely affected persons without 
treatment will die from yellow fever.  Treatment is symptomatic, aimed at reducing the 
symptoms for the comfort of the patient (WHO). 
In the middle of the 20th century a safe and effective live, and attenuated vaccine 
was created (92). However, since the 1980s the number of YF cases has increased, making 
it a reemerging disease. Besides vaccination, control of the YF mosquito Ae. aegypti and 
other species mosquitoes is of major importance in prevention YF virus (WHO). 
 St. Louis encephalitis 
St. Louis Encephalitis (SLE) is a disease transmitted caused by the Culex mosquito. 
In 1993, SLE virus was first isolated from a brain suspension obtained from a case of  
acute encephalitis during a large urban outbreak of the disease in St Louis, Missouri, and 
the neighboring St. Louis County, the epidemics have occurred sporadically and 
unpredictably in the subsequent decades. Prior to the introduction of West Nile Virus to the 
United States in 1999, SLE was the most common mosquito transmitted pathogen in 
the United State, major SLE epidemics occurred in Florida in 1959, 1961, 1962, 1977 and 
1990. A large outbreak occurred in the Ohio - Mississippi River Basin in 1975, a year 
when close to 2000 cases were reported nationwide. Occasional cases have been reported 
from Canada and Mexico. SLE virus is an emerging arbovirus in South America, with 
febrile illness and encephalitis cases reported in Argentina in 2002 and 2005, and in Brazil 
in 2004 and 2006 (93)(94). 
In general people who are infected with SLE have very mild illess or may never 
become sick, mild infection are  characteized by fever and headache, without other 
 
19 
apparent symptoms, but the symptoms of severe disease can include: headache, nause, high 
fever, neck stiffness, confusion, coma, shaking, seizures and/or paralysis (95). 
There is no effective antiviral medication for the treatment of SLE. Treatment for 
SLE is largely supportive and includes rest and medications to control vomiting (96). 
Prevent to SLE virus infected is the easiest and best way to avoid mosquito bites. 
There is no commercially available human vaccine for SLE (97)(98). 
 Japanese encephalitis 
Japanese encephalitis (JE) virus disease transmitted cause by the mosquito Culex 
tritaeniorhynchus, It was first recognised in Japan in the late 1800s (99),  represents the 
most significant etiology of arboviral encephalitis worldwide,  JE is a neurologic infection 
closely related to St. Louis encephalitis and West Nile encephalitis. JE disease is most 
prevalent in Southeast Asia, the Far East and the Pacific islands (100). Intensification and 
expansion of irrigated rice production systems in South and South East Asia over the past 
20 years have had an important impact on the disease burden. According to the World 
Health Organization, at least 30,000 - 50,000 people in Asia develop visible symptoms of 
Japanese encephalitis each year. Around 1 in 200 people develop more serious symptom, 
which can lead to permanence brain damage or death. It occurs from the islands of the 
Western Pacific in the east to the Pakistani border in the west, and from Korea in the north 
to Papua New Guinea in the south. Countries which have had major epidemics in the past, 
but which have controlled the disease primarily by vaccination, include China, Korea, 
Japan, Taiwan and Thailand. Other countries that still have periodic epidemics include Viet 
Nam, Cambodia, Myanmar, India, Nepal, and Malaysia.  
Infected mosquitoes then transmit the Japanese encephalitis virus to humans and 
animals during the feeding process. Mild infections occur without apparent symptoms 
other than fever with headache. More severe infection marked by quick onset, headache, 
high fever, neck stiffness, stupor, disorientation, coma, tremors, occasional convulsions 
(especially in infants) and spastic (but rarely flaccid) paralysis. Most infections are 
asymptomatic, but when encephalitis develops, the case - fatality rate can be as high as 
30%. Neuropsychiatric sequelae reported in 50% of survivors. 
In May 2009 and 2011 a new an effective inactivated vaccine is available for 
Japanese encephalitis, but it is expensive and requires one primary vaccination followed by 
two boosters.(101)(102)(103). According to WHO, in 2014 there are three types of 
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inactivated vaccines and one type of live attenuated vaccine currently used in the world: 1) 
mouse brain - derived, purified vaccine, which is based on either the Nakayama - NIH or 
Beijing -1  [P-1] strains; 2) primary hamster kidney (PHK) cell - derived, purified vaccine, 
based on the Beijing-3 [P-3] strain; 3) Vero - cell derived purified vaccine based on the P-
1, P-3 or SA14-14-2 strains as virus seeds; and 4) PHK cell derived live attenuated vaccine 
based on the SA14-14-2 strain of the JE virus.  
Dengue 
Dengue viruses transmitted principally in a cycle involving humans and mosquito 
vectors, the Ae. aegypti or more rarely the Ae. albopictus mosquito. The first case was 
reported the existence of dengue - like disease in 1779 but it was most likely present long 
before in first appeared in literature.  Dengue virus is major threat to health in tropical and 
sub - tropical countries, mostly found at Africa, Asia, Caribbean countries, Central and 
South America, Mexico, The Pacific. Severe dengue, previously known as Dengue 
Haemorrhagic Fever (DHF) was first recognized in the 1950s during dengue epidemics in 
the Philippines and Thailand. Before 1970, only nine countries had experienced severe 
dengue epidemics. The disease is now endemic in 144 countries in Africa, the Americas, 
the Eastern Mediterranean, South - East Asia and the Western Pacific. South - East Asia 
and the Western Pacific regions are the most seriously affected (3). 
Dengue fever is a severe, flu - like illness that affects infants, young children and 
adults, but seldom causes death.  For severe dengue, medical care by physicians and nurses 
experienced with the effects and progression of the disease can save lives. At present, the 
only method to control or prevent the transmission of dengue virus is avoid mosquito bites. 
Developing a vaccine against dengue or severe dengue has been challenging although there 
has been recent progress in vaccine development. To date, there is no vaccine to protect 
against dengue.  
 
2.2. Family Togaviridae (genus Alphavirus) 
 
2.2.1. Classification 
 
The Togaviruses was originally classified together with several groups of viruses 
predominantly transmitted by insect, more recent analyses in Taxonomic structure of the 
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family have defined them into a distinct family with two genera: the alphaviruses and the 
rubiviruses (104). The alphaviruses has been classified into seven antigenically related 
complexes (105), this genera with about 40 recognized members, while the Rubivirus 
genus is composed of a single member is rubella virus. 
 
2.2.2. Genome structure 
 
Virions contain one molecular of linear positive-sense single stranded RNA. Total 
genome length is 9700 - 11800 nt. The RNA of the virus is pure stranded and capped at its 
5' end as well as having a polyadenylene 3' tail. The virus is enveloped and forms spherical 
particles from 65 - 70 nm diameter, the capsid within is icosahedral, constructed of 240 
monomers. This structure allows the virus to act as mRNA within the host cell and easy to 
replicate. Genome first translated into four non - structural proteins (nsP1- nsP2- nsP3- 
nsP4) and structural proteins (E1- E2 - E3) (106) (107). 
 
 
 
Figure 10: Genome structure of Togaviruse (Source NCBI) (108)  
Togaviruses have an icosahedral capsid and have a surrounding envelope composed 
of two glycoprotiens. These glycoprotiens can be used to distinguish between species of 
the virus. It has been theorized that one of these protiens has a role in binding the virus to 
the host cell, allowing it to gain entry through receptors mediated endocytosis. 
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2.2.3. Vector 
 
The most common is transmitted by arthropod vectors, most usually is Ae. aegypti 
and Ae. albopictus mosquitoes, veterbrate host is birds, rodents, rabbit. The mosquitoes 
was first found in the New World in 1985 when it was isolated in Houston, Texas. It 
probably traveled there from northern Asia in ships carrying scrap tires. To further 
complicate matters, not only is Ae. albopictus now a good host for chikungunya virus, but 
also the mosquito is spreading across the globe from eastern Asia to Europe and the United 
States (109) (110). The cycles of wild bird and mosquito interactions and infectivity allow 
the virus to remain endemic. No cases of bird transmission of the disease have been 
reported, making mosquitoes the primary vector and birds simply reservoirs (111). 
 
2.2.4. Togaviridae replication cycle 
 
In the host, the most important feature of togavirus replication is that is has a 
dicistronic genome. Two mRNAs are used, one to produce non-structural proteins and 
another to produce structural proteins. In fact, there is 4 times as much subgenomic RNA 
as genomic RNA in cells infected with togavirus. Two classes of proteins are synthesiszed 
from different mRNAs, which allows temporal regulation and qualitiative replication. 
Genomic RNA can do first is make non-structural proteins (such as replicase) by 
synthesizing the minus strand, second is make structural proteins through synthesis of 
subgenomic RNA and synthesize positive strand RNA (112). 
 The virion has glycoproteins: Envelop 1 (E1) and enverlop 2 (E2) that recognize 
and bind to the host cell membrane. The virion binds and is completely released inside of 
the host cell through endocytosis. The virion is taken in and binds to an endosome. The 
endosome has an ATP dependent H+ pumps that use ATP to pump into the endosome 
hydrogen ions, which decreases the pH and degrades the outer layer thus exposing and 
releasing the viral genome to the cytoplasm. The first process that the genome does is to 
translate the nonstructural proteins. This is possible because the genome is already in a 
positive-sense single stranded RNA, therefore the genome uses the host's ribosomes and 
tRNA to produce the nonstructural proteins. These proteins are produced as a single 
polypeptide that was then cleaved into four nonstructural proteins. These proteins are 
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important in forming a complex that was involved in transcribing the viral RNA into a 
complementary negative - sense single stranded RNA template. The negative - sense RNA 
template is used to replicate into positive - sense single stranded RNA. Also, from the 3' 
end (of the positive-sense RNA) to approximately the 1/3 mark on the genome was used to 
produce structural proteins that encodes: capsid proteins, E1's, and E2's. These structural 
proteins and +ssRNA are transported to the endoplasmis reticulum (ER) where they are 
modified, and bud from the ER to go to the golgi apparatus were they are packaged into 
virions. The virion is then released from the golgi apparatus to leave the cell, and in doing 
so it acquires its lipid membrane from budding from the host cell (113). 
 
Figure 11: Replication cycle of Togaviridae (114) 
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2.2.5. Main diseases 
 
Chikungunya 
 
Chikungunya virus was first isolated from the blood of a febrile patient in Tanzania 
in 1952 (115), and there have been recent outbreaks of chikungunya in Africa, Asia and the 
Indian subcontinent. In recent decades mosquito vectors of chikungunya have spread to 
Europe and the Americas. Between 1960 and 1982, outbreaks of chikungunya fever was 
reported from Africa and Asia.  In Asia, virus strains have been isolated in Bangkok in 
1960s; various parts of India including Vellore, Calcutta and Maharastha in 1964; in Sri 
Lanka in 1969; Vietnam in 1975; Myanmar in 1975 and Indonesia in 1982. In 2007, 
disease transmission was reported for the first time in Europe. Prior to 2013, chikungunya 
virus outbreak had been identified in countries in Africa Asia Europe, and the Indian and 
Pacific Oceans. In late 2013, the first local transmission of CHIKV in the Americas was 
identified in Caribbean countries and territories. Since then, location transmission has been 
identiffied in 44 countries (116). 
 
 
Figure 12: Countries and territories where chikungunya cases reported (116) 
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The disease resembles dengue fever, and is characterized by severe, sometimes 
persistent, joint pain (arthritis), as well as fever and rash. It is rarely life - threatning. 
Nevertheless, widespread occurrence of diseases causes substantial morbidity and 
economic loss. 
There is no cure for the disease. Treatment is focused on relieving the symptoms. 
No vaccine is available against this virus infection. Prevention is entirely dependent upon 
taking steps to avoid mosquito bites and elimination of mosquito breeding sites (3). 
 Eastern Equine encephalitis 
Since 1830’s, Eastern Equine Encephalitis (EEE) is thought to have been the cause 
of virus in North American horses. EEE virus not received its name until a major outbreak 
occurred in horses in coastal areas of Delaware, Maryland, New Jersey, and Virginia in 
1933. (The U.S. Department of Agriculture, 2008). So, the virus may have been present in 
its endemic form long time before, it is maintained in nature through a bird - mosquito 
cycle, there are two mosquito species primarily involved in this portion of the cycle, they 
are Culiseta melanura and Cs. morsitans and Coquillettidia perturbans, Ochlerotatus 
canadensis, Oc.sollicitans… (117). In 1934, mosquito species of Aedes and Culex could 
become infected with and transmit EEE virus from one vertebrate to another. 
Most people bitten by an infected mosquito will not develop any symptoms. Severe 
cases of EEE virus infection, involving encephalitis (an inflammation of the brain) begin 
with the sudden onset of headache, high fever, chills, and vomiting. The illness may then 
progress into disorientation, seizures and coma. Approximately a third of patients who 
develop EEE die, and many of those who survive have mild to severe brain damage 
(118)(119). 
There is no vaccine or drug against Eastern equine encephalitis virus (EEEV) for 
humans. Reducing exposure to mosquitoes is the best defense against infection with EEEV 
and other mosquito - borne viruses (120)(121). 
 Western Equine encephalitis 
The western equine encephalitis (WEE) was first isolated in California in 1930 
from the brain of a horse with encephalitis, and remains an important cause of encephalitis 
in horses and humans in North America, but most cases have been reported from the plains 
regions of the western and central United States since 1964 and in Canada (122). The main 
mosquito is transmission is Cx. tarsalis, and WEE virus are still present over a widespread 
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geographic range, has a complex life cycle involving birds and Culex tarsalis mosquito. Cx 
tarsalis is a mosquito that often found on the West Coast of the United States and that 
prefers warm, moist environments. Other mosquitoes eg, Aedes species and, occasionally, 
small, wild mammals also have been known to spread the virus (123). 
Infection can cause a range of illnesses, from no symptoms to fatal disease. People 
with mild often have only a headache or sometimes have a fever. People with more severe 
WEE can have sudden high fever, headache, drowsiness, irritability, nausea, and vomiting, 
followed by confusion, weakness, and coma. Young infants often have seizures symptom 
(124). 
Nowadays, a vaccine is available for horses but not for humans (125). While there 
is no specific treatment for WEE, prevention involves controlling mosquitoes and avoiding 
mosquito bites (124). 
 Venezuelan equine encephalitis 
Venezuelan equine encephalitis (VEE) virus was first identified in horses in 1935 
after outbreaks in Columbia, Venezuela and Trinidad, and isolated in 1938 
(126)(127)(128).  The outbreaks usually occur after a season of heavy rains, due to 
increases in the mosquito population (72) (129)(126)(130). In the 1960’s and 1995 some 
outbreak were occurred Colombia and in Venezuela and Mexico. The epizootic and 
enzootic strains of the VEE virus range from northern Argentina to Florida and parts of the 
Rocky Mountains; however, it is most prevalent in northern South America (126) (127). 
The VEE virus is typically spread by mosquitoes, although certain types of ticks 
and mites can spread the virus as well. The Culex (Melanoconion) mosquito is normally 
responsible for the dispersal of the enzootic strain of the VEE virus (126)(128), and 
transmission by Ochlerotatus taeniorhynchus, Psorophora confinnis, Psorophora 
columbiae, Ochleratus sollicitans, Mansonia titillans and Anophilis aquasalis are some of 
the species of mosquitoes known to carry the epizootic varieties of the VEE virus (126) 
(131)(130). 
The most common symptoms are confusion, there is a sudden onset of flu - like 
symptoms including a severe headache, chills, fever, retro - orbital pain (pain behind the 
eyes), congestion, nausea and vomiting. In severe case the virus invades the central 
nervous system leading to encephalitis disorientation, convulsions, paralysis and coma. 
Adults are relatively resistant to the disease with <10% dying, but 20-30% of children 
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affected may die (International Classification of Disease Codes for Venezuelan Equine 
Encephalitis, 1999) (132). 
There is no specific drug for treatment of VEEV infection. Currently, there is a 
vaccine available for both humans and horses. The live attenuated vaccine known as TC-83 
is a strain of VEEV that was pass 83 times in guinea pig heart cells (126)(133).  
 
2.3. Family Bunyaviridae 
2.3.1. Classification 
 
Formally, the farmily Bunyaviridae was established in 1975 and now contains four 
genera of animal-infecting viruses are Orthobunyavirus, Phlebovirus, Nairovirus, and 
Hantavirus genera and one genus of plant-infecting viruses is Tospovirus (134) (135). The 
Bunyaviridae farmily of segmented negative strand RNA viruses (136). The family 
includes a number of significant human pathogens such as La Crosse virus (LACV), 
Hantaan virus (HTNV), Sin Nombre virus (SNV), Rift Valley fever virus (RVFV), and 
Crimean - Congo hemorrhagic fever virus (CCHFV) (137)(138) (139). 
Several members of the Bunyaviridae family also transmitted by mosquitoes, such 
as the Rift Valley fever virus and the California encephalitis virus, while in the others, such 
as the Crimean - Congo hemorrhagic fever (CCHF) virus, they are transmitted by ticks. 
Several of these viruses are the agents of viral haemorrhagic fevers. 
 
2.3.2. Genome structure 
 
According to the International Committee on Taxonomy of Virus, the Bunyavirus 
genome is monomeric and consists of three segments. These segments are labeled large 
(L), medium (M) and small (S) RNA segment (140). These RNA segments are single - 
stranded, and exist in a helical formation within the virion. On the other hand, they exhibit 
a pseudo - circular structure due to each segment's complementary ends. The L segment is 
6300 - 12000 nucleotides long and encodes the viral RNA polymerase.  Dependent RNA - 
polymerase, necessary for viral RNA replication and mRNA synthesis.The M segment is 
3500 - 6000 nucleotides long and encodes two glycoproteins as a single gene product that 
is usually co - translationally cleaved. The L and M segment are negative sense. The S 
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segment is 1000 - 2200 nucleotides long and encodes the nucleocapsid protein. Total 
genome size is around from 10500 - 22700 nucleotides long. For the Genera of 
Phlebovirus and Tospovirus, the S segment is ambisense, that are some of the genes on the 
RNA strand are negative sense and others are positive sense. The S segment codes for the 
viral nucleoprotein in the negative sense and a nonstructural protein in ambisense. The 
terminal sequences of each segment are base  paired. Because of the RNAs form non - 
covalently closed circles (141). 
 
 
 
Figure 13: Schematic representation of a generic bunyavirus virion, and negative-sense or 
ambisense gene expression strategies (142). 
 
Each Bunyavirus genome segment directs two RNA synthetic activities: the first is 
transcription of a single mRNA, and second is replication to generate an antigenome which 
acts as an intermediate for synthesis of further genomic strands. The nucleotide sequences 
at the 3'- terminus and the 5'- terminus are complimentary, forming panhandle structures. 
The 5'- terminus is not capped (143)(144)(145). 
 
2.3.3. Bunyaviridae replication cycle 
 
Replication begins with the attachment of viral proteins to host receptors and entry 
of virus by endocytosis. In the cell surfaces, viral proteins are used to bind to receptors. 
They are transit through the endoplasmic reticulum (ER), and Golgi apparatus, mature 
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virions bud from the Golgi apparatus into vesicles which are transported to the cell surface, 
while Bunyavirus RNA replicates in the cytoplasm via RNA and dependent RNA 
polymaerase, transcription occurs in the cytoplasm of the cell rather than in the nucleus. As 
a result, it is hypothesized that caps are stolen from mRNAs that are derived from host 
messages within the cytoplasm. Secondary transcription, three mRNA species are 
transcribed from the three segments, which occurs after replication, increases the amount 
of L, S and M mRNA segments. Most of the segments found in the cell due to secondary 
transcription are S. The least amount of segments was M, with an intermediate amount of 
L segments formed. The L and S segments of the genome translated by free ribosomes. M 
segments translated by membrane bound ribosomes. The L, S, and M segments are 
responsible for different structural and non-structural proteins. The viral progeny 
assembled within the Golgi apparatus of the cell. All of the viruses given glycoproteins and 
undergo terminal glycolysation. In addition, the viral progeny adopt pieces of host 
membrane to form the envelope (146). 
 
2.3.4. Vector 
 
The Bunyaviridae are a large group of viruses that infect a diversity of arthropod 
vectors and animal hosts, virus is transmission through mosquito, ticks, sandflies and 
midgus (Chin J, 2000; Plyusnin, 2011) (147) (148) (149). 
 Mosquitoes 
Ae. Triseriatus and Ae. Trivittatus 
Ae. Triseriatus is commonly called the tree holes mosquito, or eastern tree holes 
mosquito, is a species of mosquito found in the western hemisphere in wooded regions of 
eastern and central North America. It is quite prevalent, ranging from New Brunswick to 
the Florida Keys and stretching as far west as central Texas (150) (151). Female  Ae. 
triseriatus only mate once, and sperm are transfered into a structure known as the 
spermathecae. The female mosquito lays her eggs slightly above the water level, if water is 
present in the hole. Females require a blood by bitting human for each batch of eggs 
produced, and can produce eggs throughout their lives (152) (153)(154). Ae. triseriatus has 
been identified as a vector of Eastern Equine Encephalitis and linked to the spread of La 
Crosse Encephalitis (155)(156). 
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Ae. Trivittatus is the inland floodwater mosquito has been recorded in Canada from 
Ontario (157) and Nova Scotia (158). In 1971, the female mosquito was take in North - 
East of Pinawa, larvae was found in floodwater pool in meadows, swamps, and woodlands. 
Ae.  trivittatus  is  the  most widely  distributed  in  the  United  States,  it  occurs  Southern  
Canada  and  generally over  the  Eastern  half  of  the  United  States  and  as far  west  as 
Montana and  Colorado   (159). To most people who encounter Ae. trivittatus, the bite is 
much more painful and irritating than other mosquitoes encountered. Ae. trivittatus are 
persistent aggressive biters often attacking the human in a swarm - like manner (160). 
 Ticks 
Ixodid (hard) ticks, especially those of the genus, are both a reservoir and a vector 
for the Bunyavirus virus. Numerous wild and domestic animals, such as cattle, goats, sheep 
and hares, serve as amplifying hosts for the virus. Transmission to humans occurs through 
contact with infected animal blood or ticks, virus can be transmitted from one infected 
human to another by contact with infectious blood or body fluids (Tick-borne bunyavirus 
fever). I uriae are thought to replicate in the arthropod vectorand be transmitted to the 
vertebrate host (seabird) when the ticks feed on susceptible hosts. The virus then replicates 
in the seabird producing viraemi, infecting more ticks will also feed human. (161) 
(162)(163). 
 
2.3.5. Main disease 
 
 La Crosse encephalitis 
La Crosse encephalitis (LAC) was discover in La Crosse, Wisconsin in 1963. Since 
then, the virus has been identify in several Midwestern and Mid - Atlantic states. In 1964, 
LAC reported in US and India (164). Different mosquitoes can carry the virus including 
Aedes, Culex, and Culiseta but common in nature is virus vertical transmission by Ae. 
trivittatus mosquitoes (149). 
Although the vast majority of cases are not serious, LAC can cause severe illness, 
especially in children under age 16 (165). Similar to SLE virus, LAC virus does not cause 
disease in horses (166). 
Many people infected with LACV have no apparent symptoms. Among people who 
become ill, initial symptoms include fever, headache, nausea, vomiting, and tiredness. 
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Some of those who become ill develop severe neuroinvasive disease (disease that affects 
the nervous system). Severe LACV disease often involves encephalitis (an inflammation of 
the brain) and can include seizures, coma, and paralysis. Severe disease occurs most often 
in children under the age of 16. In rare cases, long - term disability or death can result from 
LAC. There is no specific treatment for LACV infection - care is based on symptoms 
(167). The best way to reduce your risk of infection with LACV or other mosquito - borne 
viruses is to prevent mosquito bites (168). 
 Reoviruses 
Reoviruses, which also called orthoreoviruses to avoid confusion with the family 
Reoviridae. In 1959, Sabin proposed the name reovirus to reflect the fact that viruses of 
this group had been isolated from the respiratory and enteric tracts and was orphan (reo) 
viruses without known associated disease.  According from Intestinal Health Center for 
Poultry, Reovirus was first isolated from chickens in the 1950s. In human orthoreovirus 
was isolated in 1953, Reovirus infections occur frequently, but most are mild or 
subclinical. The role of these viruses in human disease is not clear, but they are not 
consider important agents of human disease, however, during the last two decades, few 
cases of human disease have been report. These viruses also have been evaluate 
extensively in studies involving laboratory animals (35). 
No specific treatment or prevention measures have recommended for reovirus 
infections in humans because of the lack of definitive association with disease. 
 Colorado tick fever 
Colorado tick fever (CTF) virus, also known as Mountain tick fever or American 
mountain fever, is a viral disease caused by infection with the CTF virus. CTF is transmitte 
to humans most commonly by the bite of an infected adult wood tick, Dermacentor 
andersoni, CTF occurs primarily in the Rocky Mountain region of the western United 
States as well as the Canadian provinces of British Columbia and Alberta, in 1930. More 
than 90% of all CTF cases in the United States are reported from Colorado, Utah and 
Montana (169) . 
The initial symptoms of the disease often include fever, chills, headache, muscular, 
skeletal pain, and malaise. Other symptoms may include nausea, vomiting, stomach pain, 
light sensitivity and sore throat. In rare cases, patients experience illnesses of the central 
nervous system (CNS) ranging from mild to encephalitis with coma and death. CNS 
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illnesses commonly characterized by severe headache, sensory impairment, neck stiffness 
and light sensitivity. 
No specific treatment for CTF is available. Management of CTF includes treatment of 
fever and pain with analgesics and acetaminophen, along with standard infection control 
procedures. Patients infected with CTF should advise blood collection agencies of their 
illness prior to donation, due to the risk of transmitting CTF through blood transfusion (57). 
 
3. Flavivirus and Dengue 
 
3.1. Classification 
 
Dengue fever is cause by five closely related virus serotypes of the genus 
Flavivirus, family Flaviviridae; however, the differences between each serotype are 
sufficient to prevent epidemics of multiple serotypes (DENV1, 2, 3, 4, 5). Flaviviridae 
have single - stranded RNA of 9.6 - 12.3 kilobase in length with positive polarity that are 
monopartite and linear and a methylated nucleotide cap on the 5' end. The virus particles 
have spherical envelopes of about 40-60 nm in diameter (170). As other virus, the evidence 
for strain differences among DENVs was first detected serologically using antibodies made 
by inoculating laboratory animal (171). Later, nucleic acid sequencing allowed for the 
classification of DENV into genetically distinct groups or genotypes within each serotype 
(172). Various phylogenetic analysis based on complete E nucleotide or prtial E/ NS1 
(173)(174) indiated that DENV-1 are grouped in four genotypes: 1) genotype 1, 
representing strains from Southeast Asia, China, and East Africa; 2) genotype 2, 
representing strains from Thailand collected in the 1950s and 1960s; 3) genotype 3, 
representing sylvatic  strains collected in Malaysia; 4) genotype 4, representing strains 
from the West Pacific islands and Australia, and representing all strains collected in the 
America, West Africa and Asia (175)(176). 
Second, in DENV - 2, based on E nucleotide sequences of phylogenetic analysis, 
DENV - 2 comprises five genotypes: 1) the Asia genotype included are genotype 1 
representing strains from Vietnam, Thailand, Malaysia, Cambodia, and genotype 2 
representing strains from Vietnam, China, Taiwan, Sri Lanka and the Philipines; 2) the 
cosmopolitan genotype, representing strains in Australia, East and West Africa, the Pacific 
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and India ocean islands, the Indian Subcontinent and Middle East; 3) the American 
geotype is presenting strains from Latin American and older strain from Caribbean, the 
India subcontinent and Pacific Islands in the 1950s and 1960s; 4)  the  Southeast Asia and 
America genotype, representing strains from Thailand, Cambodia and Vietnam and strains 
collected  in  the Americas over last 30 years; and 5) the sylvatic genotype, representing 
strains collected from humans, mosquitoes in forest or sentinel monkey in West Afriac and 
Southeast Asia (177).  
Isolated DENV-3 based on prM/E nucleotide and then complete genome sequences 
(178) in to four genotypes are 1) genotype 1 is presenting from Indonexia, Malaysia, 
Phillipnes and recent isolates from South Pacific Islands; 2) genotype 2, from Vietam, 
Cambodia, Thailand and Bangladesh; 3) genotype 3, from India, Sri Lanka, Africa and 
Samoa, however, the complete genome phylogenetic analysis within this genotype 
includes the 1962 strainsfrom Thailand (179); and 4) Gennotype 4, from Puerto Rico, Latin 
and Central America. Sylvatic strains of DENV-3 are believed to exist in Malaysia based 
on the seroconversion of sentinel monkeys (176). 
DENV- 4 strains exhibitited greater sequence conservation than the other DENV 
serotypes (92%) and 96 -100% conservation in E protein amino acids. Currently,  DENV- 
4 phylogenies complete E gene sequences delineate four genotypes base on the E gene or 
complete genome sequence (180)(181) (182)(183)(184) are: 1) genotype 1, representing 
strains from Thailand, Cambodia, the Philippines, SriLanka, and Japan; 2) genotype 2, 
from Indonesia, Malaysia, Tahiti, the Caribbean and the Americas; 3) genotype 3, 
representing recently sampled Thailand strains, that are distinct from other Thailand strains 
(181); and 4) genotype 4 representing the sylvatic strains of DENV - 4 from Malaysia. 
The fifth and lastest addition to the existing serotypes of dengue viruses is DENV - 
5 which has been announced in Thailand, October, 2013 (185), is sylvatic strains. 
Phylogenetic evalution revealed that DENV - 5 is genetically similar to other four 
serotypes, thereby hinting to a common ancestral origine (186). 
 
3.2. Genetic evolution 
 
In DENV, genetic variability most obviously manifest in the existence of four (or 
five) antigenically distinct serotypes. The introduction of comparative gene sequence 
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analysis, it has been possible to dissect the genetic structure of DENV populations and to 
reveal the processes governing viral evolution (81)(187)(188). 
 
3.3. Vectors 
 
3.1.1 Aedes aegypti and Aedes albopictus 
 
The various serotype of the dengue virus transmitted to human through the bites of 
infected Aedes mosquitoes. The principal vector of DENV is the Ae. aegyti mosquito, an 
anthropophilic species that has adapted extremely well to the urban environment and is 
found both indoors and outdoors in close proximity to human dwelling and can complete 
their whole cycle life here, they prefer to feed during the day (189). Ae. aegypti is an 
efficient vector of DENV because of its preference for laying its eggs in artificial, rather 
natural container, bitting human, and remaining indoors, where it has acces to its favorite 
host (190). 
The Asian tiger mosquito, Ae. albopictus is a secondary of DENV in SEA, the 
Western Pacific, and increasing in Central and South America  (76), the Ae. albopictus 
mosquito appears to be following the same adaptation pattern as Ae. aegypti in becoming 
an increasing urban species. Compared to Ae. aegypti, which is the most important vector 
of Dengue, Ae. albopictus is a less competent vector of arboviruses, and the epidemics it 
causes are milder. However, Ae. albopictus is becoming an increasingly important vector 
because of its rapidly changing global distribution (191). Before1979, Ae. albopictus was 
found only in Asia and in the Western Pacific, but it has spread too much of the rest of the 
world in recent decades (76), spreading through the United state in 198 (192)(193)(194). A 
mutation increasing the fitness in Ae. albopictus was identified for another mosquito-borne 
virus, the Chikungunya virus, during an epidemic on La Réunion in 2005; a virus strain 
with the same mutation also caused an outbreak in north-eastern Italy  (195) (191) and 
recently in Caribbean (196)(197)(198). 
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3.1.2 Transmission cycle 
 
Sylvatic DENV cycle 
DENV exist in two separate cycles in nature, circulating in either non-human 
primates or humans. The endemic in humans today most likely evolved from non - human 
primate dengue viruses a few hundred years ago and have since established themselves as 
four distinct serotypes in human populations, causing periodic epidemics and severe 
disease (199) and principle on Aedes spp. as vector. The ancestral forms of DENV are 
believed to be viruses that circulate in forest habitats, presumably among nonhuman 
primates (173). There DENV sylvatic cycle have been demonstrated in Asia, where 
serological evidence as well as virus isolation suggest transmission of sylvatic strains of 
DEN-1, DEN-2, DEN-4 among  Macada and Presbytis monkeys vectored by Aedes niveus 
((200)(201). The Sylvatic DEN-2 in West Africa shown to circulate regularly between 
Erythrocebus monkeys and various sylvatic Aedes spp., such as Ae. taylori, Ae. furcifer, 
Ae. vitattus and Ae. luteocephalus (202) Rodhain, 1991 (203) and was isolated from 5 
humans in Eastern Senegal (Saluzzo et al., 1986; Zeller et al., 1992)(204) (205). All 
sylvatic isolates are generaltically distinct from all endemic isolates and are isolated 
evolutionarity (172)(206)(207). 
Endemic/epidemic DENV cycles 
Endemic / epidemic DENV circulated in both a sylvatic (enzootic) cycle invoving 
non - human primates with various species of Aedes mosquitoes including Ae. fucifer, Ae. 
luteocephalus and Ae. taylori, in a human cycle principlally vectored by Ae. aegypti and 
Ae. albopictus (208) (209). The efficiency of the endemic cycle is now completely 
independent both evolutionarily and ecologically from the ancestral, sylvatic cycles  (210). 
Time estimates for evolution of the endemic/ epidemic forms ranged from 100 to 1,500 
years ago. 
When a female Aedes bites a human for food, she injects saliva into wound where 
the anti - coagulants contained in her saliva facilitate feeding. The adult mosquitoes prefer 
to feed on human daylight hours (211), they prefers to stay indoors, do not travel great 
distance by themselves less than 200 meters. The pick of biting activity: early morning for 
2-3 hours after daybreak and in the afternoon for several hours before dark (190). Female 
mosquitoes have habit disrupting the feeding process at the slightest movement and tend to 
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feed multiple times, she can feed on several person during a single blood meal and may 
transmission DENV to multiple person in a short time (212). After a person has bitten by 
an infective mosquito, the virus suffer an incubation average period of 4 - 7 days (or 
maybe 3 to 14 days), after which the person onset of fever accompanied by a variety of 
nonspecific signs and symptoms and DENV may circulate in the peripheral blood for as 
long as 10 days. If other Ae. aegypti mosquitoes bite the patient during this febrile viraemic 
stage, those mosquitoes may become infected and subsequently transmit the virus to other 
uninfected persons, after an extrinsic incubation period of 4 to 12 days (213)(214). 
Maintenance of DENVand vertical transmission of DENV in mosquitoes 
Several factors can influence the dynamic of virus transmission, including 
environmental and climate factors, host - pathogen interactions and population 
immunological factor. In the most countries, dengue displays a seasonal pattern related to 
temperature and rainfall (215). Climate directly influences the biology of the vectors and 
thereby their abundance and distribution, this has rise the question of how the virus 
overwinters, or persist during dry and cold seasons. One possibility is that a population of 
infected mosquitoes could survive throughout the interim and introduce the virus during 
the next season. Aedes mosquitoes remain DENV infected and the longest lifespan 
recorded to date is 174 days, although a more typical survival rete is 1 - 2 weeks (72) 
(216). A second possibility is passge of the virus the next generation of the mosquitoes via 
survival in an infected egg. Vertical transmission (transovarial transmission) has been 
demonstrated in the laboratory and in the wild (217). The significance of vertical 
transmission for maintenance of the virus is not well understood (218) (219). Some 
evidence shows that Ae. albopictus mosqiuitoes are more efficient at vertical transmission 
than Ae. aegypti, which would make them a candidate for maintaining DENV during 
interepidemic period (220). Thus, vertical transmission of DENV in mosquitoes is 
possible, where or not the mechanism is truly transovatial or mediated by infection of the 
mature egg at the time of oviposition (72)(216).  Several research show that the 
asymptomatic case of dengue may be is silent transmission in humans by the reduced 
number of vectors maintains DENV circulation between epidemic season (221) 
(222)(223). 
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3.4. Dengue epidemiology 
 
3.4.1. History and origin of Dengue 
 
The origins of the word dengue are not clear, but one theory is that it is derived from 
the Swahili phrase "Ka-dinga pepo", meaning "cramp-like seizure caused by an evil 
spirit". The Swahili word "dinga" may possibly have its origin in the Spanish word "dengue" 
meaning fastidious or careful, which would describe the gait of a person suffering the bone 
pain of dengue fever. The earliest know clinical descriptions of a dengue like illnesses are 
from Chinese encyclopedia written during the Chin Dynasty. [Common Era (CE) 265– 420 
AD], Tang Dynasty ( CE 610) and Northern Sung Dynasty (CE 992) (190). These reports 
described a disease called “water poison” cause by it is association with water - associated 
with flying insects. The next report of a similar appear almost seven countries later, 
describing an acute illness with prolong convalescence in the French West Indies and 
Panama during q635 and 1699 respectively (173). A century later, 1779 - 1788 the first 
reports of a possible dengue pandemic were described in Batavia (nowadays is Jkarta) 
 (224), Cairo (225),  Philadelphia  (174),  and Cadiz and Seville, Spain (225). 
The viral etiology and the transmission by mosquitoes deciphered in the 20th 
century. The role of Ae. aegypti in transmission of dengue was confirmed in 1926 by the 
extensive and well - controlled experiments of Siler (226), followed by the incrimination 
of Ae. albopictus in 1931 (227). In 1943, the scientists of Japan was isolated dengue 
serotype 1 in Nagasaki, it is Mochizuki strain as well as other DENV-1 strain from 
affected patients in Japan (228). Then, Sabin isolated both DENV-1 (Hawaii strain) and 
DENV- 2 (New Guinea C strain)  from US Soldiers in 1944 (229) (230). The first well 
documented outbreak of dengue haemorrhagic fever took place in Manila in 1953/1954 
(231), and was followed by a larger outbreak in Bangkok in 1958 (232). The viruses 
isolated from patient during the 1956 in Phillipines epidemic were members o the DENV-3 
(H87 strain) and DENV-4 (H241 strain) (232). Since that time, DHF/DSS have become 
endemic in all countries in Southeast Asia with dramatic increase in case number and 
DENV considered an ‘emerging’ disease. At the same time the geographic range of 
DHF/DSS has expanded considerably, and since 1950s, the incidence of DHF/DSS has 
increased over 30 fold (219) (3). Nowadays, dengue spread to more than 140 countries in 
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Asia, the Pacific, the Americas, Africa, and the Caribbean. Estimated that there are 390 
million dengue infections per year, of which 96 million manifest apparently with any level 
of disease severity by using cartographic approaches (6). 
Until now, it is not clear where dengue originated from region. Gaunt et al, 2001 
suggested an African origin, principally because many of the most divergent mosquitoes - 
born flaviviruses circulate exclusively in Africa and often infect primates, implying that 
DENV has an origin in Africa. To go further, Ae. aegypti is believed to have originated in 
Africa, although this species is only likely to have been adopted as a vector for human 
transmission in the relatively recent past. Conversely, ecological and phylogenetic 
evidence argues for an Asian origin of Dengue (233)(234) (235)(236) (210) (237)(238). 
 
3.4.2. Global burden 
 
Dengue is the most rapidly spreading mosquito - borne viral disease in the world. 
In the last 50 years, incidence has increased 30 fold with increasing geographic expansion 
to new countries and, in the present decade, from urban to rural settings in tropical and 
subtropical countries in Southeast Asia, the Pacific, the Americas, Africa, European and 
the Caribbean. (Figue 14)  
 
Figure 14: Endemic or potentially endemic to 144 countries of Dengue transmission, 
2015 (23) 
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Worldwide, approximately 2.5 billion people live in dengue endemic countries and 
annually, an estimated 50 million dengue infections occur, up to 500,000 case of the life- 
threatening dengue DHF/DSS, mainly among children, with the case fatality rate 
exceeding 5% in some area (219) (239). The average number of DF/DHF cases reported to 
the WHO has increased dramatically (240). For the period 2000 - 2004, the annual average 
was 923,896 cases, almost double the figure of 429,848 cases that reported for the period 
1990 - 1999.  Cases across the Americas, South-east Asia and Western Pacific have 
exceeded 1.2 million cases in 2008 and over 2.2 million in 2010 (based on official data 
submitted by Member States). Recently the number of reported cases has continued to 
increase (240). (See figure 15).  
 
 
Figure 15: Worldwide. Dengue, cases. 
 
In 2010, 1.6 million cases of dengue were reported in the Americas alone, of which 
49 000 cases were severe dengue (241). 
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Figure 16: Average annual number of DF/DHF case reported to WHO, and average of 
countries reporting dengue, 1955-2007 (218) (3) . 
 
Before 1970, only nine countries had experienced severe dengue epidemics. In 
2001, a record 69 countries reported dengue activity to WHO (1). The disease is now 
endemic in countries of Africa, the Americas, the Eastern Mediterranean, South East Asia 
and the Western Pacific. South East Asia and the Western Pacific regions are the most 
seriously affected (241). 
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Figure 17: The change in distribution of dengue serotype. The figure shows the 
distribution in 1970 (A) and 2004(B) (240). 
 
All four DENV serotypes are now circulating in Asia, Africa and the Americas, a 
dramatically different scenario from that which prevailed 20 - 30 years ago (Figure 17), 
only DENV 5 was in Thailand. By the 1980s, the American region was experiment major 
epidemic of dengue in countries that have been free of the disease for 35 to 130 years 
(190). New DENV strains and serotypes were introduced DENV-1 in 1977, a new train of 
DENV-2 in 1981, DENV-4 in 1981, and a new strain of DENV-3 in 1994. Moreover, 
many countries of the region evolved from nonendemicity or hypoendemicity (one 
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serotype present) to hyperendemicity (multiple serotype present), and epidemic DHF 
emerged, much as it had in Southeast Asia 25 years earlier (190). 
Epidemiology trend in several regions of the world 
Epidemiology trend in the Pacific region 
Dengue has been described in the Pacific region for over 100 years  (242). Over the 
past three decades, dengue fever has affected more and more countries in Pacific region 
(65) (243). In the World War II, dengue virus was introduced throughout Southeast Asia 
and Pacific Islands, Japan (244). During the 1990s, more than 1 million cases of dengue 
reported in weastern Pacific region. The Philippines, Malaysia, Cook Islands, French 
Polynesia, New Guinea, and Australia (72) (190) all reported cases early in the decade. In 
1998 and 1999, there were 356,554 and 64,066 case of DF/ DHF with 1470 and 112 deaths 
(245). Dengue virus continues to circulate throughout the Pacific region and incidence of 
DHF may increase despite many of the inlands’geographic isolation, due to the ease 
international travel and global communities’desire for access to tropical settings. 
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Figure 18: Western Pacific region. Dengue cases (A), deaths (B). 
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 Epidemiology trend in Southeast Asia 
 
Dengue haemorrhagic fever (DHF), a potentially lethal complication of dengue 
fever, first recognized in the 1950s during dengue epidemics in the Philippines and 
Thailand. Today DHF affects most Asian countries and has become a leading cause of 
hospitalization and death among children in the region. In 1998, worldwide dengue 
epidemics accounted for 1.3 million cases of DF and DHF with 3442 deaths and Southeast 
Asia reported 218,859 dengue cases and 2075 deaths (65). Since 2000, epidemic dengue 
has spread to new areas and has increased in the already affected areas of the region. The 
main reason is by the rapid demographic increase, migration, anarchic urbanization, 
transportation, etc. The endemic transmission cycle of Dengue in SEA differs from that 
American and characterized by transmission activity all year around with peak during rainy 
season. Although all five serotypes are now found in circulation in Asia and four serotypes 
in Americas, the severe form of dengue is more than 17 fold higher in Asia. The most 
affected are group is between 5 to 9 years. However, in Singapore and Thailand, adult are 
affected with moderate clinical symptoms. Between 2001 and 2008, 1020333 cases were 
reported in Cambodia, Philippines, Vietnam and Malaysia with the high numbers of deaths 
(246) (3) 
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Figure 19: Southeast Asian region. Dengue, cases (A) deaths (B). 
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Vietnam 
 
http://www.unicef.org/infobycountry/vietnam.html 
 
Vietnam is located in South-Eastern 
Asia, bordering the Gulf of Thailand, 
Gulf of Tonkin, and South China 
Sea, China, Laos, and Cambodia. The 
climate is tropical in south; 
monsoonal in north with 4 seasons 
are spring, summer, autumn and 
winter. The environment: Slash-and-
burn agricultural practices contribute 
to deforestation and soil degradation.  
Water pollution and over fishing 
threaten marine life.  Groundwater 
contamination limits potable water 
supply.  Growing industrialization 
(and population migration) is rapidly 
in Hanoi and Ho Chi Minh City. The 
population growth rate is estimated 
1.077% and the age structure is 
25.2% 0-14 years; 69.3% 15-64 
years; 5.5% 65 years and over. The 
Vietnamese population estimated 
93.386.630 as of July 1, 2015 (247).  
Figure 20: Vietnam map. 
 
In Viet Nam, historical evidence suggests that outbreaks of dengue with four fatal 
case occurred during 1895 to 1909. Dengue was the first recorded case occurring in 1959 
in the North (Ha noi and Hai phong), and first reported in 1960 in the South 
(approximately 50 fatal cases of DHF reported from Cai Be). Since then, dengue has 
become an endemics, the rate of morbidity per 100,000 populations has been increasing 
steadily from 32 in the year 2000 to 120 in 2009, with 105,370 cases reported in the whole 
country. In the southern regional morbidity is as high as 214.5 cases per 100,000 
 
47 
populations. July and October are peak months of dengue activity. In 2009, over 70% of all 
dengue cases and 85% of all deaths due to dengue in this period occurred in the southern 
provinces, 80% of all dengue deaths occured in children under the age of 15 years (248). 
 
 
Figure 21: Distribution of DF/DHF in Vietnam in 2009. 
 
From 1 Jan - 19 Jun 2011, Vietnam reported 18 432 cases with 15 deaths, CFR 
0.08%, 13 898 cases with 17 deaths in 2010 for the same period. High activity 
reported in the southern areas of Vietnam. During 5 months from Jan - May 2011, of 
the 15 634 cases with 12 deaths, 13 999 cases with 11 deaths occurred in the 20 
provinces of southern of Vietnam (248). Up to November 2011, Vietnam was reported 
oubreaks occur with 49,011 cases, 46 fatal. Outbreaks to September in 2012 were 
reported 51,000 cases, 42 fatal, in 2013 outbreaks to August reported 25, 300 cases, 16 
fatal (249).    
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Figure 22: Vietnam. Dengue / DHF, cases (A) and death (B) 
Despite the existence of a National dengue control Program since 1998, dengue 
remains a major health problem in Vietnam. Over the past 15 years, the number of 
DENV cases has been increasing. 
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 Epidemiology trend Europe, Mediterranean, and the Middle East 
Between 1784 and 1788, in Cadiz and Seville, Spain, dengue was described in 
clinical illnesses. Disease occurred throughout the 1980s in the Middle East regions of the 
Suez in 1824, the Arabian coast in 1835, in Yemen from 1870 - 1873, and in Israrel 1889 - 
1990 (250). From 1927 - 1928, an extensive dengue outbreak occurred in Greece with 
more than one million case (251) (252) Retrospective serology investigations clearly 
implicate DENV-1 and possibly DENV-2 as causative agents (253) (254). 
Every year, numerous dengue cases are imported by travelers and expatriates, 
almost infection are acquired in the hyperendemic areas of Latin America and Southeast 
Asia (255). In 2008, 116 cases were reported, mostly in European travelers, 43% had 
travelled to Europe from South East Asia, 14% from Latin Ameria, 12 % from the Indian 
subcontinent, 11 % from the Caribbean and 4% from Africa, reflecting worldwide dengue 
activity and travel prefernces (256). Recently, first autochthonic DENV infections have 
been describle in France (257) and in Croatia (258).  
In 2009 and the first half of 2010, outbreaks of Dengue fever and haemorrhagic 
fever were reported from Saudi Arabia, Sudan and Yemen. So far outbreaks concentrated 
in the cities and urban areas along the Red Sea and Arabian Sea coasts and Pakistan (259). 
 
 
Figure 23: European Union, Dengue cases 
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Epidemiology trend in the Americas 
Mainly during the 1960s and early 1970s in American, dengue epidemics was 
characterized by the circulation of single serotype at any given time within a region. From 
1977 - 1978 in Cuba occurred major epidemic of dengue fever caused by the DENV-1 
serotype. This trend was changed following the introduction of Southeast Asia strain of 
DENV-2 into Cuba, probably from Vietnam in 1981 (260) (261), followed by an increase 
in the severity, during Cuban epidemic in 1981 (262) (263), 98% - 99% of the case 
infections. In 1989, an epidemic of DHF occurred in Venezuela, followed by a epidemic in 
Cuba in 1997 and both epidemic caused by the DENV-2 serotype (264). In 2007, 
according to Emerging and Reemerging Infectious Diseases Region of the Americas, in the 
period from 2001 - 2006 have 3,419,999 cases of dengue were reported in Americas, 
including 79,664 cases of dengue hemorrhagic and 982 deaths, with a case fatality rate of 
1.2%, and the circulation of all four serotypes (DENV1, 2, 3, 4) which increase the risk for 
the appearance of the most serious forms of the disease (265)(266). 
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Figure 24: Americas region. DHF, cases (A) and deaths (B). 
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Epidemiology trend in Africa 
Although the history of dengue in Africa is poorly documented, it is know that 
dengue has been on continent since the start of the 20th century. During the surveillance 
program started in 1964, DENV - 1 and DENV- 2 were isolated at the Virus Reseach 
Laboratory at the University of the Ibaden, Nigeria. DENV-1, DENV-2, are outbreaks in 
Comoros in various years in 1948, 1984, and 1993 (267). In 1983, the first evidence of 
autochthonous DENV - 4 transmission in Senegal was detected (268), and DENV - 3 
transmission was identified in Mozambique in 1984 (269) (270)(271). 
Despite poor surveillance for dengue in Africa, it is clear that epidemic dengue 
fever caused by all four dengue serotypes has increased dramatically since 1980, with most 
epidemics occurring in eastern Africa, and smaller extent in western Africa, though this 
situation may be changing in 2008 (218). 
 
3.5. Diagnosis 
 
Dengue has a wide spectrum of clinical presentations, often unpredictable clinical 
evolution and outcome (3). In clinical spectrum ranges from unapparent, may be mild 
febrile illness, non - severe to severe and fatal haemorrhagic diseases or vascular shock.  
Following  WHO “Dengue  Guideline for Diagnosis, Treatment, prevention and Control 
publish”, in 2009 while most patient recover following a self  limiting non  severe clinical 
course, estimated 1% proportion progress to severe disease, mostly characacterized by 
palasma leakage with or without haemorrhagic. 
 
3.5.1. Clasification in clinical 
 
In 1999, according to the WHO guideline dengue manifest in three forms are DF, 
DHF and undifferentiated fever, with plasma leakage that may lead to hypovolemic shock, 
DSS. This classification was repeatedly evaluation and could mistakenly classify dengue 
cases because it was often found inappropriate for clinical management of dengue (272). In 
2008, a WHO expert group was organized and proposed a new classification range based 
on dengue disease entity which manifest in a broad spectrum of symptoms and often with 
unpredictable evolution and outcome. The important of this classification is early 
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recognition and understanding of the clinical problem during the different phases of the 
disease, leading to a rational to case management and a good clinical outcome. In 2009, a 
new classification of dengue proposed by WHO Tropcal Disease Reaserch (TDR) was 
classifies dengue into dengue, dengue with warning signs (DW) and severe dengue (SD). 
For practical reasons, the group of non - severe dengue divided in two subgroups: patients 
with warning signs and those without (see figure 25). 
 
Figure 25: Dengue case classification and levels of severity (219) 
 
Current WHO classification is recommended for continuing use because the newly 
suggested TDR classification creates about 2 times the work - load to health care 
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personnel. More than 90% of DHF defined by WHO case definition are dengue confirmed. 
However, current WHO classification needs to be modified for more simple and friendly 
use. The suggested modification is to address plasma leakage as the major criteria. Unusual 
dengue is proposed to be added to the current WHO classification to cover those patients 
who do not fit with the current WHO classification (273). 
 
3.5.2. Disease course 
 
Dengue infection is a systemic and dynamic disease. It has a wide clinical spectrum 
that includes severe, non - severe clinical manifestation. After the incubation period, the 
illness begins abruptly and followed by the three phases: febrile, critical, and recovery (3). 
(Figure 26). 
 
 
 
Figure 26: The Course of Dengue disease (WHO, 2009) 
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Febrile phase 
Patients typically develop high-grade fever suddenly. This acute febrile phase 
usually lasts 2 - 7 days and is often accompanied by facial flushing, skin erythema, 
generalized body ache, myalgia, arthralgia and headache (274). Some patients may have 
sore throat, injected pharynx and conjunctival injection. Anorexia, nausea and vomiting are 
common. It can be difficult to distinguish dengue clinically from non-dengue febrile 
diseases in the early febrile phase. A positive tourniquet test in this phase increases the 
probability of dengue (275) (276). In addition, these clinical features are indistinguishable 
between severe and non severe dengue cases. Therefore monitoring for warning signs and 
other clinical parameters is crucial to recognizing progression to the critical phase. 
Mild haemorrhagic manifestations like petechiae and mucosal membrane bleeding 
(e.g. nose and gums) may be seen (277) (276). Massive vaginal bleeding in women of 
childbearing age and gastrointestinal bleeding may occur during this phase but is not 
common (278). The liver is often enlarged and tender after a few days of fever (276). The 
earliest abnormality in the full blood count is a progressive decrease in total white cell 
count, which should alert the physician to a high probability of dengue. 
Critical phase 
Around the time of defervescence, usually on days 3 - 7 of illness, the temperature 
drops to 37.5 - 380 C or less, an increase in capillary permeability in parallel with 
increasing haematocrit levels may occur (279) (280). This is the beginning of the critical 
phase. The period of clinically significant plasma leakage usually lasts 24 - 48 hours. 
Progressive leukopenia followed by a rapid decrease in platelet count usually 
precedes plasma leakage (276). At this point patients without an increase in capillary 
permeability will improve, while those with increased capillary permeability may become 
worse as a result of lost plasma volume. The degree of plasma leakage varies. Pleural 
effusion and ascites may be clinically detectable depending on the degree of plasma 
leakage and the volume of fluid therapy. Hence, chest x-ray and abdominal ultrasound can 
be useful tools for diagnosis. The degree of increase above the baseline haematocrit often 
reflects the severity of plasma leakage. 
Shock occurs when a critical volume of plasma is lost through leakage. It is often 
preceded by warning signs. The body temperature may be subnormal when shock occurs. 
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Recovery phase 
In critical phase, if the patient can survives the 24 - 48 hours, a gradual 
reabsorption of extravascular compartment fluid takes place in the following 48 - 72 hours. 
General well being improves, appetite returns, gastrointestinal symptoms abate, 
haemodynamic status stabilizes and diuresis ensues. Some patients may have a rash of 
“isles of white in the sea of red” (281). May be some patient have experience generalized 
pruritus, bradycardia and electrocardiographic changes. 
Due to the dilutional effect of reabsorbed fluid the haematocrit stabilizes or may be 
lower. White blood cell count usually starts to rise soon after defervescence but the 
recovery of platelet count is typically later than that of white blood cell count. 
Severe dengue 
Severe dengue is defined by one or more of the following this symptom: plasma 
leakage that may lead to shock (dengue shock) and/or fluid accumulation, with or without 
respiratory distress, and/or severe bleeding, and/or severe organ impairment. 
The patient is considered to have shock if the pulse pressure (i.e. the difference 
between the systolic and diastolic pressures) is ≤ 20 mm Hg in children or has signs of 
poor capillary perfusion (cold extremities, delayed capillary refill, or rapid pulse rate). 
Hypotension is usually associated with prolonged shock which is often complicated 
by major bleeding, severe organ impairment such as severe hepatitis, encephalitis or 
myocarditis, metabolic acidosis and disseminated intravascular coagulations, this is turn 
leads to severe haemorrhage causing the haemocrit to decrease in severe shock (3). 
 
3.5.3. Laboratory diagnosis 
 
Efficient and accurate diagnosis of dengue is of primary importance for clinical 
care. Laboratory diagnosistic method has been develope to support patient management 
and disease control. The purpose of diagnosis method depends for choice of which the 
testing is done (i.e. surveillance activities, clinical trials, vaccine development, outbreak 
control, pathogenesis). Laboratory diagnosis methods for confirming dengue infection may 
involve detection of the virus, antigens or antibodies, viral nucleic acid, or a combination 
of these techniques. (Figure 27). 
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Figure 27: Comparison of diagnostic tests according to their accessibility and 
confidence (282). 
 
Direct diagnosis methods 
After the onset of illness, 4 - 5 days during the febrile period, dengue infection 
maybe diagnosed by virus isolation in cell culture, by detection of viral RNA by nucleic 
acid amplification tests, by detection of viral antigens by ELISA or rapid tests. 
Virus detection 
Dengue virus can be isolated by the inoculation of a clinical specimen such as 
serum, plasma or cerebro - spinal fluid, for virus isolation in cell culture, it is important to 
keep blood samples cooled or frozen to preserve the viability of the virus during transport 
from the patient to the laboratory. In the cell culture in to mosquitoes are using mosquito 
cell lines such as C6/36 coloned from Aedes albopitus or mammalian cell lines such as 
Vero and NHEK cells or intracerebral inoculation of suckling mice. For virus identification 
carried out the immunofluoresen assay using flavivirus group - reactive and serotype 
specific monoclonal antibodies (mAbs). The isolation and identifiction of dengue in cell 
cultures usually takes 1 - 2 weeks. 
Viral antigen detection 
Enzyme like linked immunosorbent assay (ELISA) and rapid 
immunochromographic assays that taget NS1 protein have show that antigen can be 
detected in patients with dengue infection up to 9 days after the onset of illness. Many 
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studies investigated utility of NS1 detection as a diagnostic tool during acute phase of a 
dengue infection and showed a good sensitivity (63-94%), and excellent specificity (98.4-
100%) (283)(284)(285). The rapid dengue antigen detection test can be used in field 
settings (i.e point of care diagnotic test) and provide results in less than one hour 
(286)(287)(288). 
Viral RNA detection 
Nucleic acid detection assays with excellent performance characteristics identify 
dengue RNA. Since the 1990s, several reverse transcriptase polymerase chain reaction 
(RT-PCR) assays have been developed. They offer better sensitivity compared to virus 
isolation with a much more rapid turnaround time. In situ RT-PCR offers the ability to 
detect dengue RNA in paraffin - embedded tissues. The utilize a nested RT-PCR assay, 
using universal dengue primers targeting the C/prM region of the genome for an initial 
reverse transcription and amplification step, followed by a nested PCR amplification that is 
serotype -specific. 
Up to date, the real time RT - PCR assay is a one step assay system used to 
quantitative viral RNA and using prime pairs (289), and probes that are specific to each 
dengue serotype, use of a fluorescent probe enables the detection of the reaction products 
in real time. 
These methods demonstrate a high specificity and sensitivity, it reduces the 
possibility of cross - contamination, allow the determination of viral load and gives result 
within 24h. 
Indirect diagnosis methods 
After 3 - 5 days onset of illness, Dengue and antigens disappear from the blood 
coincidently immune host produces a primary response of antibody. Dengue infection in a 
non-previously immune host produces a primary response of antibodies characterized by a 
slow and low titer antibody response. 
IgM ELISA 
The IgM antibody - capture enzyme linked immunosorbent assay (MAC-ELISA) 
based on detecting IgM in serum using anti - human IgM that is bound to the solid phase. 
IgM detection is not useful for dengue serotype determination due to the cross - reactivity 
of the antibody observed even during primary infection, and is not specific in countries 
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with circulation of other flaviviruses as JEV or YFV in most case due to the presence of 
cross - reactive antigen shared by flaviviruses. 
The detection of dengue - specific IgM is useful diagnostic and surveillance tool. 
The sensitivity ans specificity of IgM based assay are strong influenced by the quanlity of 
the antigen used is virus - infected cell culture supernatants or suckling mouse brain 
prepatations (282) (290). 
IgG ELISA 
The  IgG  ELISA  is  used  for  the  detection  of  recent  or  past  dengue infections 
 (if paired sera are collected within the correct time frame). This assay uses the same 
antigent E/M - specific capture (GAC) as the MAC - ELISA allows detection of IgG 
antibodies over a period of 10 months after the infection. IgG antibodies are life long as 
measured by E/M antigen coated in direct IgG ELISA. In general, IgG ELISA lacks of 
specific within the flavivirus serocomplex groups. Following viral infections, newly 
produced antibodies are less avid than antibodies produced months or years after infection. 
IgM/ IgG ratio 
A dengue virus E/M protein - specific IgM/IgG ratio used to distinguish primary 
from secondary dengue virus infections. IgM capture and IgG capture ELISAs are the most 
common assays for this purpose. In some laboratories, dengue infection is defined as 
primary if the IgM/IgG OD ratio is greater than 1.2 (using patient’s sera at 1/100 dilution) 
or 1.4 (using patient’s sera at 1/20 dilutions). The infection is secondary if the ratio is less 
than 1.2 or 1.4. This algorithm also been adopted by some commercial vendors. However, 
ratios may vary between laboratories, thus indicating the need for better standardization of 
test performance (291)(292). 
Western- Blot 
Western blot is the most widely used technique for detecting specific proteins in 
complex samples like cell lysates, cell culture supernatants or body fluids. By offering a 
unique combination of specific immunodetection and size based separation, western 
blotting gives reliable, convenient, high - quality data, with a specific primary antibody. 
The relative amounts of the protein present in different samples, including: 1) Samples are 
prepared from tissues or cells that are homogenized in a buffer that protects the protein of 
interest from degradation; 2) The sample is separated using SDS-PAGE and then 
transferred to a nitrocellulose membrane for detection; 3) The membrane is incubated with 
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a generic protein (such as milk proteins) to bind to any remaining sticky places on the 
membrane. A primary antibody is then added to the solution which is able to bind to its 
specific protein; 4) A secondary antibody - enzyme conjugate, which recognizes the 
primary antibody is added to find locations where the primary antibody bound. Detect by 
enhanced chemiluminescent, the light is then detected by photographic film, and more 
recently by charge couple devide (CCD) cameras which captures a digital image of the 
western blot. 
 
3.5.4. Treatment and prevention 
 
Treatment 
At present, there is no specific treatment for dengue fever. For DHF, medical care 
by physicians and nurses experienced with the effects and progression of the complicating 
haemorrhagic fever can frequently save lives - decreasing mortality rates from more than 
20% to less than 1%. Maintenance of the patient's circulating fluid volume is the central 
feature of DHF care. At present, the only method of controlling or preventing dengue virus 
transmission is to combat the vector mosquitoes (293). 
Prevention 
Preventing or reducing dengue virus is transmission depends entirely on control of 
the mosquito vectors or interruption of human - vector contact. Activities to prevent 
transmission should target the main vector is Ae.  aegypti and Ae. albopictus mosquito. 
Integrate vector management (IVM) is the strategic approach to vector control promoted 
by WHO, 1991. Defined as” a rational decision - making process for the optimal use of 
resources for vector control” five keys of IVM considers in the management process are: 1) 
The promotion development policies, establishment legislative controls for public health; 
and the empowerment of communities; 2) The collaboration within the health sector and 
with other sectors in the programme managers the control of vector-borne diseases; 3) An 
integarated approach to disease control of non - chemical and chemical vector control 
methods; and integration with other disease control measures; 4) Routine monitoring and 
evaluation based on adaptation of strategies and interventions to local vector ecology, 
epidemiology and resources, research; 5) IVM capacity building include infrastructure, 
financial and human. 
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Historically, efforts to control dengue vectors in the WHO Region of the Americas 
resulted in the elimination of Aedes populations from much of the neotropics by the 1970s. 
However, reintroduction followed, leading to the re - establishment of vector populations. 
Today, the main target of the most programmes is to reduce the densities of vector 
populations as much as possible and maintain them at low levels. Where feasible, efforts 
may also be made to reduce the longevity of adult mosquito by the use of insecticidal 
methods in order to lessen the risk of virus transmission. 
 
 
 
Figure 28: Dengue research and training supported and encouraged by the UNICEF-
UNDP-World Bank-WHO. Special Programme for Research and Training in Tropical 
Diseases or the Initiative for Vaccine Research. 
Vaccines 
Because dengue virus is caused by five serologicallys related but distinct viruses, 
an effective dengue vaccine needs to induce a protective immune response against all four 
viruses simultaneously. Unlike other flaviviruses such as JEV, YFV and tick - born 
encephalitis virus, vaccine for dengue is no licensed exists. To the development of a 
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successful DENV vaccine is difficulties cause by reasons: 1) The need to develop a 
separate vaccine for each DENV serotype; 2) The risk of inducing enhanced disease upon 
subsequent natural infection if antibody to one or more serotype (294); 3) the lack of 
suitable animal model that reproduce human disease and can be used to evaluate candidate 
vaccines; and 4) is not fully understood  about the lack of validated correlate of protection 
since the mechanism of protective immunity against DENV infection (3). Therefore, in the 
development of a dengue vaccine, an effective vaccine must induce long lasting and 
protective immunity against all four DENV serotypes (295). Despites these many above 
mentioned challenges, DENV vaccine development have made great strides in recent 
decades. 
Nowadays, the clinical evaluation of candidate vaccines for dengue has several 
unique aspects, some of which related to the obstacles. The candidate vaccines that have 
been most extensively evaluated and are most advanced in development are live attenuated 
DENV vaccines from Sanofi Pasteur. The tetravalent dengue vaccine (TV) candidate 
utilizes the YFV (17) backbone with DENV prM and E genes from each DENV type 
replacing those of YFV. Pre - clinical studies demonstrated genetic and phenotypic 
stability, no hepatotropism, less neurovirulence than YF 17D, and failure to infect orally 
fed mosquitoes (296)(297)(298). 
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Table 2: Summarize of current dengue vaccines (299) (300). 
 
Note:  WRAI is Walter Reed Army Institute of Reseache 
GSK is GlaxoSmith- Kline 
 
3.5.5. DHF immunopathogenesis 
 
3.5.5.1. Dengue pathogenesis 
 
The understood about mechanisms leading to the severe manifestation of DENV 
infections are still not completely clear, however they are likely to be multifactorial (5), 
because no other animals develop symptoms of disease, and research, therefore, has been 
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limited to studies involving patients (301). The genetic back ground of the human host or 
other underlying diseases have been hypothesized to increase disease pathogenesis 
(302)(303)(304). Upon inoculation of DENV in the dermis, Langerhans cells and 
keratinocytes will primarily be infected. DENV subsequencetly spreads via the blood 
(primary viraemia) and infects tissue macrophages in few organs, especially the 
macrophages in the spleen. The replication efficiency of DENV in dendritic cells, 
monocytes, and macrophages (305)(306), as well as its tropism for and replication 
efficiency in endothelial cell, bone marrow stromal cells and live cells, collectively 
determine the viral load measured in blood. This viral load represents an important risk 
factor for development of severe disease. Infected cells die predominantly through 
apoptosis and to lesser extent through necrosis. Necrosis results in release of toxic 
products, which activate the coagulation and fibrinolytic systems. Depending on the extent 
of infection of bone marrow stromal cells and the levels of IL-6, IL-10, and IL-18, 
haematopoiesis is suppressed, resulting in thrombocytopenia. Platelets interact closely with 
endothelial cells, and a normal number of functioning platelets is necessary to maintain 
vascular stability. A high viral load in blood and possibly viral tropism for endothelial 
cells, severe thrombocytopenia, and platelet dysfunction may result increased capillary 
fragility, clinically manifested as bleeding symptoms which is characteristic of DHF (307). 
The infection stimulates development of specific antibody and cellular immune response to 
DENV at the same time. When IgM antibodies that cross-react with endothelial cells, 
platelets, and plasmin are produced, resulting in increased vascular permeability and 
coagulopathy is amplified. Beside, enhancing IgG antibodies bind heterologous virus 
during secondary infection and enhance infection of antigen presenting cells (APCs) and 
thereby contribute to the increased viral load that is seen during secondary viraemia in 
some patients. Furthermore, a high viral load over stimulates both low and high activity 
cross - reactive T cells. In the context of certain HLA haplotypes, cross - reactive T cells 
produce high levels of proinflammatory cytokines and other mediators. Ultimately, these 
high levels of soluble factors, many of which still remain to be identified, induce changes 
in endothelial cells leading to the coagulopathy and plasma leakage characteristic of 
Dengue shock syndrome. 
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3.5.5.2 Dengue risk factor 
 
DENV tropism 
Animal models of DENV disease have been very difficult to develop because of the 
virus’s specificity for infection and replication in certain human cells. Cell and tissue 
tropism of DENV may have a major impact on the outcome of DENV infections. In vitro 
data and autopsy studies suggest that three organ systems play an important role in the 
pathogensis of DHF/ DSS: 1) the cell of immune system such as immature Langerhans 
cells, keratinocytes in epidermis and dermis (308), and in Lymph nodes such as monocytes 
and macrophages; 2) the liver (hepatocytes and Kupffer cells) resulting in viral induced 
apoptosis and necrosis (5) and 3) endothelial cell specifically the microvessel in dermal 
papillae (309). The tropism of DENV for cells of these systems and the corresponding 
pathological effects of DENV infection of these systems contribute to the pathogenesis of 
DHF. 
Virulence 
According to the virus virulence hypothesis, certain DENV strains are responsible 
for more severe disease. DENV serotypes can be further classified into different genotypes 
on the basic of nucleotide variations. Viral genetic differences have been associated with 
differences in virulence  (310) (311)(312) (313). 
The most importance evidence of DENV virulence was observed in the Americas 
during the first outbreak of DHF occurred in 1981 after the introduction of the possibly 
more virulent DENV-2 Southeast Asian genotype, as the original American genotype 
already present was only associated with DF (314) (315). Although DHF occurs more 
frequently in secondary infection than in primary infection, however DHF also occurs in 
primary. This suggests that virulence of virus strains may contribute to the development of 
DHF (316)(311) (317). A study of Tuiskunen et al., 2011a showed that DENV isolation 
from patient with different degrees of severity could be characterized phenotypically and 
genetically in cell culture and in BALB/c mice  (318) (107) (317). The result revealed that 
a virus isolated from a DSS patient showed unique features characterized by a lower level 
of replication in mammalian cells and extensive apoptosis in mosquito cells compared to 
those isolated from DHF patients (318) (319), while in mice, a virus isolate derived from a 
DSS patient persisted longer in vivo with extensive neuroinvasion in contrast to other 
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DENV-1 isolates that originated from milder human cases (317), genomic characterization 
of the three clinical isolates identified six amino acid substitutions unique for the DSS 
isolates that were located both in structural genes (M and E) and non structural genes 
(NS1, NS3 and NS5). 
It has also been proposed that intra epidemic evolution of the circulating DENV 
might be responsible for increased severity of disease and more severe of disease 
manifestation and case fatality rates were observed toward the end of epidemic (320)(321). 
This phenomenon suggested that circulating DENV might have become more virulent 
through passage in hosts during the epidemic. In addition, epidemic with high incidence of 
DHF have been link to primary infection with DENV-1 followed by infection with DENV-
2 or DENV-3 (322) (323). Therefore, in studying DENV virulence, both host and viral 
factors should be considered. 
Activation of complement system 
The complement system is one of the main humoral components of the innate 
immunity and interacts closely with the hemostatic system to provide the first line of 
defense against pathogens (5). Activation of complement is another important in the 
clinical manifestation in DHF, it was reported that the level of capside protein (C3a and 
C5a), complement activation products, are correlated with the severity of DHF. When 
plasma leakage becomes most apparent and decreased in patients with DSS due to an 
accelerated consumption the level of C3a and C5a reached the peak at the time of 
defervescence  (324) (325). The pre - existing cross reactive antibody, high levels of 
secreted NS, immune complexes were implied in mediating complement activation 
through classical and alternative pathways (324) (326). 
Transient autoimmunity 
The presence of serum antibodies specific to NS1 also has been to correlate with 
disease severity (327)(328). Antibodies produced during a DENV infection have been 
shown to cross - react with some self - antigens, so it is not clear if production of these 
antibodies is associated with secondary DENV infection (329). Cross- reaction of anti NS1 
with cell of the liver, EC, and platelets have been observed (330) (331) (332). Anti - NS1 
antibodies specific to cross-react with human and mouse platelets leading to transient 
thrombocytopenia and hemorrhage in mice (333) and with EC causing cells apoptosis 
(330). It is not clear yet why the autoimmune phenomenon observed in some DENV 
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infected patients does not persist, thought it is likely that the cross reactive antibodies to 
self -  antigens are of the short - lived IgM isotype (334) (335). 
Host Genetic factors 
Differences in DENV disease severity can be seen at both the individual and 
population levels.  Several human HLA class I and II alleles are associated with 
development of  DHF (336) (337) (338) (339). Some epidemiological studies indicated that 
genetic factors constitute important components in disease susceptibility. Polymorphism in 
the tumor necrosis factor alpha (TNF - α), Fcγ receptor, vitaminD receptor, CTLA - 4, and 
transforming growth factor β (TGF - β) genes has been associated with development of 
DHF/DSS (336) (340). However, certain host factors, such as glucose 6 - phosphate 
dehydrogenase (G6PD) deficiency may also contribute to increased replication of DENV 
in monocytes. Polymorphism in transporters associated with antigen presentation and 
human platelet antigen, additionally, polymorphysm in the mannose - binding lectin 2 
(MBL2) gene were ĵshown to be associated with thrombocytopenia and an increased risk 
for developing DHF  (341). 
The risk to develop DHF and DSS following infection with DENV is likely to be 
determined by a combination of multiple common genetic traits, each with mild to 
moderate effects, predisposing to moderate effects, predisposing to a more severe form of 
disease. 
Anti-Denpendent Enhancement 
Studies in epidemiological have shown an increased risk of developing DHF/DSS 
after a secondary DENV infection (342) (343) (344) (345). Halsted and colleagues 
observed the incidence of DHF and DSS peaked divided in two groups of young children, 
the first group in infants from 6 to 9 months infected with different DENV serotype that 
infected from their mother, cross- reactive antibodies that lack neutralizing activity are 
induced in the primary infection.  In the second group was observed in children older than 
1 year and in secondary infection. DENV and non-neutralizing antibodies from virus - 
antibody complexes (See figure 29). 
 
 
68 
 
 
Figure 29: Model of antibodies- dependent enhancement (346) 
 
This non neutralizing cross - reactive antibodies form virus - antibodies complexes 
bind to Fcγ receptors on target cell and result in enhancement of DENV infection leading 
to high viral load and to DHF (347). In the most acute virus infection models, the presence 
of antibodies, both neutralizing and non neutralizing, correlates with control, elimination 
and eventually protection. However, a possible detrimental role of virus- specific 
antibodies has been described for several viruses as measured by in vitro enhancement of 
infection of cells (348) (349) (350) (351) (352) (353) (354). Although, some studies have 
shown a correlation between enhancing activity of serum, high levels of viraemia, and an 
increased risk for DHF/DSS, not all cases of severe  disease are associated with antibody - 
depenent enhancement or preceded infection with a heterologous serotype or by high viral 
loads  (355) (356). In some cases, when DHF/DSS is seen, the presence of viral RNA 
became undetectable (328). 
Cros reative T-cell response 
Although memory T cell cross - reactive with a heterologous virus can provide 
partial protective immunity, they can also cause substantial immunopathology (357). 
Human infected  with DENV result in the development of dengue - specific CD4+ and 
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CD8+ T cell responses with epitopes in multiple DENV antigens, primarily nonstructural 
proteins, being recognized by these T cells (358). However, this T cell responses cross-
reactivity with heterologous virus can provide partial protective immunity as well as play a 
role in dengue pathogenesis. 
T cell responses pattern is similar to the antibody response, T cells responses  are 
characterized by higher homotypic than heterotypic responses (359). During the acute 
phage of a secondary of human infection with  heterologous DENV, highly cross-reactive 
CD8+T cells with high avidity for the infecting virus are preferentially activated (360) 
(361). The majority of these cross-active T cells produce high concentrations of pro - and 
anti - inflammatory cytokines such as IFN-γ, TNF-α and IL-13, IL-6 but somewhat lower 
levels of IL-10. The phenomenon where cross-reactive memory T cells for primary 
infecting virus are more efficiently activated, due to the increased frequency and higher 
activation state of memory cells, this phenomenon referred to as “original antigenic sin”. 
However, in accordance to what has been described for several other systems, it is possible 
that during a heterologous DENV infection, only small subset of cross - reactive memory 
cells will be stimulated to expand because of a narrowing TCR repertoire with unique 
specificity within individual has a unique T cell receptor specific (362) (363). 
Soluble factors 
Several studies analyzed sample from infants, children and adult infected with 
different DENV serotypes have shown it is highly believed dengue pathogenesis to a 
“storm” of inflammatory cytokines and other mediators that lead to the increased plasma 
leakage in DHF/DSS. Higher plasma level of IL-1β,  IL‐2, IL‐4, IL‐6,  IL‐7,  IL‐8,  IL‐10,  
IL‐13,  IL‐18, TGF‐1β, TNF-α and IFN- β have been found in patients with severe DENV 
infection, in particular in Patient with DSS (355) (364) (365)(366)(366). It is reasonable to 
assume that synergistic interation between these cytokines will occur. It is more likely that 
multiple cytokines contribute simultaneously in a complex way to the development of 
DHF/DSS. Actually, DSS patients recover extremely rapidity after appropriate flruid 
therapy suggests that cytokines do not cause tissue destruction like in many 
immunopathology models but rather cause a reversible EC dysfunction. Other mediators 
and soluble factors found to be increased in severe disease include: vascular endothelial 
growth factor, granulocyte-macrophage conoly - stimulating factor, monocyte 
chemoattractant protein 1, macrophage migration inhibitory factor, thrombopoietin, soluble 
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vascular cell adhesion molecule 1 (VCAM-1), soluble  ICAM-1, von Willebrand factor 
antigen, thrombomodulin, E-selectin, tissue factor, plasminogen activator inhibitor 1, and 
tissue pasminogen activator (364)(367) (368)(369)(370)(371)(372). Apart from any other 
considerations, it is reasonable to assume that cytokines and other soluble mediators of the 
functional, and to a lesser degree the morphological, pathology characteristic of DHF/DSS 
are also essential for efficient viral clearance. 
 
4. Alphaviruses and Chikungunya virus 
 
4.1. Classification 
 
Chikungunya virus (CHIKV) is a member of the Alphavirus genus in the family 
Togaviridae. Alphavirus can be divided into New World and Old World viruses. These two 
groups have evolved distinct ways of interacting with their respective hosts, and differ in 
for instance their pahthogenicity, and tropism. Chikunginya virus is part of Semliki Forest 
(SF) group of Old World Alphaviruses. Predominantly New World viruses are associated 
with encephalistis, whereas poly-arthritis and rash is predominatly associated with Old 
World Alphaviruses. There are 29 different types of alphaviruses that cause diseases in 
human and other mammals. 
Genome structure 
CHIKV is a small, about 60-70 nm diameter, enveloped, a posistive single - trand 
RNA virus (Figue 30). In early 2006, according to NCBI/ GenBank accession 
no.DQ443544.1, the complete sequence of a chikungunya isolate from Reunion Island was 
made, the virion consists of an envelope and a nucleocapsid. The chikungunya virus 
genomes is 11,805 nucleotides long encodes for two polyproteins: 1) the nonstructural 
polyprotein consisting of four proteins from nsP1-4; 2) and the structural plyprotein 
consisting of five proteins as capsid, E1-3, 6K. The 5’ end of RNA molecule is capped 
with a 7-methylguanosine while the 3’ end is poly-adenylated (373) 
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Figure 30: Chikungunya virus Genetic and Physical Structure (373) 
 
4.2. Genetic evolution 
 
Chikungunya fever swept across many South and South East Asia countries, 
following extensive outbreak in the India Ocean Island in 2005. However, molecular 
epidemiology data explain the recent spread and evolution of CHIKV in the Asian region 
are limited. 
Many studies conducted so far to understand the origin and evolution of CHIKV 
have focused on full genome and E1 gene sequences of the virus (374) (195) (375) (376). 
Phylogenetic analyses of the CHIKV genome have shown three genetic lineages: Asian, 
West African, and East, Central and South African (ECSA) (374). It is now clear that the 
emergence of CHIKV in the Indian Ocean Islands in early 2005 was due to a newer strain 
of the ECSA lineage (195). Current epidemiological evidence suggests that this strain 
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could have moved to the Indian Ocean Islands following CHIKV outbreaks in Kenya in 
2004 (377). Although the molecular epidemiology of CHIKV in India has been thoroughly 
described (378) (375), similar data to explain the evolutionary relationships of CHIKV that 
spread in the rest of the Asian region after 2005 are still limited. In the study of H.C. 
Hapuarachchi et al., 2010 (379), they sought to analyses the evolutionary relationships of 
CHIKV in South and South-east Asian regions after 2005, in order to understand the 
possible routes of spread of the virus to Sri Lanka, Singapore, Malaysia and the Maldives. 
Moreover, a hypothetical evolutionary pathway for CHIKV strains that emerged in the 
Indian Ocean Islands and Asian region after 2005. (See figure 31). The later is circulating 
in the Caribbean and Sourth America. 
 
 
Figure 31: Chikungunya virus and dispersal and evolution. 
 
  To date, the difference genotype of ECSA CHIKV have been identified. The 
acquisition of A226 mutation in the envelope protein E1 of the ECSA genotype, as 
observed in La Reunion in 2005, has increased the transmissiblity of the CHIKV through 
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the widely distributed Ae. albopictus  mosquitoes (380). This mutated virus spread from 
the Indian Ocean to East Africa and Asia such as India, Sri Lanka, Singapore, Malaysia 
and China, and caused the chikungunya outbreak in Italy. In 2010, CHIKV strain 
responsible for autochthonous cases in France belong to the ECSA genotype but without 
the mutation at position 226 (381) (382). 
 
4.3. Replication cycle 
 
Following transmission, CHIKV replicates in the skin and then disseminates to the 
liver and   joints, presumably through the  blood . Unlike typical encephalogenic 
alphaviruses, wich infect neurons, CHIKV seems to infect the stromal cell of central 
nervous system and in particular, the lining of the choroid plexus (383). CHIKV 
replication has been extensively studied in mammalian and insect cell culture system 
(384). The replication and propagation of viruses is dependent on entry into permissive 
cells. Biological samples from acutely and chronically infected humans have been analysed 
and, toghether with the development of animal models, have provided invaluable tools for 
studying the physiopathology of infection. CHIKV share many characteristics with other 
Old world alphavirus but also displays unique and previous unexpected properties (385) 
(386) (383). 
 
4.4. Vector 
 
Aedes mosquitoes 
Historical data report the first detection of chikungunya in 1952 in the Makonde 
Plateau in Africa (387)(388) where the virus is known to be maintained in the sylvatic 
cycle of wild primates and mosquitoes such as Ae. taylori  (389) (390). Later in 1958 it 
was detected in urban Asia such as Thailand mainly transmitted by Ae. aegypti (391). In 
India, CHIKV was fist dectected in 1963 in West Begal, where Ae. aegyti and Ae. 
albopictus were  known to exist and are widely prevalent during the post monsoon season 
(391). From 1972 to 1986, CHIKV was observation in Kedougou, Senegal from forest 
mosquitoes, with most of them isolated from Ae. furcife - taylori, Ae. luteocepphalus and 
Ae. dalzieli (390), so the most recent one occurred in 1996 in Kaffrine where CHIKV 
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isolated from Ae. aegypti (390). In Europe, Ae. albopictus (Asian Tiger mosquito) has also 
recently emerged as an important vector to transmission CHIKV in temperate country 
(392) (393). 
 
 
Note: ECSA denotes eastern, central, and southern Africa. 
Figure 32: Origin, spread, and distribution of chikungunya virus and its vector. 
 
The map shows the African origine of enzootic chikungunya virus strains and the 
patterns of emergence and spread of the Asian lineage and Indian Ocean lineage (IOL) of the 
virus during epidemics since 1950s, based phylogenetic studies (394) (374). The distribution 
of the peridomestic vectors, Ae. aegypti and Ae. albopictus, are also shown (373). 
Transmission cycle 
Sylvatic Chikungunya cycle 
In Africa, CHIK virus appears to be maintained in a sylvatic cycle involving wild 
primates and forest-dwelling Aedes spp. mosquitoes. Serological studies have repeatedly 
demonstrated the presence of antibodies in humans and wild primates throughout the moist 
forests and semi - arid savannas of Africa  (395) (396) (397)(398). To date, a vertebrate 
reservoir or sylvan transmission cycle has not been identified outside Africa, supporting 
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the historical evidence (399) that CHIK virus originated in Africa and was šsubsequently 
introduced into Asia, where it is now typically associated with Ae. aegypti mosquitoes. The 
strains from Africa and Asia are reported to different biologically, indicating that distinct 
lineages may exist (400).  
Urban chikungunya cycle 
In Europe where sylvatic cycles are absent, vertical transmission may participate in 
the maintenance and/or cyclic re emergences of CHIKV. This critical issue remains to be 
investigated in diapausing temperate populations of Ae. albopictus that may have more 
efficient vertical transmission than mosquito populations in eastern Italy and tropical 
regions (401) (402). 
 
4.5. Chikungunya Epidemiology 
 
4.5.1. History and origin of chikungunya 
 
The Alphavirus genus, that include the group of viruses to which chikungunya 
virus belongs, originated around 2000 to 3000 years ago (403). The name “Chikungunya” 
was detived from a word in the Mokonde language (spoken by a population lives in the 
Mozamgique region) that mean “that which bends up” (404). These instances of 
emergence and spread beyond Africa may have begun as early as the 18th centery, when 
sailing ships carried chikungunya virus along with human and Ae. aegypti (399). In 1824, 
epidemics of fever, rash, and arthritis were cite in India and elsewhere.  But until 1952, the 
clinical features of chikungunya virus were first described during an outbreak in villages 
on the Makonde Plateau in the southern province of Tanganyika, Africa (405) (387) (406). 
The virus was isolated one year later during an epidemic in Tanzania using human sera and 
mosquitoes (406) (401). In 1955, the disease was reported be similar to a “Dengue-like 
ferver” (387) (388). Since 1955, most case of CHIKV infection have been describe  in 
Africa and India, during the last 60 years, the epidemic outbreak of CHIKV infection  have 
been reported in India, and in several countries in Africa, in the India Ocean region, and 
Southeast Asia. The first emergence of the virus in to the urban cycle during the mordern 
scientific occurred between 1897 and 1956, when a member of Eastern, Centern, and 
Southern Africa (ECSA) (373). Another ECSA lineage progenitor began in coastal Kenya 
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outbreak in 2004 (407) explosive epidemics of millions people before spreading to Indian 
Ocean islands and India (408) and South East Asia, reaching Myanmar in 2010. The Indian 
Ocean lineage (IOL) CHIKV strains transmission in the Americas during the peak of 2006 
- 2009 outbreaks (409). However, an Asian lineage CHIKV strain was introduced into the 
island of St. Martin in October 2013 (410) and subsequently spread throughout the 
Caribbean (11) and Central America asinto northern South America and Florida. It seems 
likely that there will be further spread thoughtout the Amercans where CHIKV vectors are 
widespread, as well as epidemics in Polynesia (410)(11) (373). 
 
 
Figure 33: Predicted dispersal pattern of Chikungunya virus from Africa to the Indian 
Ocean and Europe during the past 20 to 50 years (411). 
 
4.5.2. Global burden 
 
In the last 60 years, out breaks of CHIKV infection reported for the first time  in 
East Africa in 1952 - 1953, incidence has increasing geographic expansion to new 
countries and, in the present decade, from urban to rural settings in tropical and subtropical 
countries in Africa, India,  the India Ocean region, and Southeast Asia (392). More 
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recently, the CHKV diffusion area moved to European as Italy, French or North America 
countries as Canada, USA. (392) (412) (413) 
 
 
 
Figure 34: Chikungunya active transmission regions established from published data 
illustrate geographic and temporal knowledge of previous outbreaks. 
 
In 2001, CHIKV was first documented in Indonesia, and by 2007, more than 
15,000 cases had occurred there. The year 2004 witnessed an outbreak of CHIKV in Kenya 
followed by another massive outbreak on the French island of La Réunion in 2005 (401). 
By this point in time, an estimated 266,000 people had developed chikungunya virus 
(attack rate, 35%) (414). In 2006, a CHIKV epidemic reached Sri Lanka, and through 
2007, WHO rerpoted more than 37,000 Sri Lankans were affected by the disease. In 2006, 
more than 1.3 million cases of CHIKV were reported in India with attack rates as high as 
45% in some areas. In 2007, more than 17,000 were infected in Gabon, Africa. Around the 
same time in 2007, CHIKV first introduced to Europe during the aforementioned outbreak 
in Italy. However, the attack rate measured only 5.4% in Castiglionedi Cervia and 2.5% in 
Castiglione di Ravenna, a much smaller figure than in other countries (401) and more 
recently has spread to the Caribbean region  (11).  
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Figure 35: Endemic or potentially endemic to 96 countries. 
 
4.5.3. Epidemiology trend in several regions of the world 
 
4.5.3.1. Epidemiology trend in Africa 
 
Since the fist report in 1952, most cases of CHIKV infection have been in 
described in Africa and India. However, during the last 60 years, isolated cases or 
epidemic outbreaks of CHIKV infection have reported in several countries in Africa, more 
specifically West Africa from Senagal to Cameroon, Central and East Africa including 
Central African Republic, Angola, Democratic Republic of Congo, Zambia, Zimbabwe, 
Tazania, Malawi, Mozambique, eatern Botswana, and north eastern parts of South Africa, 
there is also evidence of viral presence in parts of Ethiopia and Sudan (Health Protection 
Agency reported, 2011).  Human infections in Africa have been at relatively low levels for 
a number of years, but in 1999 - 2000, there was a large outbreak in the Democratic 
Republic of the Congo, and in 2007 there was an outbreak in Gabon. (415) (416). 
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Figure 36: Map showing the distribution of chikungunya virus enzootic strains in 
Africa and the emergence and spread of the Asian lineage (red arrows and dots) and 
the Indian Ocean lineage (yellow arrows and dots) from Africa (404). 
 
4.5.3.2 Epidemiology trend in Southeast Asia 
 
In recent years, large scales epidemics of CHIKV with considerable morbidity and 
suffering in their wake have occurred in a number of Member countries of WHO South 
East Asia Region. In Asia, CHIKV strains were isolated in Bangkok in the 1960s, Sri 
Lanka in 1969, Vietnam in 1975, Myanmar in 1975 and Indonesia in 1982. Outbreaks were 
reported from Indonesia (1979, 1985, 2001 and 2003-2007), Myanmar (1975 and 1984), 
Maldives (2006-2007), Sri Lanka (1965 and 2006) and Thailand (1960, 1978, 1988 and 
1995- 1996). The outbreaks in Region prior to 2000 were due to Asian strain.  In 
Indonesia, CHIKV occurred sporadically until 1985 after which there were no reports of 
the disease till a series of outbreaks between 2001 and 2007. The reported 15207 cases 
from seven provinces with the peak observed in 2003, over 1200 suspected cases of CHIK 
were reported from 23 sub - districts in 2007, and most of the reported cases were from the 
province of Java (219). 
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4.5.3.3. Epidemiology trend in India and India Ocean region 
 
Since CHIKV identification, the first outbreaks of CHIKV in India was 
documented of the Calcutta in 1963 (417). Afterwards shortly time, several outbreaks of 
Chikungunya occurred throughout the country until 1973 (418). A gap of several years 
ensued, during which viral activity in human was thought to have disappeared or to lost its 
pathogenic potential (419). However, the virus re-emerging in India in 2005 and the 
country has so far seen more than 1.3 million suspected case of CHIK infection (418) 
(419). In Southern of India in 2006, an outbreak of CHIK began in Kerala, has so far 
affected nearly 70,000 people from 14 districts (420) and continues today, in the years of 
2009, more than 11,000 suspected cases of CHIK have been reported from Kerala state. 
The abundance of Ae. Albopictus mosquito in the region and molecular evolution by 
mutation in the glycoprotein envelope gene of CHIK virus may be contributing to the 
renewed outbreaks. 
Starting from the emergence of CHIKV in Kenya in 2004 (421) (422), after that the 
outbreaks spread to Comoros and Seychelles in early 2005, followed by Mauritius (423) 
(424) (425). Later the outbreak were reported to have spread to other islands in the Indian 
Ocean, including La Reunion Islands which is apart of France in 2005, 2006 (195) (426) 
(427). An causing major outbreaks in there regions (428).  
 
4.5.3.4. Epidemiology trend in European and Americans 
 
Between 2005- 2007, epidemic CHIKV occurred in many European countries 
(429), CHIKV infection was diagnosed in travelers coming from epidemic areas ( a person 
traveling from India ). During the summer 2007, and for the first time in a temperate 
country, an epidemic of this tropical disease occurred in Italy (430), in Castiglione di 
Cervia and Castiglione di Ravenna (Emilia Romagna, Northern Italy), which together form 
a single urban area, the mosquito was detected in local is Ae. albopictus. Erosurvaeillance 
report Ae. albopictus is found in several other European countries, including Albania, 
France, Belgium, Montenegro, Switzerland, Greece, Spain, Croatia, German, the 
Netherlands, Slovenia, Bosnia, Herzegovina, and possibly more, suggesting a potential for 
further spread of the disease (431). 
 
81 
 
 
 
Figure 37: Outbreak of Chikungunia, 2004-2007 
 
In German describes the first isolation and molercular characterization of CHIKV 
in 2009. The virus contained the E1 A226V mutation, shown to be responsible for an 
adaptation to the Asian tiger mosquito Ae. albopictus. The E1 coding sequence was 
identical to chikungunya virus isolates from Sri Lanka and showed three nt-mismatches to 
the only available E1nt sequence from the Maldives (425). One year later, in 2010, 
autochthonous transmission of chikungunya virus was recorded in Southeastern France 
(335), and in Montpellier, southern of  France, 2014 (382).  
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Figure 38: European Union, chikungunya, case. 
 
During the past four weeks in 2014, numerous imported cases reported from the 
Americas and Europe among travellers return from the Caribbean regions, in particular 
from Haiti or Dominican Republic. Such as USA in the North America; Panama, 
Suttiname, Cuba, Barbados, and Bonaire island in Central America and Caribbean; 
Venezuela, braazil, Peru, Chile in South America; France, Italy, Netherlands, and Spain in 
Europe (432). 
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Figure 39: Introduction of chikungunya to the Caribbean by epidemiological week first 
reported in December 2013 to August 2014. Data from PAHO/WHO statistics (433) 
 
4.5.4. Diagnosis 
 
Clasification in clinical 
In the clinical, serological and molecular diagnosis of CHIKV fever patients and its 
comparison with dengue viral fever. Classical clinical features of CHIKV infected patients 
were recorded to differentiate chikungunya from dengue, which were fever, arthralgia, 
myalgia and rash (434). 
Approximately, 3% - 8% of patient infected with CHIKV will remain 
asymptomatic. For people who develop symptomatic illness, the incubation period is 
typically 3-7 days (range 2-12 days) with the fever is usually of short duration (435). In 
some patients, a biphasic pattern of fever has been described with a febrile episode of 4 to 
6 days, followed by fever-free period of a few days followed by recurrence of fever 
(usually 101- 1020 F)  that may last a few days. 
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Note: The chronology of viral replication in relation to the clinical and biologic 
signs of disease, including the biomarkers used diagnostic assays to detect chikungunya 
virus infection (Suhrbier et al, 2012)(436) 
Figure 40: Timeline of Infection, Symptom, and Biomarkers  
 
Soon after the onset of fever, severe myalgias and artheralgias occure, 80% of 
patients. The joint pain is usually symmetric and localized in both arms and legs, estimated 
in 90% of patients, the large joints are almost invariably symptomatic, as are to a lesser 
extent, the small joints and the vertrbral column (437). Rash occurs in 20-80% of cases, 
less common, nonspecific signs and symptom include lymphadenopathy, prurius, and 
digestive abnormalities, more common after viremia has resolved. In acute phase, feelings 
of faintness, fainting, confusion and attention - deficit disorders (373). Rare complications 
can occur including conjunctivitis, uveitis, iridocyclitis and retinitis, with typically resolve 
(438). Manifest in severe chikungunya fever as encephalopathy and encephalitis, 
myocarditis, hepatitis, and multiorgan failure. These rare forms can be fatal and typically 
arise in patients with underlying medical conditons. Hemorrhagic complications are rare 
and consideration of alternative if coninfection with dengue virus or coexisting conditions 
such as chronic hepatopathy. In infant group, neonates at risk for severe infecton 
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associated with neurologic signs, the rare extremely, 50% of neonates born of infection to 
viremic mother, and exposed to the virus during birth, leading to severe disease and 
encepalopathy in half and resunting in long term neurology sequelae (439). 
Disease course 
After the incubation period, the illness begins abruptly and its followed by three 
phages: Acute phase, onset phase and chronic phage. 
Acute phase 
CHIK fever affects all age groups, and both genders are equally affected. The 
incubation period ranges from 2 to 12 days (usually 3-7 days)  (440) (441) (405) (442) 
(422) (443).  In susceptible populations, the attack rates can be as high as 40-85 %. 
Onset phase 
Prodromal symptoms are very rare. In the acute stage, the onset is usually 
abrupt and sudden with high - grade fever, severe arthralgias, myalgias, and skin rash 
(440) (441) (405) (442) (422) (443). Headache, throat discomfort, abdominal pain, and 
constipation may also be evident. Conjunctival suffusion, persistent conjunctivitis, 
cervical, or sometime generalized lymphadenopathy may be present. 
Chronic phage 
In a majority of the patients, the joint pains resolve in 1 to 3 weeks. In a majority of 
the patients, the joint pains resolve in 1 to 3 weeks. However, the arthritis can persist in 
about 33% of patients for 4 months, 15% for 20 months, and in 12% for 3-5 years (422) 
(444)(444) (445). The chronic stage is characterized by unpredictable relapses that include 
sensation of fever, asthenia, and exacerbation of arthralgias and stiffness. Affected patients 
may manifest inflammatory polyarthritis, severe subacute tenosynovitis/bursitis 
(consequently nerve tunnel syndromes) in hands, wrists, and exacerbation of pain on 
movement in previously injured joints (441)(446). Older individuals and those with 
underlying rheumatic and traumatic joint disorders seem to be more vulnerable to develop 
the chronic stage (441) (405) (442) (422) (443). Rarely, rheumatic manifestations resulting 
in joint destruction before resolution after 15 years have been repoted (447). Some studies 
have documented occurrence of rheumatoid arthritis following chikungunya fever, 
suggesting that the viral infection may have a role in the initiation or unmasking of 
rheumatoid arthritis (448)(449). 
 
 
86 
Laboratory diagnosis 
Laboratory diagnosis depends on antibody-capture IgM ELISA and plaque-
reduction neutralization tests of serum. Comparative serologic tests for closely related 
alphaviruses (e.g., o'nyong-nyong and Sindbis viruses) should be conducted as 
geographically appropriate, and tests for dengue usually are indicated. Virus isolation 
attempts and PCR assays are performed selectively. Serologic tests should be performed on 
both acute and convalescent phase serum specimens collected at least 2 weeks apart, but 
clinicians should not delay submission of acute phase samples pending collection of 
convalescent phase samples (CDC). There is no specific assay for assessing chronic signs 
and symptoms associted with chikungunya fever, although elevated levels of C - reactive 
protein and proinflammatory cytokines correclate with disease activity as do IgG and IgM 
(450) (436). 
 
4.5.5. Treatment and prevention 
 
Treatment 
There is curently no effective antiviral treatment for chikungunya. Treatment is 
therefore purely symptomatic and based on non - salicylate analgesics and non-steroidal 
anti-inflammatory drugs. Synergistic efficacy was  
reported between interferon - α and ribavirin on chikungunya virus in vitro (451)(452) and 
other antiviral compounds are under investigation (453). Analgesic drugs often combined 
with nonsteroid antiinflammatory  drug  (454). Althought morphine effective during the 
initial phase but seldom used (387). In the incapacitating form, corticosteroids was 
sometime prescribed to treat (454). Chloroquine used treating in certain forms of chronic 
arthralgia (455), and there was no justification for treat acute infection (456).     
Vaccines 
Chikungunya fever represents a simple vaccine target than DF, There is currently 
no commercial vaccine for chikungunya virus, although some candidate vaccines have 
been tested in human beings (457) (458). Since the 1970, CHIK vaccine approaches have 
been pursued using mainly formalin killed and live approaches (VADIP). In the trials 
conducted by the US Army Medical Research Institute, very satisfactory seroconversion 
rates (98% on day 28) and neutralising antibody titres were obtained, persisting in 85% of 
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cases at 1 year, but these American vaccine trials were interrupted in 2003. On 6 
September, 2006, the US Army Medical Research and Materiel Command signed a 
Material Transfer Agreement with the French National Institute of Health and Medical 
Research focusing on the records of previous clinical studies. Have tested a live vaccine 
(TSI-GSD-218) in Phase I and II where the vaccine was shown to be safe and 
immunogenic in 88 voluntees, although some vaccines experienced transient arthralgia 
(457). A phase III trial of the US Army candidate vaccine is in preparation (US Embassy in 
France; press release, Sept 14, 2006). The candidate vaccine is a live vaccine (TSI-GSD-
218) based on chikungunya virus strain 15561 and 1962 isolated from a patient in Thailand 
and attenuated by serial passage in MRC-5 cells (458) (459). The status of TSI-GSD-218 is 
currently unclear although the US government allowed French authorities to collaborate 
based on the situation in La Reunion. In 2008 new vaccine candidates were proposed (460) 
(461). In 2009, a formalin inactivated vaccine candidate prepared used Indian strain 
implicated in epidemic in 2006 (462). This vaccine candidate has very good immunogenic 
potential to neutralize the virus infectivity.  
Prevention and control 
The immediate prospects for the control of chikununya fever are poor. There are no 
specific therapeutic agent to treat patients and no licensed vaccine to prevent CHIKV. 
Pending vaccine development, the only effective preventive measures consist of individual 
protection againts mosquito bites and vector conrol. Control of both adult and larval 
mosquito populations uses is the same model as for dengue and has been relatively 
effective in many countries and settings. Mosquito control is the best available method for 
preventing chikungunya, as reduce the vector and limite the contact between human and 
Ae. aegypti and Ae. albopictus  mosquito (463), including wearing protective clothing, 
bednet or curtains with  insecticides impregnated.  The focus on reduce or treat water 
containers or wet discard products where eggs are laid and larve develop. Mosquito 
population is reduce through traditional larvicide and adultticide applications penetrate the 
house and premises where mosquito rest and feed. Another reduce transmission is use of 
wolbachia bacteria (464)(465) and a novel strategies for vector control include the release 
of transgenic Ae. aegypti engineered to carry a late- acting lethal genetic system (466).  
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4.5.6. Chikungunya immunopathogenesis 
 
4.5.6.1. CHIK pathogenesis  
 
The pathogenesis of chikungunya in human and the mechanism by which it causes 
arthritic disease is poorly understood (467). Apart from the clinical manifestation of CHIK 
infection, the information about the pathogenesis of the virus in human is little document. 
Some study in clinical of CHIK patients reported the occurrence of rhabdomyolysis with 
elevated creatine phosphokinase levels. To determine whether pathogenesis of CHIK is 
based on studied of the arthritogenic alphaviruses in vitro, and a mouse model of virus - 
induced arthritic/arthralgia has been used to study the pathology and immunology (468), 
infection results in severe inflammation and necrosis of skeletal muscle. The 
histopathological and immunohistochemical (IHC) finding in human are similar in the 
CHIKV - infected mice (467). 
 
4.5.6.2 Risk factors 
 
The many experts in the field of infectious diseases, epidemiology, entomology, 
and risk assessment were to assess the short - term risk of Chikungunya virus in Europe. 
An artificial distinction was made between the risks of establishment of CHIKV 
transmission in Europe related to the three key determinants: 1) Risk related to the 
introduction of the virus, considering the highest likelihood for virus introduction comes 
from viraemic persons. That is the high frequency of travel between high incidence areas 
in the Indian Ocean and Europe, limited likelihood for introduction through blood 
transfusion from a viraemic donor; 2) Risk related to the presence and characteristics of the 
vector were the spread of Ae. albopictus in Europe has been documented, but the map 
would need to be update, such as taking in to account ecological and climatic information, 
and considering a more detailed administrative level, the vectorial capacity (host 
preference, longevity density) and competence (Susceptibility of local strain) for 
transmitting CHIKV in Europe, needs to further investigation particular in highly infested 
areas; 3) Risk related to interaction with the host was factors influencing the host and 
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related risk include the likelihood of being bitten, immunological susceptibility, duration 
and level of viraemia, proportion of asymptomatic case and capability to detect a case. 
 
5. Combinated arboviral infections 
 
5.1. Combinated Flavivirus infections 
 
Dengue and encephalitis 
Although both dengue and Japanese encephalitis virus (JEV- is one of the most 
important cause of viral encephalitis worldwide) belong to the genus Flaviviridae, 
however, the biological characteristics of these two viruses are somewhat different. JEV is 
mainly transmitted by mosquitoes of the genus Culex (469), isolated of this virus are also 
reported from Anophelinae mosquitoes (470). 
The investigation on the activity of two DENV and JFV were conducted in and 
around Malina, Philippines, and Luzon islands, they could not demonstrate the DENV and 
JFV combination (470). But encephalopathy has been well reported and has classically 
been thought to result from the multisystem derangement that occurs in severe dengue 
infection with liver failure, shock, and coagulopathy causing cerebral insult, there is 
increasing evidence for DENV neurotropism, these may be an element of direct viral 
encephalitis (471). DENV infections represent a significant burden of disease in the 
tropics, and neurologic manifestations are increasingly recognized, but remain relatively 
poorly understood. 
Dengue and Yellow fever 
Dengue and Yellow fever viruses are single - stranded RNA viruses in the 
Flaviridae, they are endemic to and epidemic in tropical and subtropical regions (472). In 
their original habitat, both are Zoonotic infection transmitted by forest-dwelling 
mosquitoes, Aedes. There is little doubt that the yellow fever virus (YFV) originated in 
Africa, and that viruses circulating in the New World are of African origin (473). 
Curiously, YFV never been recorded in Asia, although Ae. aegypti is widespread there 
(473) (See figure 41). 
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Figure 41: Distribution of Dengue, Yellow Fever, and their principal vector, the Aedes 
aegypti mosquito. 
 
Although YFV is now largely controlled by vaccination and successful mosquitoes 
eradication campaign, many regions are susceptible to a reemergence if the movement of 
infected person (472), and both of viruses continually rising (474) (475). The large urban 
outbreaks of yellow fever were common until the early 20th century remain a real and 
constant danger in enzootic countries that do not enforce routine vaccination. However, it 
is reasonable to assume areas were prone to dengue transmission was equally prone to 
YFV, so areas without history of the latter, including those in South East Asia, may well be 
at risk (473). 
 
5.2. Combinated Dengue and Chikunguni viruses in the world 
 
Dengue and Chikungunya co-infection 
           Co - infection by DENV and CHIKVin patient has been known for along time. The 
first described in patients, and reports of co - infections with DENV and CHIKV in 1964 in 
South India (476), a co - infection in human can occur following the bite of two main 
mosquitoes infected with one virus or to the bite of a mosquito infected with two viruses. 
In the some outbreaks, CHIKV affected areas overlap with dengue fever - endemic areas 
and provide opportunities for mosquitoes to become infected with both the viruses, and co 
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- infection are increasing, particularly after the emergence of CHIK in the India Ocean in 
2005 - 2006 due to a new variant highly transmitted by Ae. albopictus, a dengue outbreak in 
the same geographic area transmitted by Ae. albopictus was shortly before the emergence of 
chikungunya, and co - infections (476).  In Asia, the first case report of CHIKV and DENV 
co-infection confirm by molecular methods was from Sri Lanka  (477)  and the CHIKV 
affected areas overlap with DENV in endemic areas  (478). In 1967, co - infections with 
DENV and CHIKV reported in Calcutta, India. Subsequent serologic investigation in 
Southern India indicated that the two viruses can co-exist in the same host (418).  
In clinical, the common symptom of both disease included fever, joint and bone 
pain, nausea, vomiting, headache, and fatigue. Therefore, while screening considering both 
dengue and chikungunya infection is necessary because though the clinical features are 
similar, the outcomes maybe different, chikungunya is nonfatal while dengue may lead to 
severe health complication and including death (479). A study from Department of 
Microbiology, Sri Venkateswara Institute of Medical Sciences, Tirupati, India showed that 
the co - infection with dengue and chikungunya fever was found in 2.7% of the cases in 
India (479). 
 Dynamic Dengue and Chikungunya co-infection 
In the past years, DENV and CHIKV have caused large and geographically wide 
ranging epidemics (6)(480) (481). The actual situation of co - infection is much more 
complex. Fist, Ae. alpopictus was repeatedly show to be highly competent vector of 
CHIKV during the recent outbreak in the Indian Ocean and Italy (482). Second, the overall 
distribution of Aedes mosquitoes is rapidly changing. Specifically, Ae.  albopictus has 
dispersed globally in to new territories previously occupied by Ae. aegypti. As a 
consequence, the characteristics of DENV and CHIKV circulation and their outbreak 
dynamics are likely to be modified (483). The CHIKV affected areas overlap with DENV 
endemic areas and provide opportunities for mosquitoes to become infected with both 
viruses  (484). Co - infection with DENV- 1 and DENV- 2 was reported in Puerto Rico in 
1982 (485). Since then, many cases of concurrent infections with multiple DENV 
serotypes have been reported in many countries, such as co - infections with more than two 
DENV serotypes in India in 1967 and 2006. The  co - infection with DENV and CHIKV in 
Calcutta, India show that subsequent serologic investigation the two viruses can coexist in 
the same host (486) (418). 
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Seasonal trend observed with both the fevers with rise of the cases during the post 
monsoon period.  Ae. aegypti is sensitive to changes in temperature and available moisture, 
they decrease in number in dry and cool seasons, and increase when temperatures increase 
and when the wet season begins (487) (488). 
Beside, in the some countries setting, overcrowding, low  socioeconomic 
conditions, and poor sanitary conditions, mixed population of mosquitoes thriving together 
cannot be excluded is reason to make dynamic of CHIKV and DENV co - infection. 
Mechanisms of Dengue and Chikungunya co-infection 
The exact mechanisms of the DENV and CHIKV co - infection still remain a 
mystery. Despite the threat of this virus to public health and its importance to research on 
viral hemorrhagic fevers our understanding of the virulence, pathogenesis, and 
mechanisms of re - emergence of the dengue virus is limited. Unlike dengue, chikungunya 
typically consists of a self - limiting and nonfatal acute illness characterised by fever, rash 
and incapacitating arthralgia. Several mechanisms including a complex interaction between 
various factors such as the susceptibility of humans and the mosquito vectors to the virus, 
conditions facilitaring mosquito breeding resulting in a high vector density, ability of the  
vector to efficiently transmit the  both of virus are  all thought to play a role. 
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CHAPTER 1 
ROLE OF AEDES SPECIES IN THE TRANSLISSION OF DENGUE IN URBAN 
AREAS IN NORTH VIETNAM 
 
1.1. Context of study 
 
Hanoi, capital of Vietnam, is an urban center located in the northern part of the 
country. It is a large city with a population estimated at 2.6 million for the urban districts 
and 6.5 million for the metropolitan jurisdiction (489) (490). 
 
 
Figure 43: Location of the eight selected study districts in Hanoi, Vietnam 
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Hanoi is known as a low-transmission area for DF (491), but recently DF appeared 
to be emerging (492). Public health authorities in Vietnam are now considering dengue as 
an emerging health problem in Hanoi. The climate is contrasted with hot and humid 
summers and a rainy season from May to September with temperatures from 38 - 400 C. 
Winters are relatively dry and cool from November to March with temperatures as low as 
60 C. Spring is marked by light rains. The period from June to September is suitable for the 
deverlopment of mosquito vectors (493). Besides, Hanoi experiences annual seasonal 
dengue outbreaks with the peaks of epidemics usually falling in September/October and 
ending in November/December. There are only few studies published on the epidemiology 
of dengue in Hanoi all based on public surveilance data rountinely collected by the 
Ministry of Health (494). DF was first described in northern Vietnam in 1958, where DHF 
was first reported (495) (496), and later expanded to the southern area where it was 
described in 1960 (497). During the first 1958 DHF outbreak in Hanoi, 68 patients with 
identical clinical symptoms were hospitalized with a mortality rate of 7% (19). Dengue 
infections have been regularly reported since then, but during the 1998-2009 decade, two 
large outbreaks occurred in the central urban area of Hanoi, which resulted in a total 25983 
cases mostly among young adults (494) (498). Incidence rates of DF have increased 
significantly during the last few years in many province and cities, especially Hanoi. 
The invason of Aedes mosquito is assumed to be high in tropical, dengue endemic, 
countries like Vietnam. A. aegypti is considered the most important vector of DENV while 
A. albopictus is generally believed to be a less competent vector resulting in milder 
epidemics (18). However, dengue outbreaks have been attributed to both A. aegypti and A. 
albopictus in different regions of the world including Asia (499) (495) (18) (500). Each 
species displays a specific ecology, behavior and geographical distribution. A. aegypti 
prefers urban habitats, whereas A. albopictus is primarily a forest species that has become 
adapted to rural, suburban and urban human environments (18) (501) (502). Owing to this 
co-circulation of both mosquito species in Vietnam (503) (504), and although Hanoi has a 
cool winters (505), both species are found in Hanoi (506). 
 
1.2. Objective 
 
To assess the spread of dengue virus and the risk factors for this virus, we 
conducted a surveillance of mosquitoes and blood samples from hospitalized patients 
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collected during outbreaks from August 2011 to December 2011 in eight districts of Hanoi 
as Ba Dinh, Hai Ba Trung, Dong Da, Ha Dong, Thanh Xuan, Thanh Oai, Thanh Tri, and 
Tu Liem. This study was conceived to investigate thei respective role of A. aegypti and A. 
albopictus in DENV transmission and correlation between mosquito abundance and size 
and duration of outbreaks in Ha Noi, Vietnam. 
 
1.3. Discussion and conclusions 
 
This study conducted in Hanoi, Vietnam, reported 140 confirmed cases of DF in 24 
outbreaks over eight districts. The patients were mainly males older than 15 with the 
highest number of dengue cases found in the 15-34 years age class. Only 10% of patients 
were under 15 years old. The age distribution reported in this study differs from other 
works which reported dengue mainly in children (507) (508) (509) (510) (511) (512) (513)  
(514). However, our result are supported by reports from both Latin America and 
Southeast Asia where increasing dengue incidence has been found among older age groups 
(515) (516) (517) (518) . During the study period, we also found proportionately more 
males affected than females. Others have reported similar findings in Vietnam, China and 
Nepal (519) (520) (507). There is no clear explanation for this bias which might be 
associated to an occupational factor. 
The presence of only DENV 1 and DENV 2 along with the predominance of 
DENV 2 reported in this work are in agreement with previous reports on from Hanoi in 
recent years (494) (519). This suggests that DENV 1 and DENV 2 were already co-
circulating during previous outbreaks in the same area and most likely maintained over 
time through transmission in mosquito populations. This importance of mosquito 
populations in the maintenance and development of outbreaks is clearly highlighted in this 
work with the widespread distribution of A. aegypti together with high local densities 
during the outbreak period in Dong Da, Hai Ba Trung, Ba Dinh, Ha Dong and to a lesser 
extent in other districts. Ae. aegypti was also the single vector in simultaneous outbreaks of 
dengue fever in Hanoi. Furthermore, high population densities of A. aegypti was corelated 
with the number of human cases reported in outbreaks.The number of A. aegypti 
individuals collected in the early period of outbreaks was higher than the number collected 
towards the end of the outbreaks. However, due to the small size of mosquito samples 
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collected in Thanh Tri, Thanh Oai and Tu Liem districts, we cannot exclude that this result 
was biased as mosquitoes may have been collected under different meteorological 
conditions or time periods. Nevertheless, altogether these results provide evidence that A. 
aegypti populations from eight districts were involved in dengue virus transmission, and 
probably played a pivotal role during the 2011 dengue outbreaks and before as a 
maintenance host. 
Despite the fact that is considered to be a less efficient vector, Ae. albopictus is 
adapted to urban domestic environments and was described as vector in DENV outbreaks 
in different regions including China, Gabon or Madagascar (521) (18) (522). However, in 
this work, DENV were not detected in Ae. albopictus and no correlation was found 
between Ae. albopictus populations and increase in number of human cases. These data 
corroborate other reports suggesting that Ae. albopictus is not an important vector in urban 
environment when compared to Ae. aegypti (523) (502) (524) (525)(526). 
The importance of mosquito population densities in the dynamic of dengue fever 
highlighted by this work might however be underestimated. Indeed, a limitation to this 
study is that it only covered the latter part of the rainy season, considered an ideal time for 
dengue transmission. Additionally, no information was available for artificial containers 
that might have acted as breeding habitats for Aedes mosquitoes. There may also have been 
case ascertainment biases as we relied on patients presenting themselves to health services, 
thus milder and asymptomatic cases may not have been identified. Nevertheless, this work 
strongly supports the need of further investigation in other geographic areas and 
environment, i.e. suburban and rural, to determine the distribution and relative role of Ae. 
aegypti and Ae. albopictus in the transmission of DF and DHF in Vietnam. This work also 
underline the need of a better understanding of the dynamics of mosquito populations to 
implement efficient and adapted mosquito population monitoring and mosquito control 
strategies, which is at the moment the best way of controlling dengue and other mosquito-
borne diseases. 
The results of this work are summarized in the article entitled “Role of Aedes aegypti and 
Aedes albopictus during the 2011 dengue fever epidemics in Hanoi, Vietnam”. This article 
published  in “Asian Pacific Journal of Tropical Medicine” is presented thereafter. 
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CHAPTER 2 
SURVEILLANCE OF DENGUE AND CHIKUNGUNYA VIRUS INFECTION  
IN DONG THAP 
 
2.1. Context of the study 
 
Dengue is endemic throughout Vietnam, but transmission is highest in the South 
where very large epidemics occur regularly (527). Dengue occurs year-round, but a marked 
seasonal peak occurs during the rainy season from June to December. Since 1960, DF 
epidemics tend to spread widely with a continuous increase in number of patient and 
deaths (528)(529)(527). 1,518,808 DHF cases and 14,133 deaths were reported between 
1963 and 1995 (530). The dengue surveillance program in Southern Vietnam shows 
epidemic peaks of increasing magnitude occurring approximately every 5 years between 
1975 and 1987, with a longer period of 11 years preceeding a large epidemic of 119,429 
DHF cases and 342 fatalities in 1998 (531). All four DENV serotypes were found to 
circulate in Southern Vietnam (532). Over the past 15 years, the number of DENV cases 
has been increasing (529). 
Although chikungunya was first described in Vietnam in the 1960s (533), national 
serological evidence of its activity in Vietnam remains sparse and mainly historical. 
In1966, ten America soldiers were identified (534), and serological surveys among 
children identified antibodies to CHIKV in 1967 (535). A number of review articles have 
also shown that Vietnam is one of several Asian countries to have reported chikunguny. 
(536)(537)(538)(539)(540). 
Dong Thap general hospital located in Dong thap province in the Mekong Delta 
region of southern Vietnam. Dong Thap is 165 km away from Ho Chi Minh city, shares a 
48-km border with the Preay Veng province of Cambodia. In recent years, Cambodia, 
already endemic for dengue, declared chikungunya infection in provinces bordering 
Vietnam (541). The disease can easily be imported by travellers and spread rapidly 
resulting social, economic and healthcare system impacts. This is currently threatening 
Vietnam and may happen in the comming year. 
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2.2. Objective 
 
Vietnam being at risk of joint DENV and CHIKV infections, characterized by 
overlapping clinical manifestations and differences in clinical management, clinicians 
should be aware of the need to include CHIK in the differential diagnosis of DF. This work 
was conducted to evaluate the real burden of dengue infection in the general population 
and to identify the presence of CHIKV in Dong Thap. Another objective was to determine 
whether underdiagnosis of CHIKV was occurring through prospective screening of sera 
from patients admitted with an acute febrile episode in one hospital in southern Vietnam. 
In addition, the study also examined DENV serotypes in the same cohort of patients, and 
whether there was co-infection with CHIKV. 
 
2.3. Discussion and conclusions 
 
The initial objective of this work was to assess within 13 months the occurrence of 
dengue and chikungunya among patients from Dong Thap general hospital admitted for 
acute fever and dengue/chikungunya-related symptoms. The most common symptoms on 
the day of admission were headache, fever, myalgia, arthralgia, and a positive tourniquet 
test. Although the majority of clinical manifestations were similar between adult and 
pediatric patients, adults were significantly more affected by arthralgia than pediatric 
patients. More males were found to be affected than females. The most affected age class 
was the 5-14 year class which in agreement with oter studies which have reported dengue 
mainly in children. 
The co-circulation of four serotypes of DENV is in agreement with the status of 
region of hyperendemicity of both southern Vietnam and Cambodia with a predominance 
of DENV2 and DENV4. Reports from Cambodia have stressed the predominance of 
DENV2 and DENV3. Although, the 13-months surveillance described in this work did not 
show any presence of CHIKV, the risk is still present and this surveillance should be 
maintained.  
An important outcome from this work is the differential efficiency of detection of 
dengue through serology. DENV infection was hardly detected in acute phase through 
serological tests with only 29% of plasma and 14% of sera to be positive. Conversely, 
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DENV infection was detected at 53% in clinical samples obtained during the 
convalescence phase and up to 74% when using PCR. Time of seroconversion should be 
taken into account when implementing detection procedures. Indeed there is no control on 
the time between onset and admission and this time might varies greatly from one patient 
to another. Time for seroconversion should be taken into account when implementing 
detection procedures. However, for practical reasons, admission is the only time when 
blood samples can be taken since patients can hardly be followed up after leaving the 
hospital. The best solution would be therefore to implement multiplex PCR detection on 
blood sample taken at admission. Cost of PCR is nowadays not higher than that of 
serological tests and the possibility to combine several detection tests, i.e. dengue and 
chikungunya, at the same time in a one-step single tube procedure as well as the higher 
efficiency of PCR make it a highly cost-effective option. A recommendation from this 
work would therefore be to replace current procedures for serological detection of dengue 
by a standard operating procedure for DENV-CHIKV multiplex single step PCR. 
26% of patients hospitalized with acute fever symptoms were negative for both 
DENV and CHIKV. This unknown etiology may need further work to identify what the 
causative pathogens involved. Other limitations of this study is the limited number of 
patients enrolled and therefore of samples available. Owing to the dynamics of both 
chikungunya and dengue and the potential of emergence for chikungunya in Vietnam it is 
of importance to implement a larger surveillance system which will provide valuable 
information on the prevalence and incidence of DENV infection and CHIKV circulation 
which are essential for planning an appropriate public health strategy. 
This work is presented in an article currently in press at Asian-Pacific Journal of 
Tropical Medicine (Elsevier) and entitled “Surveillance of dengue and chikungunya 
infection in Dong Thap, Vietnam: A 13-months study ». The corrected proof version of the 
article is presented there after. 
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CHAPTER 3 
DENGUE VIRUS, CHIKUNGUNYA VIRUS AND RISK FACTORS IN SEVERALS 
PROVINCES OF VIETNAM. 
 
3.1. Context of study 
 
With an estimated 93 Million people, Vietnam undergoes a rapid urban population 
growth due to the influx of workers and students from rural areas (247). Vietnam is a 
country with poor health and economic indicators. The S-shaped country shares borders 
with China, Laos and Cambodia. 
 
 
Figure 42: Location of the five selected study provinces in the north, center, south of 
Vietnam. 
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Vietnam is recognized as one of five countries in Southeast Asia with the highest 
dengue burden (542). Dengue fever (DF) was first described in northern Vietnam in 1958 
and expanded to the southern area in 1960 (543). Despite the existence of a National 
Dengue Control Program since 1998, Dengue remains a major health problem in Vietnam. 
Over the past 15 years, the number of DENV cases has been increasing (529), DF and 
DHF are leading causes of hospitalization, period 1991 - 2004 accounting for 1.000.866 
case reported in Vietnam, and increasing year to year in the high urban central areas of 
Hanoi (544). Dengue is highly endemic in tropical southern Vietnam, while increasing 
larger seasonal epidemics have occured in northern Vietnam over the last decade (545). All 
four dengue virus serotypes have been found circulating in Vietnam with the dominant one 
varying over time (546). The predominant circulating viruses have DENV 1 and DENV 2, 
but until the late 1990s, DENV 3 emerged and was responsible for the large outbreak of 
1998, whereas DENV 4 was also detected between 1999 and 2003 (547). Dengue 
transmission occurs throughout the year in Vietnam, with peaks in the number of cases 
(72% of total cases) reported between June and November. In the Northern and Central 
Highland regions, dengue notifications are low during the winter time from December to 
March (548) (549). In the South, dengue transmission is higher in the rainy season from 
July to September, specially transmission is highest in the South where very large 
epidemics occur regularly (550), Aedes mosquitoes, which are the vectors of dengue and 
chikungunya, are widely prevalent in the region (551). 
Chikungunya virus (CHIKV) was first isolated in Tanzania in 1953 (552) and was 
until 2004 known to cause debilitating rheumatologic disease in many parts of Sub-
Saharan Africa and Asia (553). The symptoms of CHIKV infection are quite similar to 
those caused by many other infectious agents in the endemic areas. One particular 
difficulty in identifying CHIKV infection is its overlapping distribution with dengue 
viruses. It has been postulated that many cases of dengue virus infection were 
misdiagnosed. In many endemic areas of Asia, CHIKV overlaps with DENV, providing 
thus opportunities for Aedes mosquitoes to be coinfected by both viruses. Co-circulation of 
CHIKV and DENV is not uncommon in South - East Asia (14). Although CHIKV affected 
areas often overlap with DENV - endemic areas (554), however, simultaneous outbreak are 
rare. So far, no case of chikungunya has been reported in Vietnam, excepted in 1966 with 
10 infected American soldiers (555) and and a study on IgM in children between 2 and 14 
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years in Tien Giang general hospital (556). There is currently a lack of information on 
CHIKV in Vietnam. 
There is in Vietnam the simultaneous presence of the primary vector of dengue and 
chikungunya, i.e. A. aegypti in Vietnam and of the considered secondary vector, A. 
albopictus. Besides, weather conditions and local Vietnamese habit of storing water in 
containers at their house favor the development of mosquitoes. Identification of vectors 
and potential vectors of CHIKV and DENV in a given geographical areas has therefore 
important implications with respect to outbreak control. 
There are many reasons to believe that dengue and chikungunya are expanding and 
cocirculating in Vietnam. Movement of human populations from neighboring countries is 
considered a cause of expansion. Chikungunya infection was recently identified as a 
problem in Cambodia. During this reemergence of CHIKV in 2011, 24 patients was 
detected positive with CHIKV, during tests for Flaviviruses and Alphaviruses (557), with 
two chikungunya cases in two provinces border with Vietnam. In 2012, chikungunya 
outbreaks were reported in Laos with 197 cases in the Moonlpamok and Khong Districts of 
the Chamasak province (29). Vietnam shares borders with Cambodia and Laos and people 
mobility and trade between the neighboring countries may be a cause of transmission to 
Vietnam. 
 
3.2. Objective 
 
The objective of this part of the PhD was to understand the potential role of 
CHIKV and DENV as a cause of febrile illnesses in five provinces border with Laos and 
Cambodia in three regions of north, center and south of Vietnam during a non-epidemic 
period. In this section we investigated the incidence and clinical features of dengue and 
chikungunya infections. We also surveyed the populations of mosquitoes collected in the 
five provinces in order to identify circulating viruses. In addition, a phylogenetic analysis 
of the collected adult mosquitoes was conductedti cahcaterize the potential vectors. 
 
3.3. Discussion and conclusions 
 
To monitor the dissemination of the dengue and chikungunya viruses in Vietnam, 
we conducted active surveillance of acute febrile syndromes suspect DENV and CHIKV 
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throughout Vietnam from 2012 - 2014. To our knowledge, this study is the first to 
prospectively investigate the circulation of DENV and CHIKV, and the risk factors i.e. 
mosquitoes and water containers in three different regions, north, centre and south of 
Vietnam. Mosquito samples were collected in five provinces sharing borders with 
Cambodia and Laos. DENV is still a high burden in Vietnam but the presence of 
chikungunya is still unclear, for part because of lack of proper laboratory diagnosis 
capacity in patients samples. Although, both CHIKV and DENV have been detected in 
Cambodia and Laos, no CHIKV was detected among the hospitalized patients in Vietnam. 
However, CHIKV was detected in adult A. aegypti mosquitoes. 
The number of symptoms in patients under 18 was higher than in the older group. 
The most common symptoms on admission were myalgia, headache, fever, rash, petechia, 
and arthralgia. The dominant symptoms were myalgia and headache. From the clinical 
survey presented in this work, the only similar symptom between adult and pediatric 
patients was rash. Several symptoms, i.e. myalgia, fever, petechia and athralgia (p < 001), 
were shown to be significantly different between adult and pediatric patients. More males 
were found affected than females, in agreement with other reports in Nepal, China and 
Vietnam (558) (559) (560). There is no clear explanation for this bias which might be 
associated to occupational factors. Although all four DENV serotypes were circulating in 
three regions throughout the study period, the predominant serotype was DENV-1, 
circulating in both human and mosquito samples. The presence of the co-circulating four 
serotypes of DENV along with predominance of DENV- 1 reported in this work was 
similar to the result of previous research on DENV in Vietnam (561) and Cambodia (562).  
Entomological investigations conducted in this work provided an interesting insight 
on the potential dynamic of infection over the two years of the study. With the exception of 
Hue, where A. albopictus were as numerous as A. aegypti, the latter was overwhelming 
present in households in all other provinces. The most important ratio in favor of A. 
aegypti was found in Long An. These results match those from a previous survey 
conducted in 2010 where A. aegypti dominated in the south and A. albopictus was more 
present in the cool mountainous areas. This work provides however an insight on dengue 
dynamic different from what was expected. First, although A. aegypti is the most 
represented species most of the dengue-infected mosquitoes captured were A. albopictus. 
This species thus appears to be the main vector in Vietnam. This situation is particularly 
 
105 
 
sticking in the Southern province of Long An, neighbour of both Cambodia and Ho Chi 
Minh City and where the main tranboundary road system is located. In addition, Long An 
is the province where the highest number of mosquitoes have been captured with A. 
albopictus making less than 1% of the mosquitoes. Nevertheless, although A. albopictus 
represents 0.9% of the sampled population, it represents 50% of the infected mosquites in 
Long An. Another important conclusion from this work is that if there is indeed a regular 
introduction of dengue virus to Vietnam, the suspected introductions from Cambodia or 
Laos might represent only a small part of the process. As shown by phylogenetic data, 
there is no single local endemic population of mosquitoes but rather the cocirculation of 
several distinct populations countrywide. With the exception of QT_LB_albo_55M1 which 
belonged to the haplotype alb9 described in Thailand, all the other dengue-infected A. 
albopictus individuals belonged to the same population, with no haplotype name, 
characterized in Romania and described as an invasive population in Europe. The alb9 
dengue-infected-mosquito was a male indicating thus the presence of vertical transmission, 
a trait already known in dengue. The last dengue-infected mosquito was found not to be A. 
albopictus but instead Culex vishnui. This is to our knowledge the first time, C. vishnui, 
known for transmitting Japanese encephalitis, is found infected with dengue. 
Further indication of involvement of exogenous mosquitoes is also provided by the 
A. aegypti individuals. The dengue-infected A. aegypti mosquitoes were found to be 
associated to haplotypes described in Tamil Nadu, India (i.e. BUZOO-M-Aa), in the 
Martinique Island in the French West Indies (i.e. Martinique1) and in Thailand (i.e. aeg7). 
Interestingly, other individuals from the same haplotypes described in India and 
Martinique Island, i.e. BUZOO_M_Aa and Martinique 1, were found to be infected by 
CHIKV. Tamil Nadu and Martinique Island have been heavily infected by chikungunya  
(563) (564) (565) and the similarity of haplotypes also suggests that the chikungunya 
dynamic, like that of dengue, might be significantly supported by long distance-travelling 
mosquitoes rather than local populations.  
It seems important to decipher the movement of mosquitoes but not only at the Lao 
PDR and Cambodian borders as previously considered but rather through routes of 
international trade. This work is stressing the need to establish a genotype-based survey of 
circulating mosquitoes in Vietnam, not based as currently done on the species but instead 
on the population at the infra-species level. An integrative analysis encompassing the 
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genetic study of viral lineages on human patents and in mosquitoes along with the 
genotyping of mosquito population should be undertaken to provide clear information on 
the dynamic of dengue and chikungunya. Although no clinical chikungunya case was 
declared and no CHIKV was found on human samples in this work, the detection of 
CHIKV in mosquito haplotypes bound to worldwide movements and to areas with major 
chikungunya outbreaks indicate that the threat should be taken seriously and a dedicated 
surveillance programme should be implemented. From this work, dengue and 
chikungunya, appear as global threats that should not be addressed at a national or even 
regional scale but rather at a global, worldwide dimension of permanent exchanges and 
movements. 
This part of the PhD is presented in Manuscript under final stage of preparation for 
submission to Emerging Infectious Diseases. The manuscript, entitled “Aedes mosquitoes 
mobility, diversity and risk factors for the diffusion of dengue and chikungunya in 
Vietnam” is presented thereafter. 
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Abstract 
 
An active surveillance was conducted in Vietnam to assess the presence of dengue 
and chikungunya virus in patients hospitalized with acute fever in five Vietnam provinces 
neighbouring Lao PDR and Cambodia. This work conducted from 2012 to 2014 was 
completed by a survey of the mosquitoes found in the same areas. A total 558 human 
serums were collected along with 1104 adult mosquitoes (991 A. aegypti and 113 A. 
albopictus) and 10995 larvae (8542 A. aegypti and 2453 A. albopictus) from 2250 
households. Dengue virus was found in 17 (3%) human serum samples. No chikungunya 
virus was detected in human. Differing densities of mosquito populations were found with 
the highest one being in the Long An province border with Cambodia. Dengue viruses 
were detected mostly in A. albopictus. But CHIKV was also detected in A. aegypti. The 
phylogenetic analysis of the collected mosquitoes showed a large diversity of genotypes, 
all of them having been described in other parts of the world. New haplotypes were found, 
a Culex vishnui mosquito was found positive for dengue, making this species a potential 
vector. 
 
 
 3 
Introduction 
 
 In the current absence of vaccines and efficient therapeutic drugs, both dengue and 
chikungunya are expanding. There is an estimated number of 390 million dengue 
infections per year, out of which 96 million are asymptomatic (1). Over the past 50 years 
dengue has spread inexorably from 9 countries reporting dengue transmission prior to 1970 
to over 124 today (2).   Incidence has also increased 30 fold (2). Vietnam is one of five 
countries in the Southeast Asia with the highest dengue burden (3). Dengue fever was first 
described in northern Vietnam in 1958 and expanded to the southern area in 1960 (4). 
Despite the existence of a National Dengue Control Program since 1998, Dengue remains a 
major health problem in Vietnam and the number of cases has increased over the last past 
15 years (5). Dengue Fever (DF) and Dengue Haemorrhagic Fever (DHF) were leading 
causes of hospitalization from 1991 to 2004, accounting for 1,000,866 case over the whole 
country (6). It also increased every year in the urban central areas of Hanoi (7), while 
seasonal outbreaks have occurred in northern Vietnam over the last decade (8). Vietnam is 
a hyperendemicity country with all four dengue virus serotypes circulating, the dominant 
one varying over time (9). DENV 1 and DENV 2 are the most predominant serotypes, 
however DENV 3 emerged in the late 1990s and was responsible for the large outbreak of 
1998 whereas DENV 4 was also detected between 1999 and 2003 (10). Dengue transmission 
occurs throughout the year in Vietnam, with peaks (72% of total cases) reported between 
June and November, in especially in the southern part of the country during the rainy season 
from July to September (11). In the Northern and Central highland regions, dengue 
notifications are low during the winter time from December to March (12, 13). 
Chikungunya, a disease caused by an alphavirus, was isolated in Tanzania in 1953 
(13),  but has been present in Asia where a specific genotype circulates since the 1960s and 
was described in Vietnam in 1967 with 10 cases of American soldiers (14). In 2004, a new 
variant of CHIKV emerged in East Africa which quickly spread and generated major 
outbreaks over the Indian Ocean, India and Thailand (15, 16, 17, 18). This East-African 
reemerging CHIKV has been described in Cambodia in 2011 and in 2012, chikungunya 
outbreaks were reported in Laos with 197 cases in the Moonlpamok and Khong districts of 
the Chamasak province. However until now no clinical case of chikungunya has been 
described in Vietnam. Vietnam shares a border with Cambodia and Laos and there is thus 
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the possibility that CHIKV might circulate already in Vietnam but without being detected. 
Dengue and chikungunya symptoms are very similar, in particular in the early stage (19) 
making thus easy to confuse both diseases and underestimate the burden of chikungunya. 
Surveillance studies in Vietnam focus on dengue and detection of chikungunya is not 
considered. There are many reasons to suspect that chikungunya might have already 
expanded to Vietnam and might cocirculate with dengue. Long distance migration of 
DENV and CHIKV in Asia as well as transboundary movements of human populations can 
contribute to it. Furthermore, the same Aedes mosquito species are vectoring both viruses 
and are widely prevalent in the region (20). Co-circulation of CHIKV and DENV have 
already been reported, however, simultaneous outbreaks are rare.  
 
This work was therefore undertaken in connection with the National Vietnamese 
programs dengue surveillance to investigate a potential co-circulation of DENV and 
CHIKV and assess their respective role in febrile illnesses in several provinces in three 
regions of North, Central and South Vietnam having borders with Laos and Cambodia. 
This survey was conducted over two years to assess the prevalence of both viruses in 
patients hospitalized with acute fever and in mosquito populations present around the 
patient’s households.  
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Material and Methods 
 
Ethics. The study was approved by the Scientific and Ethical Committee of the National 
Institute of Hygiene and Epidemiology (NIHE), Hanoi, Vietnam, under supervision by the 
Ministry of Health. The study was conducted jointly with the Provincial Preventive 
Medicine Offices and the study received clearance and approval from the regional health 
directors. 
 
Location of sampling. Active surveillance of acute febrile syndromes was and collection 
of human blood samples were conducted from September 2012 to September 2014 in five 
preventive medicine centres in Ha Tinh, Thua Thien Hue, Quang Tri, Dac Nong and Long 
An (Figure 1). Mosquitoes were collected from districts of Huong Khe, Ha Tinh, A Luoi, 
Huong Hoa, Dac min, Moc Hoa belonging to the Ha Tinh, Hue, Quang Tri, Dac Nong and 
Long An provinces, respectively. All collection points were recorded by GPS. All selected 
provinces have borders with either Laos or Cambodia. 
 
Case definition and sampling. Acute phase blood samples were collected from patients 
admitted with high fever (> = 38.50C) and at least two of the following symptom: rash, 
myalgia, joint pain, swelling of joints, nausea/vomiting, and headache. Sera of acute febrile 
cases were obtained within 7 days after the onset of disease. Informed consent was 
obtained from the patient or from the parent or legal guardians of minors before the 
collection of sample. The information collected for each patient included a unique 
identification number and demographic data such as full name, age, gender, residential 
address, date of symptom onset or diagnosis, date of the first and second sample collection. 
Samples were coded and sent to the virology laboratory, National Institute of Hygiene and 
Epidemiology (NIHE), Hanoi, Vietnam. Acute phase serum samples was collected follow 
up serum sample taken from 3 to 5 ml, stored at 40C or in ice dry during the time for 
transferring in the day to preventive medicine centers of provinces in - 200C until being 
transfer to NIHE for RNA extraction and stored at - 800C. 
 
Mosquito collection. Collection of larvae, pupae and adult mosquitoes were conducted 
four times, i.e. in rainy and dry seasons, over two years from September 2012 to 
 
 6 
September 2014. For each province, collections were conducted in four communes of a 
district border with either Laos or Cambodia. Each selected commune was geo-referenced 
using a portable global positioning system (GPS). Door to door entomological survey was 
also conducted. However, procedures were slightly different for adult collection and for 
larvae and pupae collections. Adult mosquitoes were collected in and around households. 
A household was defined as single residential building, including any storage building, 
kitchen, latrine huts and garden as well as the outside areas up to the fenced partition 
separating a house from its neighbour. Household selection was performed in a systematic 
random manner. If it was not possible to include a house chosen in the study due to the 
absence of the owner, the closest neighbouring household was chosen instead. Mosquitoes 
were captured outdoor and indoor during day time day from 5 to 10 AM and 4 to 8 PM 
using a backpack aspirator. A total of 30 households were investigated in each commune. 
Collected mosquitoes were stored in RNAlater (Qiagen) and kept refrigerated at 40C prior 
to identification. Only A. aegypti and A. albopictus were retained and identification was 
performed according to morphological criteria following binocular examination. Mosquito 
samples were sorted according to species, sex, date of collection, geographical coordinates 
and number of mosquitoes for each location, and then stored at -800C in RNA later 
solution until further use. For the collection of larvae and pupae, all accessible artificial 
larval developmental sites such as discarded tires, water containers, fish water pot, flower 
pot, water jar/ pot, water tank, vase, wet container, etc., were searched for potential larval 
habitats in indoor and outdoor. Developmental sites were inspected using dippers, as 
previously described (21, 22). The equipment used for collection consisted of a standard 
mosquito dipper with extendable handle, pipette, spoon and torchlight. All of the potential 
developmental sites were examined using a flashlight. All collected mosquitoes were 
placed into plastic vials and labelled according to the date, location and container type. 
Identification was performed using morphological taxonomic keys. Only A. aegypti and A. 
albopictus were retained. 
 
DNA, RNA extraction and cDNA synthesis. Viral RNA was extracted from the human 
serum samples, and mosquito’s abdomens, DNA was extracted from the heads of mosquito 
samples using the QIAamp viral RNA Mini kit and QIAamp® DNA Micro Kit procedure 
(QIAgen, Hildden, Germany). .Elution was performed in 60 µl according to the supplier 
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and DNA, RNA stored at - 800C until further use. Purified RNA templates were 
transcribed into cDNA using Super transcript III reverse transcriptase (RT- Invitrogen). 
RNA templates were mixed with RNase-free DNase and incubated at 370C for 30 minutes 
and then 750C for 15 minutes. Annealing was performed at 250 C for 5 minutes, followed 
by extension at 420 C for 60 minutes and reaction was terminated by holding the mixture at 
700C for 15 minutes. 
 
PCR detection of DENV, CHIKV and COI gene. Multiplex PCR amplification was 
performed for dengue virus detection whereas Real Time PCR was implemented for 
chikungunya virus. For DENV, a one-step single tube serotype specific multiplex PCR was 
adapted from previously reports of Lanciotti et al. Amplification was carried out in 50µl 
with a dengue-virus group specific consensus forward primer and four serotype-specific 
reverse primers. Nonstructural protein 2 (nsP2) primers were used for CHIKV and COI 
primers for genome of mosquitoes (Table 1). PCR products were analyzed in a 2% (W/V) 
agarose gel containing 10% SYBR safe DNA gestain (Invitogen, S33102) in Tris- acetate- 
EDTA (TAE) buffer 1%. A 100-bp ladder was used as a molecular weight marker. The 
expected size of amplicons was 492 bp, 119 bp, 290 bp and 392 bp for DENV1, DENV2, 
DENV3 and DENV4, respectively. Chikugunya virus was detected by using quantitative 
Real-Time PCR. The non-structural protein 2 of CHIKV was used as template and 
amplified using light cycler 480 Syber Green I master enzyme (Roche). RT-PCR was run 
in a final volume of 50 μl. The standard cycling conditions were incubation at 95°C for 10 
min, followed by 40 cycles of denaturation at 95°C for 15 sec, annealing at 56°C for 30 
sec, extension at 72°C for 30 sec, and to monitor potential non-specific amplification, one 
cycle of 95°C for 15 sec, 60°C for 1 min, and 95°C for 15 sec. Data collection occurred 
during the 72°C extension step. Amplification was done using a Rotor-gene RG3000 
(Corbett Research). 
 
Entomological data analysis. All statistical analysis were done using R. All results were 
summarized in terms of medians and ranges for continuous data, odds ratio (OR), Chi 
square and Fisher exact tests were used as appropriate. Abundance was defined as the 
number of individuals of a species per container and used rainy and dry season relative as 
variables. The presence or absence of larvae of A. aegypti and/or A. albopictus or both 
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species co-occurrence were treated as binary dependent variables. Predictor variables were 
season collection, physiographic, container type and their possible two-way interactions. 
Entomological indices were defined as follows: House Index (HI), which is the percentage 
of houses infested with larvae and/or pupae. Container Index (CI), which is the percentage 
of positive containers (i.e. infested with larvae and /or pupae). Breteau Index (BI), which is 
the number of positive containers per 100 households. The 95% confidence interval was 
calculated for using an exact binomial test. 
 
Phylogeny analysis. Multiple sequence alignment was conducted using the MUSCLE 
program (23) available in the Seaview 4.5.1 package (24, 25). To determine the best fit 
model of nucleotide substitution, we used the MODELTEST program (26). Phylogenetic 
analysis was performed using maximum likelihood (ML) approach available within the 
PHYML package (27) and incorporating the GTR+Γ4 model of nucleotide substitution. A 
bootstrap resampling process (1,000 replications) was performed to assess the robustness 
of individual nodes on each phylogeny utilizing the ML substitution model.  
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Results 
 
General description of the study patient population. A total of 558 serum samples were 
collected from patients admitted in the 2012-2014 period in the five preventive medicine 
centres with acute fever and symptoms compatible to DENV- CHIKV infection. The 
patient cohort consisted of 253 females and 305 males, ranging from 4 months to 74 years 
with a median age of 24 years, and a mean age of 26 years (Table 2). No significant 
difference was recorded with respect to age with 269 patients below 18 (from 0.4 to 18) 
and 289 patients above 18 (from 19 to 74). The sex ratio was slightly biased towards males 
with 305 males patients out of 558 (54.6%) for 259 females patients out of 558 (45.4%). 
The most frequent symptom was myalgia (59%), followed by headaches (41%) and 
arthralgia (21%) (Table 2). All symptoms were significantly more represented in the 
population over 18 with the exception of rash which was similarly represented in both 
populations and nausea/vomiting which was more frequent for patients under 18 (Table 2). 
 
Frequency of DENV and CHIKV in the human cohort. 100, 91, 97, 142 and 128 serum 
samples were collected from Ha Tinh, Hue, Quang Tri, Long An and Dac Nong, 
respectively (Table 3). Out of these 558 acute-phase serum samples collected, 17 (3.05 %) 
were positive for dengue (Table 3). Dengue-positive samples were detected in all five 
provinces. The percentage of positive samples ranged from 2.06% to 5.47%. The highest 
rate was found in the southern province of Dac Nong. Rates of positive DENV samples 
were 2.06%, 2.11%, 3.00%, 3.30% and 5.47% for Quang Tri, Long An, Ha Tinh, Hue and 
Dac Nong, respectively (Table 3). The four serotypes were simultaneously found only in 
Dac Nong. The combination of DENV1 and DENV2 was found only in Hue and Long An 
whereas the combination of DENV1 and DENV3 was found in Ha Tinh and Quang Tri 
(Table 3). Altogether, the most frequent serotype was DENV1 (1.25 %), followed by 
DENV2 (0.90 %); DENV3 (0.72 %) and DENV4 (0.18 %). No positive CHIKV sample 
was identified. 
 
Frequency of DENV and CHIKV in adult mosquitoes. A total of 1104 adult Aedes 
mosquitoes have been captured from an overall 2268 households. A. aegypti made up 89.8 
% (991 individuals) of the captures while A. albopictus represented only 10.2 % (113 
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individuals) (Table 4). When considering the breakdown per province, the two 
southernmost provinces displayed a far higher density of adult mosquitoes in the vicinity 
of households with 285 and 580 individuals captured in Dac Nong and Long An, 
respectively whereas in Ha Tinh, Hue and Quang Tri, the number of adults captured was 
74, 92 and 70, respectively (Table 4). This Southern / Central-North Central difference was 
also observed in the A. aegypti / A. albopictus ratio (Table 4). Out of 580 individuals 
captured in Long An, no A. albopictus was identified and in Dac Nong only 3 A. albopictus 
were present for 285 A. aegypti. In Ha Tinh the rate of A. albopictus was 25.7 % (19 out of 
74) and in Quang Tri 9.35 % were A. albopictus (6 out of 64). In Hue the ratio was 
reversed with a strong predominance of A. albopictus (92.4 % or 85 out 92 individuals) 
(Table 4). Out of the 1104 adults Aedes mosquitoes collected, 9 (0.8%) were infected with 
dengue. 4 positive samples were found in Long An, 3 bearing a DENV2 virus and 1 
bearing a DENV4 strain. 2 dengue-positive mosquitoes were found in Dac Nong, each one 
bearing a different DENV serotype (DENV1 and DENV4). Two infected mosquitoes were 
also found in Quang Tri, both with a DENV1 virus and only one DENV1-infected 
mosquito in Ha Tinh. No infected mosquito was found in Hue. With respect to species 
distribution, only A. aegypti were infected in the two southern provinces whereas only A. 
albopictus individuals were found infected in the central/north central provinces (Table 4). 
Two mosquitoes were found to be infected by CHIKV, both in the southern province of 
Long An, and both in A. aegypti which was the only species captured in this province 
(Table 4). 
 
Distribution of mosquito populations. A total 8269 water containers coming from 2698 
households were sampled from September 2012 to September 2014. A total of 12041 
larvae were collected from the five provinces. 9588 larvae (80%) were identified as A. 
aegypti whereas 2453 (20 %) were A. albopictus individuals (20%) (Table 5). When 
considering the provincial breakdown, the ratio between A. aegypti and A. albopictus was 
1046/551, 1147/423, 1147/1022, 760/411 and 5126/46 for Ha Tinh, Quang Tri, Hue, Dac 
Nong and Long An, respectively (Table 5). Entomological indexes indicated some 
disparities between the provinces and no correlation between the number of infected 
houses, number of containers and mosquito density (Table 5). In Long An, while about 
five more times open water containers were present, only 19.2% of the containers were 
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positive for mosquito larvae and only 3 % of the houses were infected. The Breteau Index 
(205) was highest of all the provinces analysed while the House Index (3.02) was the 
lowest. Conversely, in Dac Nong the Breteau Index (35.71) was 6 times lower than in 
Long An and the number of larvae 10 times lower (1693 vs. 16480) while the House Index 
(9.21) was three time higher (Table 5). 
 
Vectoring capacity and genetic structure of mosquito populations. DENV- positive 
adult mosquitoes were found in four out of the five provinces studied (Table 4). In Dac 
Nong, two adult females were found positive, an A. albopictus individual infected with 
DENV4 and an A. aegypti mosquito infected with DENV1. In Long An four infected 
mosquitoes were identified, an A. albopictus female harbouraging DENV4 and three other 
individuals, one A. albopictus and two A. aegypti, all infected with DENV2. In Ha Tinh, 
one infected mosquito was captured, an A. albopictus female carrying DENV2. In Quang 
Tri, two A. albopictus individuals infected with DENV2 were found, one of those being a 
male which indicates the occurrence of vertical transmission. No infected mosquito was 
found in Hue. With respect to CHIKV, two infected A. aegypti mosquitoes were found, one 
in the province of Long An and the second one in the province of Dac Nong (Table 4). 
The COI phylogenetic analysis of the captured mosquitoes revealed the 
simultaneous presence in all sites of genetically diverse populations (Figure 2). Two main 
groups were found which corresponded to the main vectoring species, i.e. A. aegypti and A. 
albopictus. Each group was divided into several clusters of identical or nearly identical 
sequences (Figure 2). No geographic discrimination was found. Several mosquito 
individuals did not fall within any of the clusters and when analysing their sequence on 
BLAST, they were found to correspond either to unknown haplotypes, to known 
haplotypes described in other countries (i.e. Colombia, or to different mosquito species 
mistakenly identified as A. albopictus when sampling, i.e. Aedes w-albus, Aedes mcintoshi, 
Aedes cogilli, Culex vishnui and Ochlerotatus flavescens. One of these misidentified 
mosquito, i.e. Culex vishnui, was found to harbor the dengue virus DENV4 (Table 6). 
Interestingly, the COI mosquito haplotypes found in the five provinces covered by the 
study and distributed over the 10 clusters identified (Figure 2; Table 6) have been 
described in other parts of the world (Table 6). 
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Discussion 
 
To our knowledge, this study is the first to investigate vectors distribution, DENV 
and CHIKV circulation and occurrence in patients hospitalized with acute febrile 
symptoms, in a comparative way over several provinces throughout Vietnam. Results 
coming from this active surveillance conducted over two years in five provinces 
neighbours with Lao PDR where dengue is present and Cambodia where both dengue and 
chinkungunya are present bring a new perspective on the dynamic of these diseases. 
 
The average rate of dengue among acute fever patients was about 3% and ranged 
from 2.06 % to 5.7% depending on the province. This is 10- to 5-times less than previously 
reported incidence rates among acute fever inpatients (28, 29). This lower incidence could 
be related to an improved primary dengue diagnostic, the current study being more recent. 
It could also be a consequence of the focus of this study on regional health centres while 
suspected dengue cases might be directed to major hospitals. The presence of all four 
serotypes of dengue is in accordance with the hyper-endemic status of Vietnam (30, 8). 
 
The main result of this work is the lack of correlation observed between the 
incidence rates, the mosquito population density and the data on their genetic diversity 
which could shed a new light on the complex dynamic of dengue in Vietnam. Dengue virus 
was shown to undergo a complex dynamic involving both serotype and lineage 
replacements (31, 32, 33, 34, 35). Although many parameters could be involved in this 
mechanism, replacement was thought to be more stochastic than selective (32, 36). 
Raghwani et al. (36) reported the occurrence of differential dynamics depending upon rural 
or urban areas in South Vietnam. They demonstrated that infections were moving from 
urban to rural populations, which in turn could explain, at least in part, the lower incidence 
rate observed in this work, with Ho Chi Minh City playing a major role as an infection 
foci. The transmission gradient was linked to the human population density and the low 
rate of virus dispersal, i.e. 20km/year, associated to mosquito-mediate dispersal (36). 
Although in full agreement with these conclusions, the data reported here lead to a slightly 
different insight on the dynamic of dengue in Vietnam. 
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Dengue is considered being regularly introduced to Vietnam from Cambodia, 
mostly through people mobility (36). South-Vietnam and the Mekong River delta represent 
therefore regions at risk for high incidence. The data reported here provide a slightly 
different picture. The province of Long An, neighbour to Cambodia on one side and to Ho 
Chi Minh City on the other did not display the higher rate of incidence as expected but 
instead one of the lowest despite a very high Breteau Index indicative of a bad mosquito 
management system, proximity to high human population density and presence of the main 
cross border road system. The province with the highest incidence rate was the southern 
province Dac Nong. However, the province was also the one with the lowest population 
density of mosquitoes, i.e. Long An  10-times less than the other provinces. The Breteau 
and Container Indexes were the second lowest ones whereas the House Index was the 
highest one, in agreement with the observed incidence rate. This suggest that it is not the 
overall Aedes density that should be considered but rather some specific populations, 
perhaps less numerous but more actively involved in the effective transmission of the 
virus. 
 
Another set of data from this work could bring together these conclusions and those 
from Raghwani et al., 2011 (36). The phylogeny and genetic diversity of the adult 
mosquitoes captured near the health centres investigated shed a new light on the 
mechanisms involved in the dynamic of dengue. The captured mosquitoes corresponded to 
COI haplotypes described in other parts of the world. Furthermore, unknown haplotypes 
were sequences along with other species mistakenly identified as A. albopictus. The high 
genetic diversity observed combined with clearly delineated cluster gathering mosquitoes 
from the different provinces indicated the absence of geographic discrimination. The 
sampled mosquito haplotypes are present all over the country but also in other countries 
and continents. It is not possible to say whether these mosquito populations originated in 
Vietnam and were moved to other places or conversely were moved to Vietnam from other 
parts of the world. Nevertheless, this worldwide description of the same haplotypes 
indicates a very large mobility of mosquitoes, most likely due to international trade, and 
therefore of viruses. This could participate to the explanation for regular virus replacement 
(31, 32,33, 34, 35), for the stochastic determinism of these replacements (32, 35), and for 
the higher presence in urban areas more prone to international trade exposure (36). It 
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seems that if there is indeed a regular introduction of dengue virus to Vietnam, the 
suspected introductions from Cambodia might represent only part of the process. As shown 
by phylogenetic data, there is no single local endemic population of mosquitoes but rather 
the cocirculation of several distinct populations countrywide. This conclusion is reinforced 
by the presence of unknown haplotypes among the samples. Two interesting facts also 
emerged from the study. The first one is that although A. aegypti outnumbered A. 
albopictus, the latter appeared to be more present among the infected individuals. This is 
particularly true for the southern province of Long An where A. albopictus made 50 % of 
the infected mosquitoes while they only represented 0.9% of the sampled mosquitoes. In 
the Northern/Central provinces of Ha Tinh and Quang Tri, where A. albopictus made up to 
27-28% of the sampled mosquitoes, this species was the only one to harbour dengue 
viruses. Interestingly, in Hue where A. albopictus represented 47% of the captured 
mosquitoes, no infected individual was found. The other interesting fact relates to the 
haplotype of the dengue-infected A. albopictus mosquitoes. With the exception of 
QT_LB_albo_55M1 which belonged to the haplotype alb9 described in Thailand, all the 
other dengue-infected A. albopictus individuals belonged to the same population, with no 
haplotype name, characterized in Romania and described as an invasive population in 
Europe (37). The alb9 dengue-infected-mosquito was a male indicating thus the presence 
of vertical transmission, a trait already known in dengue (38, 39, 40). The last dengue-
infected mosquito was found not to be A. albopictus but instead Culex vishnui. This is to 
our knowledge the first time, C. vishnui, known for transmitting Japanese encephalitis, is 
found infected with dengue. There is no evidence from the data reported here that C. 
vishnui can efficiently transmit dengue to human through a blood meal. However, there is 
at least the demonstration that C. vishnui can take the dengue virus and therefore be 
considered a potential vector. Further research should be considered to investigate the 
occurrence of efficient transmission of dengue in this already medically-important 
mosquito group. 
 
Further indication of involvement of exogenous mosquitoes is also provided by the 
A. aegypti individuals. The dengue-infected A. aegypti mosquitoes were found to be 
associated to haplotypes described in Tamil Nadu, India (i.e. BUZOO-M-Aa), in the 
Martinique Island in the French West Indies (i.e. Martinique1) and in Thailand (i.e. aeg7). 
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Interestingly, other individuals from the same haplotypes described in India and 
Martinique Island, i.e. BUZOO_M_Aa and Martinique 1, were found to be infected by 
CHIKV. Tamil Nadu and Martinique Island have been heavily infected by chikungunya  
(18, 41, 42) and the similarity of haplotypes also suggest that the chikungunya dynamic, 
like dengue, might be significantly supported by long distance-travelling mosquitoes rather 
than local populations.  
 
It seems important to decipher the movement of mosquitoes but not only at the Lao 
PDR and Cambodian borders as previously considered but rather through routes of 
international trade. High human population density foci are thus important to target as 
proposed by Raghwani et al. 2011 (35), but perhaps more because of their exposure to 
international exchanges than purely because of population density. 
 
This work is stressing the need to establish a genotype-based survey of circulating 
mosquitoes in Vietnam, not based as currently done on the species but instead on the 
population at the infra-species level. An integrative analysis encompassing the genetic 
study of viral lineages on human patents and in mosquitoes along with the genotyping of 
mosquito population should be undertaken to provide clear information on the dynamic of 
dengue and chikungunya. Although no clinical chikungunya case was declared and no 
CHIKV was found on human samples in this work, the detection of CHIKV in mosquito 
haplotypes bound to worldwide movements and to areas with major chikungunya 
outbreaks indicate that the threat should be taken seriously and a dedicated surveillance 
programme should be implemented. From this work, dengue and chikungunya, appear as 
global threats that should not be addressed at a national or even regional scale but rather at 
a global, worldwide dimension of permanent exchanges and movements. 
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Table 1: Oligonucleotide primers used to amplify and type dengue, chikungunya viruses 
and COI gene 
 Primer Sequence Position1 Size 
DENV D1 5’-TCAATATGCTGAAACGCGCGAGAA ACCG-3’ 616-644 511 
TS1 5’-CGTCTCAGTGATCCG GGGG-3’ 568-586 482 ( D1 and TS 1) 
TS2 5’-CGC CAC AAG GGC CAT GAA CAG-3’ 232-252 119 ( D1 and TS 2) 
TS3 5’-TAA CAT CAT CAT GAG ACA GAGC-3’ 400-421 290 ( D1 and TS 3) 
TS4 5’-TGTTGTCTTAAACAAGAGAGGTC-3’ 506-527 392 ( D1 and TS 4) 
CHIKV NSP2-F 5’-GGCACTGGTCCCAGATAATTCAAG-3’ 3181-3241 120 
 NSP2-R 5’- GCTGTCTAGTACCACCCCATACATG-3’   
COI 
gene 
COI F 5’- TATCGCCTAAACTTCAGCC -3’  1651 
COI R 5’- CCTAAATTTGCTCATGTTGCC -3’   
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Table 2: Frequency of symptoms upon admission 
Patient ( n = 558) Value 
   
Odds ratio 
(OR) 
<18 years 
n = 269 
>18 years 
n = 289 
P-value 
Age (years);(mean, range) 26 (0.4-74)  (0.4-18) (19-74)  
Sex (M/F) (%)  305/253(54.6%/45.4%) 1.2    
Duration of febrile (mean, range)  3.6  (1-7 days)     
Signs and symptoms Temperature on admission (°C) (range) 38.8 (38-40 °C)     
 Headache 248 (44%) 0.8 36.4% 51.9% 0.0003 
 Myalgia 328 (59%) 1.4 30.8% 64.8% 0.0001 
 Arthralgia 117 (21%) 0.3 10.0% 31.1% 0.0001 
 Rash 189 (16%) 0.5 35.3% 32.5% 0.5311 
 Petechia 156 (10%) 0.4 15.6% 38.8% 0.0001 
 Nausea/ Vomiting 68 (3.2%) 0.13 13.7% 1.04% 0.0001 
 Positive Tourniquet test 53 (9.5%) 0.1 4.5% 14.2% 0.0001 
Warning sign Back pain 56 (10%) 0.11 1.85% 17.7% 0.0001 
 Bleeding gums 18 (3.2%) 0.03 0.74% 5,54% 0.0001 
 Abdominal pain 38 (6.8%) 0.07 3.34% 10.03% 0.001 
 
Note: Value are the mean (range) or number (%)
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Table 3 : Frequency of DENV and CHIKV in the human serum. 
________________________________________________________________________________ 
Province  Nb patients         Dengue serotype  Chikungunya  
      _____________________ 
      D1 D2 D3 D4 
________________________________________________________________________________ 
Ha Tinh  100   1 0 1 0  0 
Hue     91   1 2 0 0  0 
Quang Tri    97   1 0 1 0  0 
Dac Nong  128   2 2 2 1  0 
Long An  142   2 1 0 0  0 
Total   558   7 5 4 1  0 
_________________________________________________________________________ 
 
Table 4: Incidence of dengue and chikungunya virus in collected adult mosquitoes 
Province Number of mosquito Dengue-positive Chikungunya-positive 
A. aegypti A.albopictus A. aegypti A. albopictus A. aegypti A. albopictus 
Ha Tinh 55 (5.55%) 19 (16.81%)  1 x DENV 1 0 0 
Hue 7 (0.7%) 85 (75.2 %)   0 0 
Quang Tri 64 (6.46%) 6 (5.3%)  2 x DENV 1 0 0 
Dac Nong 285 
(28.8%) 
3 (2.65%) 1 x DENV 1 
 
1 x DENV 4 1 0 
Long An 580 
(58.5%) 
0 (0%) 2 x DENV 2 
 
1x DENV 2 
1 x DENV 4 
1 0 
 991 (100%) 113 (100%) 3 6 2 0 
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Table 5. Distribution of Aedes larvae and entomological indexes 
______________________________________________________________________________________________________________ 
Province N° Houses N° Positive N° Containers N° Positive A. aegypti A. albopictus BI CI HI 
  Explored Houses  Explored Containers Larvae  Larvae 
Ha Tinh  450  41 (8.1%) 936  79 (8.4%) 1046       
 551  17.56 8.44 8.12 
Quang Tri 420  24 (4.9%) 778  170 (21.9%) 1147  423  40.48 21.85 4.82 
Hue  480  40 (6.8%) 730  202 (27.7%) 1147  1022  42.08 27.67 6.77 
Dac Nong 420  47 (9.2%) 807  150 (18.6%) 760  411  35.71 18.59 9.21 
Long An  480  18 (3.0%) 5128  984 (19.2%) 5126  46  205 19.19 3.02 
Total  2250  170 (7.5%) 8549  1585 (18.5%) 8542  2453 
 
BI: Breteau Index =   Nb Positive Containers / Nb Houses Explored x 100 
CI: Container Index = Nb Positive Containers / Nb Containers Explored x 100 
HI: House Index = Nb Positive Houses / Number Houses Explored x 100 
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Table 6. Distribution of haplotypes among captured adult mosquitoes 
 
Strain  Cluster   Species   Haplotype  Country    Accession number 
19M22  Individual  Aedes aegypti  Unknown  Unknown   NA 
19M32  Individual  Aedes aegypti  Unknown  Unknown   NA 
22F4  Individual  Aedes aegypti  Unknown  Unknown   NA 
19M34  Individual  Aedes aegypti   Haplotype 68  Colombia   KM203207 
19M25  Individual  Aedes aegypti  Haplotype 80  Colombia   KM203219 
22F7  Individual  Aedes aegypti   Haplotype 14  Colombia   KM203153 
39F2  Individual  Aedes aegypti  Unknown  Unknown   NA 
49F7  Individual  Aedes aegypti  Unknown  Unknown   NA 
20M3  Individual  Aedes aegypti  Unknown  Unknown   NA 
19M24  Individual  Aedes aegypti  Unknown  Unknown   NA 
19M20  root individual  Aedes aegypti  CDC11   Colombia   KM452747 
19M29  Individual/C1  Aedes aegypti   Guinea 1   Guinea    JQ926700 
19M33  Individual/C1  Aedes aegypti  BUZOO-M-Aa  India    KR817731 
34M14  Cluster 1   Aedes aegypti  Haplotype 70  Colombia   KM203209 
24F1  Cluster 1   Aedes aegypti   BUZOO-M-Aa  India    KR817731 
26F3  Cluster 1   Aedes aegypti   BUZOO-M-Aa  India    KR817731 
19M23  Root Cluster 2  Aedes aegypti  Haplotype 37  Colombia   KM203176 
34M7  Root Cluster 2  Aedes aegypti   BUZOO-M-Aa  India    KR817731 
9M5  Root Cluster 2  Aedes aegypti  None   India    KJ680548 
19M10  Cluster 2   Aedes aegypti  aeg7   Thailand    KP843388 
30F5  Cluster 2   Aedes aegypti   aeg7   Thailand    KP843388 
19M21  Cluster 2   Aedes aegypti   aeg7   Thailand    KP843388 
28F5  Cluster 2   Aedes aegypti   aeg7   Thailand    KP843388 
06F3  Root Cluster 3  Aedes aegypti  Isolate 4   Brazil    JX456414 
19M5  Cluster 3   Aedes aegypti  Martinique 1  Martinique (French Caribbean) JQ926696 
06F2  Cluster 3   Aedes aegypti  Martinique 1  Martinique (French Caribbean) JQ926696 
01F4  Cluster 3   Aedes aegypti  Martinique 1  Martinique (French Caribbean) JQ926696 
47F2  Cluster 3   Aedes aegypti  Isolate 2   Brazil    JX456412 
29F3  Cluster 4   Aedes aegypti   BUZOO-M-Aa  India    KR817731 
01F10  Cluster 4   Aedes aegypti  Vietnam 5  Vietnam    JQ926687 
59F3  Cluster 5   Aedes aegypti  BUZOO-M-Aa  India    KR817731 
20M1  Cluster 5   Aedes aegypti   Haplotype 94  Colombia   KM203233 
72F1  Cluster 6   Aedes albopictus    AB7   Thailand    KM613099 
7M6  Cluster 6   Aedes albopictus  alb9   Thailand    KP843400 
49f13  Cluster 6   Aedes albopictus  alb9   Thailand    KP843400 
49f11  Cluster 6   Aedes albopictus   AB7   Thailand    KM613099 
49f3  Cluster 6   Aedes albopictus  None   Romania    HF536717 
22F5  Cluster 6   Aedes albopictus  None   Romania    HF536717 
37F2  Cluster 6   Aedes albopictus  None   Romania    HF536717 
45m4  Cluster 6   Aedes albopictus  alb9   Thailand    KP843400 
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46F4  Cluster 7   Aedes albopictus  None   Romania    HF536717 
50m4  Cluster 7   Aedes albopictus  None   Romania    HF536717 
19m13   Cluster 7   Aedes albopictus  None   Romania    HF536717 
55M1  Cluster 7   Aedes albopictus  alb9   Thailand    KP843400 
50M1  Cluster 8   Aedes albopictus   alb9   Thailand    KP843400 
50M14  Cluster 8   Aedes albopictus  alb9   Thailand    KP843400 
49F10  Cluster 9   Aedes albopictus  alb9   Thailand    KP843400 
56F1  Root C10   Aedes albopictus  None   Romania    HF536717 
17F6  Cluster 10  Aedes albopictus  None   Romania    HF536717 
72F7  Cluster 10  Aedes albopictus  None   Romania    HF536717 
36F3  Cluster 10  Aedes albopictus  alb9   Thailand    KP843400 
19m26  Individual (72%)  Aedes aegypti  BUZOO-M-Aa  India    KR817731 
44f6  Individual  Aedes w-albus  NIBGE MOS-00132 Pakistan    KF406649 
63f1  Individual  Aedes mcintoshi  SEN5   Senegal    KJ940759 
50m8   Individual  Aedes albopictus  H_5   Vietnam    LM999976 
64F2  Individual  Ochlerotatus flavescens NHM014_5  UK    KC602635 
01F8  Individual  Culex vishnui  564IRI2008  Unknown   AB738195 
39F1  Individual  Aedes cogilli  NIBGE MOS-01588 Pakistan    KF406621 
39F3  Individual  Aedes cogilli  NIBGE MOS-01588 Pakistan    KF406621 
38M2  Individual  Aedes cogilli  NIBGE MOS-01588 Pakistan    KF406621 
38M3  Individual  Aedes cogilli  NIBGE MOS-01588 Pakistan    KF406621 
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 Figure 1: Viet Nam map and sampling sites 
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 Figure 2:  The genetically diverse populations of mosquitoes 
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GENERATION CONCLUSSION AND PERSPECTIVES 
 
 
This work on the surveillance and dynamic of dengue and chikungunya in Vietnam 
has brought a new insight and raised questions upon situations, which happened to be 
preconceived ideas. First of all this work is to our knowledge the first one to have been 
conducted in a comparative way at such a scale over the whole country. All previous 
reports have described local events and outbreaks and although rightful conclusions have 
been drawn, they reflected the local dynamic. A broader view was needed to understand 
the dynamic of these diseases. 
 
 The first conclusion is that it very difficult to draw general conclusions on the main 
vector of dengue. In this work, two opposite conclusions were reached depending on 
location and perhaps time. In the dengue outbreak in Hanoi in 2011, A. aegypti was clearly 
shown to be the vector responsible for the diffusion dengue. A clear correlation was 
observed between the density of local populations of A. aegypti and clinical cases of 
dengue. A. albopictus did not play any role. When the global analysis was conducted in 
several provinces from North, Central and South Vietnam, the main vector was clearly A. 
albopictus and even more importantly haplotypes described in other parts of the world, 
including the haplotype recently described as invasive in Europe. Several hypotheses could 
be drawn to explain this apparent discrepancy. This difference could be explained by a 
specific situation in Hanoi, which is a highly densely populated urban area where A. 
aegypti might be more prevalent owing to its adaptation to the urban environment when 
compared to A. albopictus. A. aegypti is indeed far more anthropophilic than A. albopictus 
and then might be logically more important in high urban areas like the capital city. The 
survey conducted within this PhD work on the several provinces where A. albopictus was 
found to be the most important vector was conducted on rural areas where A. albopictus 
might be more competitive than A. aegypti. Another explanation might be found in the fact 
that the Hanoi analysis was conducted in 2011 whereas the several provinces analysis was 
conducted in 2012-2014. It is not possible to exclude a replacement of mosquito 
populations in the meantime. This hypothesis is however not very strong since in the 
several provinces study, A. aegypti was clearly the dominant species. A last explanation 
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might be found in the way the analysis was designed, which could be also a self-criticism 
of this work. The conclusions from the Hanoi study were based essentially on the 
correlation between the density and time of occurrence of mosquito populations and the 
number of clinical cases. However the ample size was limited. In the several provinces 
analysis, A. albopictus was shown to be the main vector for dengue although population 
density of A. aegypti was higher. This is particularly true for the Long An province were A. 
albopictus made 0.9% of the mosquitoes captured and 50% of the dengue-infected 
individuals. However, if the number of clinical cases in Long An had been correlated to the 
population density of mosquitoes using a smaller sample, the study might have instead 
concluded in the overwhelming role of A. aegypti. 
 
 This PhD work demonstrates the need of a comprehensive and coordinated 
approach when analyzing the dynamic of dengue, and chikungunya. Such studies should 
not be conducted on isolated outbreaks as the sum of individual studies does not 
necessarily give a true vision of the whole context. Instead, surveillance studies should be 
designed at the national level and based on the same master plan including both clinical 
and entomological studies with virus detection in all samples. Genotyping of mosquito 
populations should be mandatorily performed but also virus genotyping, from both human 
and insect samples, in order to be able to conduct the analysis of the dynamic of the disease 
at the level of the viral lineage. The viral lineage is the true level at which virus circulation 
should be considered, just like populations, i.e. infra specific, for the mosquitoes. The 
species and serotype levels are not accurate enough to allow for a precise analysis of 
circulation and association mapping. A first recommendation and perspective from this 
work would be therefore to develop such an integrated analysis framework and propose it 
to NIHE and at the national level. This should also include an homogeneous and integrated 
database and database management system compatible with spatio-temporal analysis. 
 
This is particularly relevant when considering, another major conclusion from this 
PhD work, that mosquito populations involved are not local populations but instead 
populations circulating worldwide. The analysis should therefore not concentrate on local 
populations of mosquito, although they can play a role, but instead on the regular 
monitoring of mosquito populations, and in particular at the points of entry like seaports. 
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Such procedures should also be developed, and this could be another perspective from this 
work. Genotyping, suitable databases and comparative analysis of worldwide mosquito and 
virus sequences must be developed but also geographic analysis and international trade 
movements. 
 
A last aspect unveiled by this work is the limited adaptation of the current 
surveillance and monitoring procedures implemented at hospitals and public health centers. 
As shown in the Dong Thap surveillance work, serological tests done upon admission are 
underestimating the number of dengue-positive patients. In addition, it does not allow for 
lineage identification. Chikungunya is not tested at all. It would be too expensive and 
practically difficult to implement a multi-step serological test and still the results would not 
be fully satisfactory. We therefore propose as a final recommendation and perspective 
from this PhD work to implement a multiplex-PCR test detecting at once the four types of 
dengue virus and the old an reemerging chikungunya viruses associated with the 
sequencing of the positive samples. The cost of PCR and sequencing is now very low and 
the public health benefits largely compensate the cost of the surveillance. This should be 
linked to the same integrated system of dynamic databases as for mosquito surveillance. A 
proposal should be made at NIHE and at the national level for such a procedure. 
 
As a final word, this PhD work as underlined some key issues to be addressed in a 
coordinated way in order help developing an efficient surveillance and monitoring system 
for both dengue and chikungunya in Vietnam. Developing these systems and tools will 
thus be both a challenge and an exciting outcome of this work. 
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Summary 
 
Dengue and chikungunya are both transmitted by Aedes aegypti and Aedes albopictus 
and can cause potentially severe and or debilitating chronic disease. They are the fastest 
spreading diseases, in part because of the climate change. Vietnam is a hyperendemicity 
country for dengue and is at risk to be like neighboring Cambodia affected both by dengue 
and chikungunya and be an overlapping area of distribution for both viruses. The aim of 
this PhD work was therefore to assess the status of single and dual infections all over the 
country, investigate the presence of chikungunya, assess the efficiency of the surveillance 
procedures routinely established and assess the diversity of mosquito populations and their 
potential respective role. A first part of the PhD dissertation is devoted to a bibliographic 
review. The second part comprises three chapters associated to three different publications. 
The first chapter is devoted to a surveillance study in the general hospital if the Southern 
Province of Dong Thap. A cohort of 131 patients with acute fever symptoms was 
investigated for the presence of dengue and chikungunya. 101 patients out of 131 were 
confirmed with dengue. All four dengue serotypes were detected with a predominance of 
DENV2 and DENV4. No chikungunya infection was detected although reported in 
neighboring Cambodia. A differential efficiency of serological dengue detection was 
observed. Efficiency was 29% upon admission and 53% after seven days on the same 
patients. There is thus a clear risk of dengue being underestimated while chikungunya is 
not systematically detected. Changes in detection and surveillance procedures are therefore 
proposed to increase the efficiency of dengue detection and continue the monitoring the 
emergence of CHIKV. The second Chapter is dedicated to the respective role of A. aegypti 
and A. albopictus in the 2011 outbreak in the Northern capital city of Hanoi. Only DENV-
1 and DENV-2 serotypes were detected from the 140 patients hospitalized. A positive 
correlation was found between the population density of A. aegypti and the number of 
human cases and duration of outbreaks. This was not observed for A. albopictus. Three 
pools of A. aegypti were positive with dengue virus, two with DENV-1 and one with 
DENV-2. This work indicate clearly the role of A. aegypti in the 2011 Hanoi epidemics. 
The last chapter of the PhD is devoted to a crosscutting country wide survey in five 
provinces border with Lao PDR and Cambodia. In this work, a total of 558 serum samples 
were collected from patients admitted in the 2012-2014 period in five provincial preventive 
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medicine centers with acute fever and symptoms compatible to DENV-CHIKV infection. 
All four dengue serotypes were found altogether but not in the same province. Only two 
serotypes were found at the maximum in a single province. No CHIKV was detected. A 
total of 1104 adult mosquitoes were collected inside and outside houses at the same place. 
Mosquito population density and vector indexes were assessed following capture of larvae. 
Differing densities of mosquito populations were found with the highest one being in the 
Long An province border with Cambodia. Dengue viruses were detected mostly in A. 
albopictus. CHIKV was also detected in A. albopictus mosquitoes. The phylogenetic 
analysis of the collected mosquitoes showed a large diversity of genotypes, all of them 
having been described in other parts of the world. This part of the PhD work underline the 
dual role of A. aegypti and A. albopictus, the increasing role of the latter and the high level 
of man-related very long distance mobility of mosquitoes. This work underlines the need 
of novel approaches for surveillance both at the clinical and at the entomological level to 
efficiently tackle the risk of dengue and chikungunya outbreaks. 
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Résumé 
 
La dengue et le chikungunya sont des maladies transmises par Aedes aegypti et Aedes 
albopictus pouvant causer des pathologies sévères et des atteintes incapacitantes 
chroniques. Ce sont aussi les maladies qui se diffusent le plus rapidement, en partie à cause 
du changement climatique. Le Vietnam est une zone d’hyperendémicité pour la dengue et à 
risque pour le chikungunya comme le Cambodge voisin qui est atteint par les deux 
maladies.et représente une source de diffusion. L’objectif de cette thèse est d’évaluer le 
statut de ces deux maladies et la présence du chikungunya, d’évaluer l’efficacité du 
système de surveillance et d’évaluer la diversité des populations de moustiques vecteurs et 
leurs rôles respectifs dans la transmission. Une première partie de la thèse est dévolue à 
une revue bibliographique. La seconde partie comprend trois chapitres associés à trois 
publications. Le premier chapitre est consacré à une étude de la surveillance à l’hôpital 
général de la province sud de Dong Thap. Une cohorte de 131 patents avec une fièvre 
aigue a été étudiée pour tester la présence de dengue et de chikungunya. 101 patients sur 
131 ont été positifs pour la dengue et les quatre sérotypes ont été détectés avec une 
prédominance de DENV1 et DENV4. Aucun cas de chikungunya n’a été détecté. Une 
variation d’efficacité dans la détection sérologique de la dengue a été observée avec un 
passage de 29% lors de l’admission à 53% sept jours après admission. Il y a donc 
clairement un risque de sous-estimation de la dengue alors que le chikungunya, n’est pas 
du tout testé. Des changements dans la procédure de détection et de surveillance sont 
proposés pour améliorer l’efficacité de la surveillance et surveiller l’émergence du 
chikungunya. Le deuxième chapitre est consacré à l’étude du rôle respectif d’A. aegypti et 
A. albopictus dans l’épidémie de Dengue de 2011 à Hanoi. Seuls DENV1 et DENV2 ont 
été détectés chez les 140 patients étudiés. Une corrélation positive a été observée entre la 
densité de population d’A. aegypti et le nombre de cas humains et la durée des épidémies. 
Ceci n’a pas été observé chez A. albopictus. Trois lots d’A. aegypti se sont révélés positifs 
pour la dengue, deux pour DENV1 et un pour DENV2. Cette étude montre clairement le 
rôle d’A. aegypti dans l’épidémie de 2011 à Hanoi. Le dernier chapitre est consacré à une 
analyse transversale sur 5 provinces frontalières du Laos et du Cambodge. 558 sérums 
collectés chez des patients admis pour fièvre aigue et de symptômes compatibles avec la 
dengue et chikungunya entre 2012 et 2014 dans des centres de médecine préventive. Les 
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quatre sérotypes ont été détectés mais pas tous dans la même province. Seulement deux 
sérotypes ont été détectés au maximum dans une même province. Le chikungunya n’a pas 
été détecté. Un total de 1104 moustiques adultes a été prélevé dans les mêmes zones à 
l’intérieur et à l’extérieur des habitations. La densité de population de moustiques et les 
indices entomologiques ont été évalués suite à la capture de larves. Des densités très 
différentes ont été observées et la densité la plus importante a été obtenue dans la province 
de Long An, voisine du Cambodge. Le virus de la dengue a été détecté principalement 
chez A. albopictus. Le virus du chikungunya a également été détecté chez A. albopictus. 
L’analyse phylogénétique des moustiques collectés a montré une grande diversité 
génétique avec des génotypes décrits sur d’autres continents. Cette partie de la thèse met 
en évidence le rôle différentiel d’A. aegypti et A. albopictus, le rôle croissant de ce dernier 
et le transport anthropique des moustiques sur de grandes distances. Ce travail souligne le 
besoin de nouvelles approches de surveillance, au niveau clinique et au niveau 
entomologique, pour s’attaquer de façon efficace au risque épidémique de dengue et de 
chikungunya. 
 
 
 
 
 
